View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2016	Mar. 10, 2017	Jun. 30, 2016
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	FY
Trading Symbol	MNKD
Entity Registrant Name	MANNKIND CORP
Entity Central Index Key	0000899460
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		95,776,246
Entity Public Float			$ 372,097,776

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 22,895	$ 59,074
Accounts receivable	302
Receivable from Sanofi	30,557	23
Inventory	2,331
Asset held for sale	16,730
Deferred costs from commercial product sales	309
Deferred costs from collaboration		13,539
Prepaid expenses and other current assets	4,364	4,018
Total current assets	77,488	76,654
Property and equipment - net	28,927	48,749
Other assets	648	1,009
Total assets	107,063	126,412
Current liabilities:
Accounts payable	3,263	15,599
Accrued expenses and other current liabilities	7,937	7,929
Facility financing obligation	71,339	74,582
Deferred revenue - net	3,419
Deferred payments from collaboration	1,000	140,231
Deferred sales from collaboration		17,503
Recognized loss on purchase commitments - current	5,093	12,475
Total current liabilities	92,051	268,319
Note payable to principal stockholder	49,521	49,521
Accrued interest - note payable to principal stockholder	9,281	6,380
Senior convertible notes	27,635	27,613
Sanofi loan facility and loss share obligation		62,371
Recognized loss on purchase commitments - long term	95,942	53,692
Warrant liability	7,381
Milestone rights liability and other liabilities	8,845	8,845
Total liabilities	290,656	476,741
Commitments and contingencies (Note 13)
Stockholders' deficit:
Undesignated preferred stock, $0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at December 31, 2016 and 2015
Common stock, $0.05 par value - 140,000,000 and 110,000,000 shares authorized at December 31, 2016 and 2015, respectively; 95,680,831 and 85,734,188 shares issued and outstanding at December 31, 2016 and 2015, respectively	4,784	4,287
Additional paid-in capital	2,549,212	2,508,633
Accumulated other comprehensive loss	(24)	(20)
Accumulated deficit	(2,737,565)	(2,863,229)
Total stockholders' deficit	(183,593)	(350,329)
Total liabilities and stockholders' deficit	$ 107,063	$ 126,412

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Undesignated preferred stock, par value	$ 0.01	$ 0.01
Undesignated preferred stock, shares authorized	10,000,000	10,000,000
Undesignated preferred stock, shares issued	0	0
Undesignated preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.05	$ 0.05
Common stock, shares authorized	140,000,000	110,000,000
Common stock, shares issued	95,680,831	85,734,188
Common stock, shares outstanding	95,680,831	85,734,188

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenue:
Net revenue - collaboration	$ 171,965
Net revenue - commercial product sales	1,895
Revenue - bulk insulin sales	898
Total net revenue	174,758
Expenses:
Costs of revenue - collaboration	32,971
Cost of goods sold	17,121	$ 64,745
Research and development	14,917	29,674	$ 100,244
Selling, general and administrative	46,928	40,960	79,383
Property and equipment impairment	1,259	140,412	0
(Gain) loss on foreign currency translation	(3,433)	2,697
(Gain) loss on purchase commitments	(2,265)	66,167
Total expenses	107,498	344,655	179,627
Income (loss) from operations	67,260	(344,655)	(179,627)
Other income (expense):
Change in fair value of warrant liability	5,369
Interest income	85	18	9
Interest expense on notes	(15,576)	(21,231)	(17,549)
Interest expense on note payable to principal stockholder	(2,901)	(2,894)	(2,894)
Gain (loss) on extinguishment of debt	72,024	(1,049)
Other (expense) income	(597)	1,366	1,679
Total other income (expense)	58,404	(23,790)	(18,755)
Income (loss) before benefit for income taxes	125,664	(368,445)	(198,382)
Income tax benefit	0	0	0
Net income (loss)	$ 125,664	$ (368,445)	$ (198,382)
Net income (loss) per share - basic	$ 1.37	$ (4.54)	$ (2.57)
Net income (loss) per share - diluted	$ 1.36	$ (4.54)	$ (2.57)
Shares used to compute basic net income (loss) per share	92,053	81,233	77,045
Shares used to compute diluted net income (loss) per share	92,085	81,233	77,045

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Net income (loss)	$ 125,664	$ (368,445)	$ (198,382)
Other comprehensive loss:
Cumulative translation loss	(4)	(6)	(10)
Comprehensive income (loss)	$ 125,660	$ (368,451)	$ (198,392)

Statements of Stockholders' (Deficit) - USD ($) $ in Thousands	Total	TEL AVIV STOCK EXCHANGE	Common Stock	Common Stock TEL AVIV STOCK EXCHANGE	Additional Paid-in Capital	Additional Paid-in Capital TEL AVIV STOCK EXCHANGE	Accumulated Other Comprehensive Income (Loss)	Deficit Accumulated During the Development Stage
Beginning Balance (in shares) at Dec. 31, 2013			73,878,000
Beginning Balance at Dec. 31, 2013	$ (30,713)		$ 3,697		$ 2,261,996		$ (4)	$ (2,296,402)
Exercise of stock options (in shares)			650,000
Exercise of stock options	10,978		$ 35		10,943
Issuance of common shares from the release of restricted stock units (in shares)			799,000
Issuance of common shares from the release of restricted stock units	(26,908)		$ 38		(26,946)
Issuance of common shares pursuant to warrant exercises (in shares)			2,315,000
Issuance of common shares pursuant to warrant exercises	$ 27,779		$ 115		27,664
Issuance of common shares under Employee Stock Purchase Plan (in shares)	61,015		65,000
Issuance of common shares under Employee Stock Purchase Plan	$ 1,363		$ 2		1,361
Stock-based compensation expense	25,660				25,660
Issuance of common shares pursuant to debt conversions by Deerfield (in Shares)			3,505,000
Issuance of common shares pursuant to debt conversions by Deerfield	93,501		$ 174		93,327
Remeasurement of performance based grants pursuant to the modification of terms	$ 22,962				22,962
Return of loaned common stock (in shares)	(1,800,000)
Unrealized gain/(loss) on foreign currency translation	$ (10)						(10)
Net income (loss)	(198,382)							(198,382)
Ending Balance (in shares) at Dec. 31, 2014			81,212,000
Ending Balance at Dec. 31, 2014	(73,770)		$ 4,061		2,416,967		(14)	(2,494,784)
Exercise of stock options (in shares)			340,000
Exercise of stock options	3,258		$ 17		3,241
Issuance of common shares from the release of restricted stock units (in shares)			144,000
Issuance of common shares from the release of restricted stock units			$ 7		(7)
Issuance of common shares pursuant to warrant exercises (in shares)			843,000
Issuance of common shares pursuant to warrant exercises	$ 10,123		$ 42		10,081
Issuance of common shares under Employee Stock Purchase Plan (in shares)	64,245		54,000
Issuance of common shares under Employee Stock Purchase Plan	$ 887		$ 3		884
Stock-based compensation expense	8,725				8,725
Restricted stock units taxes paid in cash	(1,856)				(1,856)
Capital contribution	40				40
Issuance of common shares pursuant to conversions of certain 2015 note holders (in shares)			375,000
Issuance of common shares pursuant to conversions of certain 2015 notes	7,926		$ 19		7,907
Issuance of common stock for lender financing fees (in shares)			8,000
Issuance of common stock for lender financing fees	160				160
Discount on notes-for-stock exchange	169				169
Return of loaned common stock (in shares)			(1,800,000)
Return of loaned common stock			$ (90)		90
Issuance of common stock	27,843	$ 34,710	$ 89	$ 139	27,754	$ 34,571
Issuance of common stock (Shares)			1,788,000	2,771,000
Issuance of warrant liability	(202)				(202)
Reclassification of warrant liability to equity	109				109
Unrealized gain/(loss) on foreign currency translation	(6)						(6)
Net income (loss)	(368,445)							(368,445)
Ending Balance (in shares) at Dec. 31, 2015			85,735,000
Ending Balance at Dec. 31, 2015	$ (350,329)		$ 4,287		2,508,633		(20)	(2,863,229)
Exercise of stock options (in shares)	55,231		55,000
Exercise of stock options	$ 467		$ 3		464
Issuance of common shares from the release of restricted stock units (in shares)			131,000
Issuance of common shares from the release of restricted stock units			$ 7		(7)
Issuance of common shares under Employee Stock Purchase Plan (in shares)	104,758		51,000
Issuance of common shares under Employee Stock Purchase Plan	$ 426		$ 2		424
Stock-based compensation expense	5,135				5,135
Restricted stock units taxes paid in cash	(165)				(165)
Issuance of direct placement - common stock and warrants (value)	50,000		$ 485		49,515
Issuance of direct placement - common stock and warrants (shares)			9,709,000
Issuance costs associated with direct placement	(2,037)				(2,037)
Issuance of warrant liability	(12,750)				(12,750)
Unrealized gain/(loss) on foreign currency translation	(4)						(4)
Net income (loss)	125,664							125,664
Ending Balance (in shares) at Dec. 31, 2016			95,681,000
Ending Balance at Dec. 31, 2016	$ (183,593)		$ 4,784		$ 2,549,212		$ (24)	$ (2,737,565)

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 125,664,000	$ (368,445,000)	$ (198,382,000)
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Depreciation, amortization and accretion	4,158,000	13,276,000	18,575,000
Stock-based compensation expense	5,135,000	8,725,000	48,622,000
Change in fair value of warrant liability	(5,369,000)
(Gain) loss on foreign currency translation	(3,433,000)	2,697,000	(10,000)
(Gain) loss on extinguishment of debt	(72,024,000)	1,049,000
Interest incurred through borrowings under Sanofi Loan Facility	4,478,000	1,652,000
Interest on note payable to principal stockholder	2,901,000	2,894,000	2,894,000
Series A Warrant issuance costs	653,000
Other, net	19,000
Loss on sale, abandonment/disposal or impairment of property and equipment	1,259,000	140,582,000	97,000
(Gain) loss on purchase commitments	(2,265,000)	66,167,000
Write-off of inventory		36,104,000
Write-off of Tranche B commitment asset			1,753,000
Write-off of derivative liability			(363,000)
Changes in operating assets and liabilities:
Accounts receivable	(302,000)
Receivable from Sanofi	(30,534,000)
Inventory	(2,331,000)	(26,434,000)	(9,670,000)
Receivables from collaboration		50,413,000	(50,436,000)
Deferred costs from commercial product sales	(309,000)
Deferred costs from collaboration	13,539,000	(13,539,000)
Prepaid expenses and other current assets	(346,000)	13,481,000	(14,734,000)
Other assets	361,000	150,000	(615,000)
Accounts payable	(12,118,000)	8,413,000	3,622,000
Accrued expenses and other current liabilities	348,000	(12,467,000)	2,276,000
Deferred revenue	3,419,000
Deferred payments from collaboration	(134,056,000)	950,000	200,436,000
Deferred sales from collaboration	(17,503,000)	17,067,000
Recognized loss on purchase commitments	40,566,000
Milestone rights liability and other liabilities		33,000	21,000
Net cash (used in) provided by operating activities	(78,090,000)	(57,232,000)	4,086,000
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(1,144,000)	(10,285,000)	(24,097,000)
Proceeds from sale of property and equipment	17,000	82,000
Net cash used in investing activities	(1,127,000)	(10,203,000)	(24,097,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from direct placement of common stock and warrants	50,000,000
Issuance costs associated with direct placement	(2,690,000)
Payment of notes payable to Deerfield	(5,000,000)
Payment of employment taxes related to vested restricted stock units	(165,000)	(1,858,000)	(26,908,000)
Proceeds from issuance of common stock	893,000	4,146,000	12,341,000
Exercise of warrants for common stock	0	10,123,000	27,779,000
Payment of 2015 notes		(64,287,000)
Payment of debt issuance costs on 2018 notes		(831,000)
Proceeds from issuance of facility financing obligation and milestone rights			40,000,000
Proceeds from issuance of Tranche B of the facility financing obligation			20,000,000
Milestone payment		(4,219,000)	(3,150,000)
Proceeds from issuance of common stock pursuant to at-the-market issuance		28,392,000
Issuance costs associated with the Tel Aviv Stock Exchange		(548,000)
Other		40,000
Net cash provided by financing activities	43,038,000	5,668,000	70,062,000
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(36,179,000)	(61,767,000)	50,051,000
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	59,074,000	120,841,000	70,790,000
CASH AND CASH EQUIVALENTS, END OF PERIOD	22,895,000	59,074,000	120,841,000
SUPPLEMENTAL CASH FLOWS DISCLOSURES:
Interest paid in cash, net of amounts capitalized to construction in progress	8,991,000	13,355,000	11,218,000
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Payment of 2015 notes and interest through issuance of common stock		8,253,000
Issuance of common stock pursuant to debt conversion by Deerfield			93,500,000
Non-cash construction in progress and property and equipment	588,000		1,768,000
Reclassification of deferred payments from collaboration to Sanofi loan facility and loss share obligation	5,174,000	59,337,000	$ 3,034,000
Reclassification of property and equipment to asset held for sale	$ 17,294,000
TEL AVIV STOCK EXCHANGE
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock		36,142,000
Issuance costs associated with the Tel Aviv Stock Exchange		$ (1,432,000)

Description of Business

12 Months Ended

Dec. 31, 2016

Description of Business

1. Description of Business

Business — MannKind Corporation and subsidiaries (the “Company”) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. The Company’s only approved product, Afrezza, (insulin human [rDNA origin]) inhalation powder, is a rapid-acting inhaled insulin that was approved by the U.S. Food and Drug Administration (the “FDA”) on June 27, 2014 to improve glycemic control in adult patients with diabetes.

Basis of Presentation — On August 11, 2014, the Company entered into a license and collaboration agreement (the “Sanofi License Agreement”) with Sanofi-Aventis Deutschland GmbH (which subsequently assigned its rights and obligations under the agreement to Sanofi-Aventis U.S. LLC (“Sanofi”)), pursuant to which Sanofi was responsible for Afrezza global commercial, regulatory and development activities for Afrezza.

On January 4, 2016, the Company received written notification from Sanofi of its election to terminate in its entirety the Sanofi License Agreement. The effective date of termination (the “Termination Date”) was April 4, 2016, which was when the Company assumed responsibility for worldwide development and commercialization of Afrezza. Under terms of a transition agreement, Sanofi continued to fulfill orders for Afrezza in the United States until the Company began distributing MannKind-branded Afrezza product to major wholesalers in late July 2016. The Company began recognizing commercial product sales revenue when MannKind-branded Afrezza was dispensed from pharmacies to patients in August 2016.

On November 9, 2016, the Company entered into a settlement agreement with Sanofi (the “Settlement Agreement”). Under the terms of the Settlement Agreement, the promissory note (the “Sanofi Loan Facility”) between the Company and Aventisub LLC (“Aventisub”), a Sanofi affiliate, was terminated, with Aventisub agreeing to forgive the full outstanding loan balance of $72.0 million, which includes $0.5 million of previously uncharged costs pursuant to the Sanofi License Agreement. Sanofi also agreed to purchase $10.2 million of insulin from the Company in December 2016 under an existing insulin put option as well as make a cash payment of $30.6 million to the Company in early January 2017 as acceleration and in replacement of all other payments that Sanofi would otherwise have been required to make in the future pursuant to the insulin put option, without the Company being required to deliver any insulin for such payment. The Company and Sanofi also agreed to a general release of potential claims against each other.

During their initial transition of the commercial responsibilities from Sanofi, the Company utilized a contract sales organization to promote Afrezza while the Company focused its internal resources on establishing a channel strategy, entering into distribution agreements and developing co-pay assistance programs, a voucher program, data agreements and payor relationships. In early 2017, the Company recruited their own sales force, which included some of the sales reps that previously were employed by the contract sales organization. The Company intend to continue the commercialization of Afrezza in the United States through their own commercial organization. The Company’s current strategy for the future commercialization of Afrezza outside of the United States, subject to receipt of the necessary foreign regulatory approvals, is to seek and establish regional partnerships in foreign jurisdictions where there are appropriate commercial opportunities.

It has been costly to develop our therapeutic product, conduct clinical studies, and market and sell Afrezza. As of and for the year ended December 31, 2016, the Company has reported an accumulated deficit of $2.7 billion and has reported negative cash flow from operations for each year since inception, except for 2014, when the Company received the $150.0 million upfront payment from Sanofi.

At December 31, 2016, the Company’s capital resources consisted of cash and cash equivalents of $22.9 million. The Company expects to continue to incur significant expenditures to support commercial manufacturing and sales and marketing of Afrezza and the development of other product candidates. The facility agreement (the “Facility Agreement”) with Deerfield Private Design Fund II, L.P. (Deerfield Private Design Fund) and Deerfield Private Design International II, L.P. (collectively, “Deerfield”) and the First Amendment to Facility Agreement and Registration Rights Agreement (the “First Amendment”) that resulted in additional sales of an additional tranche of notes (the “Tranche B notes”) (see Note 7 — Borrowings) requires the Company to maintain at least $25.0 million, which can be comprised of cash and cash equivalents and available borrowings under the loan arrangement, dated as of October 2, 2007, between the Company and The Mann Group LLC (as amended, restated, or otherwise modified as of the date hereof, “the Mann Group Loan Arrangement”), as of the last day of each fiscal quarter.

Additional funding sources that are, or in certain circumstances may be available to the Company, include approximately $30.1 million principal amount of available borrowings under The Mann Group Loan Arrangement. A portion of these available borrowings may be used to capitalize accrued interest into principal, upon mutual agreement of the parties, as it becomes due and payable under The Mann Group Loan Arrangement (see Note 6 — Related-party Arrangements). The Company cannot provide assurances that its plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. The Company will need to raise additional capital, whether through a sale of equity or debt securities, a strategic business collaboration with a pharmaceutical company, the establishment of other funding facilities, licensing arrangements, asset sales or other means, in order to continue the commercialization of Afrezza and development of other product candidates and to support its other ongoing activities. The Company cannot provide assurances that such additional capital will be available on acceptable terms or at all. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

On September 14, 2016, the Company received notice from the Listing Qualifications Department of the NASDAQ Stock Market indicating that, for the previous 30 consecutive business days, the bid price for the common stock closed below the minimum $1.00 per share required for continued inclusion on The NASDAQ Global Market. The notification letter stated that the Company would be afforded 180 calendar days, or until March 13, 2017, to regain compliance with the minimum bid price requirement. In order to regain compliance, shares of the Company’s common stock must maintain a minimum bid closing price of at least $1.00 per share for a minimum of 10 consecutive business days.

Reverse Stock Split — On March 1, 2017, following stockholder approval, the Company’s board of directors approved a reverse stock split ratio of 1-for-5. On March 1, 2017, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of the Company’s Amended and Restated Certificate of Incorporation to effect the 1-for-5 reverse stock split of the Company’s outstanding common stock and to reduce the authorized number of shares of the Company’s common stock from 700,000,000 to 140,000,000 shares. The Company’s common stock began trading on The NASDAQ Global Market on a split-adjusted basis when the market opened on March 3, 2017. See Note 20 — Subsequent Events for further information. As a result, all common stock share amounts included in these consolidated financial statements have been retroactively reduced by a factor of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the Company’s common stock par value.

Principles of Consolidation — The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated.

Segment Information — Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company has viewed its operations and manages its business as one segment operating in the United States of America.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2016

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Financial Statement Estimates — The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies, and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. The more significant estimates reflected in these accompanying consolidated financial statements include revenue recognition, assessing long-lived assets for impairment, accrued expenses, including clinical study expenses, inventory recoverability, valuation of the facility financing obligation, loss on purchase commitment, warrant liability, milestone rights, stock-based compensation and the determination of the provision for income taxes and corresponding deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets.

Reclassifications — Certain amounts from previous periods have been reclassified to conform to the 2016 presentation. Specifically, accrued interest — note payable to principal stockholder has been reclassified from the previously reported classification of other liabilities in the accompanying consolidated balance sheets. Additionally, the remaining balance from the previously reported classification of other liabilities is now identified as milestone rights liability, and is disclosed as a separate line item on the consolidated statements of cash flows. Additionally, on the consolidated statement of operations, product manufacturing has been renamed to cost of goods sold. The Company also reclassified (gain) loss on foreign currency translation from the previously reported classification of product manufacturing in the accompanying consolidated statements of operations. Additionally, certain balances from prepaid expenses and other current assets were reclassed to (gain) loss on foreign currency translation in the consolidated statements of cash flows.

Revenue Recognition — Revenue is recognized when the four basic criteria of revenue recognition are met: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. When the accounting requirements for revenue recognition are not met, the Company defers the recognition of revenue by recording deferred revenue on the consolidated balance sheets until such time that all criteria are met. To date, the Company has had revenue from collaborations, commercial sales of Afrezza, and from sales of bulk insulin, which are described more fully below.

Revenue Recognition — Net Revenue — Collaborations — The Company enters into collaborations under which we must perform certain obligations and we receive periodic payments. We evaluate the collaborations under the multiple element revenue recognition accounting guidance. Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered elements have stand-alone value to the customer. When deliverables are separable, consideration received is allocated to the separate units of accounting based on the relative selling price of each deliverable and the appropriate revenue recognition principles are applied to each unit.

The assessment of multiple element arrangements requires judgment in order to determine the appropriate units of accounting and the points in time that, or periods over which, revenue should be recognized. The terms of and the accounting for the Company’s collaborations are described more fully in Note 8 — Collaboration Arrangements.

Revenue Recognition — Net Revenue — Commercial Product Sales — Between July 1, 2016 and December 15, 2016, the Company sold Afrezza to Integrated Commercialization Solutions Direct (ICS) and title and risk of loss transferred to ICS upon shipment. After December 15, 2016, ICS became a third party logistics provider and stopped taking title and risk of loss upon shipment of Afrezza to ICS. The Company sells Afrezza in the United States to wholesale pharmaceutical distributors through ICS, and ultimately to retail pharmacies, which are collectively referred to as “customers”.

The Company provides the right of return to ICS (through December 15, 2016) and its wholesale distributors and, through them, to its retail pharmacy customers for unopened product for a period beginning six months prior to and ending twelve months after its expiration date. Once the product has been prescribed and dispensed to the patient, any right of return ceases to exist.

Given the Company’s limited sales history for Afrezza, the Company cannot reliably estimate expected returns of the product at the time of shipment into the distribution channel. Accordingly, the Company defers recognition of revenue on Afrezza product shipments until the right of return no longer exists, which occurs at the earlier of the time Afrezza is dispensed from pharmacies to patients or expiration of the right of return. The Company recognizes revenue based on Afrezza patient prescriptions dispensed as estimated by syndicated data provided by a third party. The Company also analyzes additional data points to ensure that such third-party data is reasonable including data related to inventory movements within the channel and ongoing prescription demand.

For the year ended December 31, 2016, net revenue from commercial product sales consisted of $1.9 million of net sales of Afrezza dispensed to patients. As of December 31, 2016, the Company recorded $3.4 million in deferred revenue on its consolidated balance sheet, of which $1.6 million (net of estimated gross-to-net adjustments) represents product shipped to the Company’s third-party logistics provider and wholesale distributors, but not yet dispensed to patients. The difference represents deferred revenue from bulk insulin sales, which is described more fully under the heading Revenue Recognition — Revenue — Bulk Insulin Sales below.

Gross-to-net Adjustments — Estimated gross-to-net adjustments for Afrezza include wholesaler distribution fees, prompt pay discounts, estimated rebates and patient discount and co-pay assistance programs, and are based on estimated amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of the Company’s agreements with its customers and the levels of inventory within the distribution and retail channels that may result in future rebates or discounts taken. In certain cases, such as patient support programs, the Company recognizes the cost of patient discounts as a reduction of revenue based on estimated utilization. If actual future results vary, the Company may need to adjust these estimates, which could have an effect on product revenue in the period of adjustment. The Company records product sales deductions in the consolidated statements of operations at the time product revenue is recognized. At December 31, 2016, year to date total gross-to-net adjustments were approximately $0.8 million, which represents 30% of gross revenue from product sales.

Wholesaler Distribution Fees — The Company pays distribution fees to certain wholesale distributors based on contractually determined rates. The Company accrues the distribution fees on shipment to the respective wholesale distributors and recognizes the distribution fees as a reduction of revenue in the same period the related revenue is recognized.

Prompt Pay Discounts — The Company offers cash discounts to its customers, generally 2% of the sales price, as an incentive for prompt payment. The Company accounts for cash discounts by reducing accounts receivable by the prompt pay discount amount and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized.

Rebates — The Company participates in federal and state government-managed Medicare and Medicaid rebate programs and intends to pursue participation in certain other qualifying federal and state government programs whereby discounts and rebates are provided to participating federal and state government entities. Rebates provided through these other qualifying programs are included in the Medicaid and Medicare rebate accrual. The Company accounts for these rebates by establishing an accrual equal to the estimate of rebate claims attributable to a sale and determines its estimate of the rebates accrual based on historical payor data provided by a third-party vendor along with additional data including a forecasted participation rate for Medicare and Medicaid. From that data, as well as input received from MannKind’s commercial team, an estimated participation rate for Medicare and Medicaid is determined and applied at the mandated rate for those sales. Any new information regarding changes in the programs’ regulations and guidelines or any changes in the Company’s government price reporting calculations that would impact the amount of the rebates will also be taken into account in determining or modifying the appropriate reserve. The time period between the date the product is sold into the channel and the date such rebates are paid ranges from approximately six to nine months. As such, continuous monitoring of these estimates are performed on a periodic basis and if necessary, adjusted to reflect new facts and circumstances. Rebates are recognized as a reduction of revenue in the period the related revenue is recognized.

Patient Discount and Co-Pay Assistance Programs — The Company offers discount card programs to patients for Afrezza in which patients receive discounts on their prescriptions or a reduction in their co-pay amounts that are reimbursed by the Company. The Company estimates the total amount that will be redeemed based on levels of inventory in the distribution and retail channels and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized.

Product Returns — The Company does not provide a reserve for product returns of sales of Afrezza due to its revenue recognition policy of deferring recognition of revenue on product shipments of Afrezza until the right of return no longer exists.

Revenue Recognition — Revenue — Bulk Insulin Sales — In 2016, revenue from bulk insulin sales was recognized after delivery and customer acceptance of the bulk insulin. When the accounting requirements for revenue recognition of bulk insulin sales are not met, the Company defers recognition of revenue by recording deferred revenue on the balance sheet until such time that all criteria are met.

Deferred revenue includes $1.8 million received from a sale of surplus bulk insulin to a third party that was delivered prior to, but accepted after, December 31, 2016. No deferred cost was recognized related to this sale because the inventory was written off on December 31, 2015.

Deferred Costs from Collaboration — Deferred costs from collaboration represents the costs of product manufactured and sold to Sanofi, as well as certain direct costs associated with a firm purchase commitment entered into in connection with the collaboration with Sanofi. During the third quarter of 2016, the costs related to the Sanofi product sales were recognized as costs of revenue — collaboration in the consolidated statements of operations, as related revenue was recognized at that time.

Deferred Costs from Commercial Product Sales — Deferred costs from commercial product sales represents the cost of product (including labor, overhead and costs to ship to third party logistics) shipped to ICS and wholesale distributors, but not yet dispensed by pharmacies to patients.

Cost of Goods Sold — Cost of goods sold includes the costs related to Afrezza product dispensed by pharmacies to patients as well as under-absorbed labor and overhead and inventory write-offs, which are recorded as expenses in the period in which they are incurred, rather than as a portion of the inventory cost.

Cash and Cash Equivalents — The Company considers all highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase, that are readily convertible into cash to be cash equivalents. As of December 31, 2016 and 2015, cash equivalents were comprised of money market accounts with maturities less than 90 days from the date of purchase.

Concentration of Credit Risk — Financial instruments which potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Cash and cash equivalents are held in high credit quality institutions. Cash equivalents consist of interest-bearing money market accounts, which are regularly monitored by management.

Accounts Receivable and Allowance for Doubtful Accounts — Accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectability of its accounts receivable in its calculation of the allowance for doubtful accounts. As of December 31, 2016 and 2015, there was no allowance for doubtful accounts.

Inventories — Inventories are stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out, or FIFO, method. The Company capitalizes inventory costs associated with the Company’s products based on management’s judgment that future economic benefits are expected to be realized; otherwise, such costs are expensed as cost of goods sold. The Company periodically analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value, and writes down such inventories as appropriate. In addition, the Company’s products are subject to strict quality control and monitoring which the Company performs throughout the manufacturing process. If certain batches or units of product no longer meet quality specifications or become obsolete due to expiration, the Company will record a charge to write down such unmarketable inventory to its estimated net realizable value.

The Company analyzed its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value. The Company performed an assessment of projected sales and evaluated the lower of cost or net realizable value and the potential excess inventory on hand at December 31, 2016 and 2015. As a result of these assessments, the Company recorded a $0.2 million charge at December 31, 2016 to write-off inventory that will expire prior to sale. At December 31, 2015, the Company recorded a charge of $39.3 million to record the inventory raw materials on hand at the lower of cost or net realizable value, inventory expiry and write-off other inventory related assets.

State Research and Development Credit Exchange Receivable — The State of Connecticut provides certain companies with the opportunity to exchange certain research and development income tax credit carryforwards for cash in exchange for foregoing the carryforward of the research and development credits. The program provides for an exchange of research and development income tax credits for cash equal to 65% of the value of corporation tax credit available for exchange. Estimated amounts receivable under the program are recorded as a reduction of research and development expenses. These amounts are included in prepaid expenses and other current assets on the consolidated balance sheets.

Prepaid Expenses and Other Current Assets — As of December 31, 2016 and 2015, prepaid expenses and other current assets primarily consist of prepaid expenses for goods and services to be received and includes a certificate of deposit for $350,000 as collateral as required by an agreement with the bank.

Sale of intellectual property — On July 18, 2014, the Company entered into an assignment agreement with a third party whereby the third party acquired all proprietary rights, technology and know-how that related to a small molecule inhibitor compound and all pre-clinical data and results related thereto. Under the terms of the assignment agreement, the Company received total consideration of $9.3 million and accrued $1.4 million in expense for a net amount of $7.9 million recorded as other income. In 2015, the Company recorded other income of $1.4 million related to the relief of the $1.4 million accrual for expenses associated with the sale of intellectual property related to oncology in 2014, which was subsequently resolved without payment.

Assets Held for Sale — The Company classifies long-lived assets anticipated to be sold within one year as held for sale at the lower of their carrying value or fair value less estimated selling costs.

Property and Equipment — Property and equipment are depreciated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the term of the lease or the service lives of the improvements, whichever is shorter. Maintenance and repairs are expensed as incurred. Assets under construction are not depreciated until placed into service.

Impairment of Long-Lived Assets — The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Assets are considered to be impaired if the carrying value may not be recoverable.

If the Company believes an asset to be impaired, the impairment recognized is the amount by which the carrying value of the asset exceeds the fair value of the asset. Fair value is determined using the market, income or cost approaches as appropriate for the asset. Any write-downs are treated as permanent reductions in the carrying amount of the asset and an operating loss would be recognized.

The Company recorded an asset impairment of $1.3 million and $140.4 million for the years ended December 31, 2016 and 2015, respectively. No asset impairment was recognized during the year ended December 31, 2014 (see Note 4 — Property and Equipment and Note 20 — Subsequent Events).

Recognized Loss on Purchase Commitments — The Company assesses whether losses on long term purchase commitments should be accrued. Losses that are expected to arise from firm, non-cancellable, commitments for the future purchases of inventory items are recognized unless recoverable. The recognized loss on purchase commitments is reduced as inventory items are purchased. Changes in estimates are recorded in the relevant period in (gain) loss on purchase commitments.

During the year ended December 31, 2015, the Company recorded a loss on purchase commitments amounting to $116.2 million offset by $50 million expected to be recovered from Sanofi, primarily due to a long term purchase commitment for insulin raw materials. During the year ended December 31, 2016, the balance was adjusted for the recovery received from Sanofi, current purchases on the contracts and a reduction in the recognized loss related to amendments to purchase contracts. No new contracts were identified in 2016 requiring a new loss on purchase commitment accrual.

Milestone Rights Liability — On July 1, 2013, in conjunction with the execution of the Facility Agreement, the Company issued Milestone Rights to Deerfield whereby the Company agreed to provide Deerfield with pre-specified Milestone Payments upon the achievement of 13 specific Milestone Events related to the commercial release and future cumulative net sales of Afrezza. The Company analyzed the Milestone Rights and determined that the agreement does not meet the definition of a freestanding derivative. Since the Company has not elected to apply the fair value option to the Milestone Rights Purchase Agreement, the Company recorded the Milestone Rights at their estimated initial fair value and accounted for the Milestone Rights as a liability.

The initial fair value estimate of the Milestone Rights was calculated using the income approach in which the cash flows associated with the specified contractual payments were adjusted for both the expected timing and the probability of achieving the milestones and discounted to present value using a selected market discount rate. The expected timing and probability of achieving the milestones was developed with consideration given to both internal data, such as progress made to date and assessment of criteria required for achievement, and external data, such as market research studies. The discount rate was selected based on an estimation of required rate of returns for similar investment opportunities using available market data. The Milestone Rights liability will be remeasured as the specified milestone events are achieved. Specifically, as each milestone event is achieved, the portion of the initially recorded Milestone Rights liability that pertains to the milestone event being achieved, will be remeasured to the amount of the specified related milestone payment. The resulting change in the balance of the Milestone Rights liability due to remeasurement will be recorded in the Company’s consolidated statements of operations as interest expense. Furthermore, the Milestone Rights liability will be reduced upon the settlement of each milestone payment. As a result, each milestone payment would be effectively allocated between a reduction of the recorded Milestone Rights liability and an expense representing a return on a portion of the Milestone Rights liability paid to the investor for the achievement of the related milestone event (see Note 7 — Borrowings). As of December 31, 2016, the remaining liability balance is $8.9 million.

Fair Value of Financial Instruments — The Company utilizes fair value measurement guidance to value its financial instruments. The guidance includes a definition of fair value, prescribes methods for measuring fair value, establishes a fair value hierarchy based on the inputs used to measure fair value and expands disclosures about the use of fair value measurements. The valuation techniques utilized are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect internal market assumptions. These two types of inputs create the following fair value hierarchy:

Level 1 — Quoted prices for identical instruments in active markets.

Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

Level 3 — Significant inputs to the valuation model are unobservable.

Income Taxes — The provisions for federal, foreign, state and local income taxes are calculated on pre-tax income based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce net deferred income tax assets to amounts that are more likely than not to be realized.

Income tax positions are considered for uncertainty. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no liabilities for uncertain income tax positions have been recorded. If a tax position does not meet the minimum statutory threshold to avoid payment of penalties, the Company recognizes an expense for the amount of the penalty in the period the tax position is claimed in the tax return of the Company. The Company recognizes interest accrued related to unrecognized tax benefits in income tax expense, if any. Penalties, if probable and reasonably estimable, are recognized as a component of income tax expense.

Significant management judgment is involved in determining the provision for income taxes, deferred tax assets, deferred tax liabilities, and any valuation allowance recorded against deferred tax assets. Due to uncertainties related to the realization of the Company’s deferred tax assets as a result of its history of operating losses, a full valuation allowance has been established against the total deferred tax asset balance. The valuation allowance is based on management’s estimates of taxable income by jurisdiction in which the Company operates and the period over which deferred tax assets will be recoverable. In the event that actual results differ from these estimates or the Company adjusts these estimates in future periods, a change in the valuation allowance may be needed.

Contingencies — The Company records a loss contingency for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These accruals represent management’s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may revise its estimates.

Stock-Based Compensation — As of December 31, 2016, the Company had three active stock-based compensation plans, which are described more fully in Note 12 — Stock Award Plans. The Company accounts for all share-based payments to employees, including grants of stock awards and the compensatory elements of the employee stock purchase plan. All share-based payments to employees, including grants of stock options, restricted stock units, performance-based awards and the compensatory elements of employee stock purchase plans, are recognized in the consolidated statements of operations based upon the fair value of the awards at the grant date. The Company uses the Black-Scholes option valuation model to estimate the grant date fair value of employee stock options and the compensatory elements of employee stock purchase plans. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate and the expected dividend yield. The expected volatility assumption is based on an assessment of the historical volatility, with consideration of implied volatility, derived from an analysis of historical trade activity. Restricted stock units are valued based on the market price on the grant date. The Company evaluates stock awards with performance conditions as to the probability that the performance conditions will be met and estimates the date at which the performance conditions will be met in order to properly recognize stock-based compensation expense over the requisite service period.

Warrants — The Company has issued warrants to purchase shares of its common stock. The Company accounts for its warrants as either equity or liabilities based upon the characteristics and provisions of each instrument and evaluation of sufficient authorized shares available to satisfy the obligations. Warrants classified as derivative liabilities are recorded on the Company’s consolidated balance sheets at their fair value on the date of issuance and are revalued at each subsequent balance sheet date, with fair value changes recognized in the consolidated statements of operations. The Company estimates the fair value of its derivative liabilities using a third party valuation analysis that utilizes a Monte Carlo pricing valuation model and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as expected volatility, expected life, yield and a risk-free interest rate. The expected volatility assumption is primarily based on an assessment of the historical volatility, with consideration of implied volatility, derived from an analysis of historical trade activity. Warrants classified as equity are recorded within additional paid in capital at the issuance date and are not re-measured in subsequent periods, unless the underlying assumptions change to trigger liability accounting.

Comprehensive Income (Loss) — Other comprehensive income (loss) requires that all components of comprehensive income (loss) to be reported in the financial statements in the period in which they are recognized. Other comprehensive income (loss) includes certain changes in stockholders’ equity that are excluded from net income (loss). Specifically, the Company includes unrealized gains and losses on foreign exchange translation in accumulated other comprehensive loss on the consolidated balance sheets.

Research and Development Expenses — Research and development expenses consist of costs associated with the clinical trials of the Company’s product candidates, manufacturing supplies and other development materials, compensation and other expenses for research and development personnel, costs for consultants and related contract research, facility costs, and depreciation. Research and development costs, which are net of any tax credit exchange recognized for the Connecticut state research and development credit exchange program, are expensed as incurred. The Company began commercial manufacturing in the latter part of the fourth quarter of 2014. Commercial manufacturing costs incurred in the fourth quarter of 2014 were included in research and development expense and were immaterial for the year ended December 31, 2014.

State Research and Development Credit Exchange Receivable — The State of Connecticut provides certain companies with the opportunity to exchange certain research and development income tax credit carryforwards for cash in exchange for forgoing the carryforward of the research and development income tax credits. The program provides for an exchange of research and development income tax credits for cash equal to 65% of the value of corporation tax credit available for exchange. Estimated amounts receivable under the program are recorded as a reduction of research and development expenses. During the years ended December 31, 2016, 2015 and 2014, research and development expenses were offset by research and development tax credits of $246,000, $743,000 and $816,000, respectively.

Clinical Trial Expenses — Clinical trial expenses, which are reflected in research and development expenses in the accompanying consolidated statements of operations, result from obligations under contracts with vendors, consultants and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The appropriate level of trial expenses are reflected in the Company’s consolidated financial statements by matching period expenses with period services and efforts expended. These expenses are recorded according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. Clinical trial accrual estimates are determined through discussions with internal clinical personnel and outside service providers as to the progress or state of completion of trials, or the services completed. Service provider status is then compared to the contractually obligated fee to be paid for such services. During the course of a clinical trial, the Company may adjust the rate of clinical expense recognized if actual results differ from management’s estimates.

Interest Expense — Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized. Interest cost capitalized for the years ended December 31, 2015 and 2014 was $0.1 million and $0.8 million, respectively. There were no capitalized interest costs for the year ended December 31, 2016.

Net Income (Loss) Per Share of Common Stock — Basic net income (loss) per share excludes dilution for potentially dilutive securities and is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share reflects the potential dilution under the treasury method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. For periods where the Company has presented a net loss, potentially dilutive securities are excluded from the computation of diluted net loss per share as they would be antidilutive.

Recently Issued Accounting Standards — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s consolidated financial position or results of operations upon adoption.

In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which requires an entity to recognize the amount of revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. This new guidance supersedes previous revenue recognition requirements, along with most existing industry-specific guidance. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In 2016 the FASB has issued additional ASUs which clarify certain aspects of the new guidance.

The Company will adopt the new guidance for the year beginning January 1, 2018. The Company has the option to either apply the new guidance retrospectively for all prior reporting periods presented (full retrospective) or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (modified retrospective). The Company currently anticipates it will apply the new guidance using the modified retrospective approach with the cumulative effect of initial application recognized as of January 1, 2018. The Company plans to continue analyzing the potential impacts of the application throughout 2017 and, depending on factors that may impact the results, could elect to apply the new guidance on a full retrospective basis.

Currently, for commercial sales of Afrezza, the Company has limited sales and returns history, and as such, is unable to reliably estimate expected returns of the product at the time of shipment into the distribution channel. Accordingly, the Company defers recognition of revenue on Afrezza product shipments until the right of return no longer exists, which occurs at the earlier of the time Afrezza is dispensed from pharmacies to patients or expiration of the right of return. The Company recognizes revenue based on Afrezza patient prescriptions dispensed, a sell-through model, as estimated by syndicated data provided by a third party. The Company also analyzes additional data points to ensure that such third-party data is reasonable, including data related to inventory movements within the channel and ongoing prescription demand.

Upon adoption of the new guidance, the Company expects that it will move from its current sell-through model to a sell-to model for revenue related to commercial sales of Afrezza and will record revenue at the time title and risk of loss passes to its distributors (generally at shipment or delivery to the distributors) along with an estimate of potential returns as variable consideration. The Company also anticipates that its ability to estimate potential returns will improve with an additional 12 months of sales history that it will have obtained by January 1, 2018.

In addition, the Company has historically entered into collaborative agreements with third-parties under which periodic payments have been received. Revenue recognition for certain payments received has been deferred until the price is fixed and determinable. Further, revenue for certain payments to be received in the future has been prohibited from recognition until received. The Company expects that some of these amounts will be considered variable consideration and may be able to be recognized earlier under the new guidance.

The Company has begun its evaluation of the impact of adoption and plans to continue its evaluation throughout 2017. The financial impact upon adoption will be dependent upon a number of factors including; the amount of revenue that has been deferred under the sell-through model for Afrezza, the amount of the revenue deferred under collaborative arrangements and the Company’s estimates of variable consideration at the date of adoption. At this time, the Company has not completed its evaluation of the inputs, assumptions and methodologies that will be used to recognize revenue related to variable consideration under the new guidance.

In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. Topic 330 currently requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. The amendments indicate that after adoption an entity should measure inventory within the scope of this ASU at the lower of cost or net realizable value. The amendments are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The amendments should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of ASU No. 2015-11 will have no impact on the Company’s annual consolidated financial statements because the Company currently measures inventory at the lower of cost or net realizable value.

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements — Going Concern, which requires management of an entity to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued or available to be issued. This update was effective for annual periods ending after December 15, 2016. The adoption of this standard did not have a material impact on its consolidated financial statements.

In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments — Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The update is intended to improve the recognition and measurement of financial instruments. The update is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company is evaluating the impact the adoption of ASU 2016-01 will have on its consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The new standard will be effective on January 1, 2019. The Company is evaluating the impact the adoption of ASU No. 2016-02 will have on its consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. For public business entities, the amendments in this standard are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company has evaluated the effect that this guidance will have on its consolidated financial statements and related disclosures and has determined it will not result in a material impact.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new standard seeks to reduce diversity in practice related to the classification of certain transactions in the statement of cash flows. For public business entities, the amendments in this standard are effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. The amendments should be applied using a retrospective transition method to each period presented. If it is impracticable to apply the amendments retrospectively for some of the issues, the amendments for those issues would be applied prospectively as of the earliest date practicable. The Company is evaluating the impact the adoption of ASU No. 2016-15 will have on its consolidated financial statements.

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. This ASU requires that the reconciliation of the beginning-of-period and end-of-period amounts shown in the statement of cash flows include cash and restricted cash equivalents. ASU 2016-08 is effective for fiscal years beginning after December 15, 2018, including interim periods within those periods, using a retrospective transition method to each period presented. The Company has evaluated the effect that this guidance will have on its consolidated financial statements and related disclosures and has determined it will not result in a material impact.

Inventories

12 Months Ended

Dec. 31, 2016

Inventories

3. Inventories

Inventories consist of the following (in thousands):


	December 31,
	2016		2015
Raw materials	$	—	$	—
Work-in-process		2,120		—
Finished goods		211		—

Total Inventory	$	2,331	$	—

As of December 31, 2015, the Company recorded a write-off of all of its inventory. There were no raw materials as of December 31, 2016 because purchases of raw materials in 2016 were recorded at zero value because they had been accrued at December 31, 2015 through the loss on purchase commitment. Work-in-process and finished goods as of December 31, 2016 include conversion costs but not materials cost because the materials used in its production were previously written off.

Property and Equipment

12 Months Ended

Dec. 31, 2016

Property and Equipment

4. Property and Equipment

Property and equipment consist of the following (in thousands):


	Estimated Useful Life (Years)		December 31,
	Estimated Useful Life (Years)		2016			2015
Land		—	$	875		$	3,435
Buildings		39-40		17,389			21,590
Building improvements		5-40		34,957			60,584
Machinery and equipment		3-15		62,992			68,434
Furniture, fixtures and office equipment		5-10		3,556			4,114
Computer equipment and software		3		8,531			9,519
Construction in progress				202			586

				128,502			168,262
Less accumulated depreciation				(99,575	)		(119,513	)

Total property and equipment, net			$	28,927		$	48,749

Depreciation and amortization expense related to property and equipment for the years ended December 31, 2016, 2015 and 2014, was $2.4 million, $11.0 million and $9.8 million, respectively.

The December 31, 2016 amounts do not include the Valencia property because it is classified as held for sale as of that date.

In connection with the Company’s quarterly assessment of impairment indicators, the Company evaluated the continued lower than expected sales of Afrezza as reported by Sanofi throughout the fourth quarter of 2015, revised forecasts for sales of Afrezza provided by Sanofi in the fourth quarter of 2015 and level of commercial production in the fourth quarter of 2015, as well as the uncertainty associated with Sanofi’s announcement during the fourth quarter of their intent to reorganize their diabetes business. These factors indicated potentially significant changes in the timing and extent of cash flows, and the Company therefore determined that an impairment indicator existed in the fourth quarter of 2015 and recorded an impairment for the year ended December 31, 2015. No such indications were identified in the current year ended December 31, 2016.

The Company identified two primary asset groups to be evaluated for impairment: the Danbury manufacturing facility, which currently performs all the manufacturing of Afrezza, and the Valencia facility, which was previously the Company’s corporate headquarters. The Danbury manufacturing facility was the primary asset group that was impacted by the impairment indicators noted above but the Company also evaluated the Valencia facility for potential impairment given the circumstances and identified an impairment charge of $1.8 million based on a valuation utilizing a combination of market, income and cost approaches. Within the Danbury manufacturing facility, the Company identified the machinery and equipment as the primary assets within the asset group as they are associated with the production of Afrezza. As such, the Company performed the fixed asset impairment test and performed the first step to test for recoverability of the Danbury manufacturing facility by utilizing two undiscounted cash flow projections and applying a probability weighted average to those cash flow projections. The first undiscounted cash flow projection was developed under a scenario assuming Sanofi would continue to sell and market Afrezza as the termination of the arrangement by Sanofi was not known as of the balance sheet date. The second undiscounted cash flow projection assumed Sanofi would terminate the Sanofi License Agreement and that the Company would manufacture, sell and market Afrezza independently.

Based on the evaluation performed, the probabilities assigned to the two undiscounted cash flows were not significant to the evaluation due to the projected negative cash flows over the estimation period, and it was determined that the probability weighted undiscounted cash flows were not sufficient to recover the carrying value of the Danbury manufacturing facility. As such, the Company was required to determine the fair value of the Danbury manufacturing facility to recognize an impairment loss if the carrying amount exceeds its fair value. The Company determined the fair value of the Danbury manufacturing facility by applying the highest and best use valuation concept and utilizing the market approach valuation technique to value the machinery and equipment and a combination of the market approach and cost approach in valuing the land, buildings and building improvements. As a result of this assessment, the Company recorded, as of December 31, 2015, an impairment charge of $138.6 million for the Danbury manufacturing facility.

The December 31, 2015 balances have been reclassified to the current year presentation by allocating an impairment of $140.4 million, which was previously disclosed in total, to the individual asset groups. An additional impairment of $0.7 million was charged to the individual asset groups for the year ended December 31, 2016, which is included in property and equipment impairment in the accompany consolidated statements of operations, additionally with a $0.6 million impairment charge related to assets held for sale.

Accrued Expenses and Other Current Liabilities

12 Months Ended

Dec. 31, 2016

Accrued Expenses and Other Current Liabilities

5. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities are comprised of the following (in thousands):


	December 31,
	2016		2015
Salary and related expenses	$	3,814	$	2,634
Restructuring		1,376		3,028
Sales and marketing services		144		—
Professional fees		875		931
Discounts and allowances for commercial product sales		754		—
Accrued interest		619		615
Other		355		483
Construction in progress		—		238

Accrued expenses and other current liabilities	$	7,937	$	7,929

Related-Party Arrangements

12 Months Ended

Dec. 31, 2016

Related-Party Arrangements

6. Related-Party Arrangements

In October 2007, the Company entered into The Mann Group Loan Arrangement, which has been amended from time to time. On October 31, 2013, the promissory note underlying The Mann Group Loan Arrangement was amended to, among other things, extend the maturity date of the loan to January 5, 2020, extend the date through which the Company can borrow under The Mann Group Loan Arrangement to December 31, 2019, increase the aggregate borrowing amount under The Mann Group Loan Arrangement from $350.0 million to $370.0 million and provide that repayments or cancellations of principal under The Mann Group Loan Arrangement will not be available for reborrowing.

As of December 31, 2016, the total principal amount outstanding under The Mann Group Loan Arrangement was $49.5 million, and the amount available for future borrowings is $30.1 million. Interest, at a fixed rate of 5.84%, is due and payable quarterly in arrears on the first day of each calendar quarter for the preceding quarter, or at such other time as the Company and The Mann Group mutually agree. All or any portion of accrued and unpaid interest that becomes due and payable may be paid-in-kind and capitalized as additional borrowings at any time upon mutual agreement of the parties, and has been classified as non-current. The Mann Group can require the Company to prepay up to $200.0 million in advances that have been outstanding for at least 12 months, less approximately $105.0 million aggregate principal amount that has been cancelled in connection with two common stock purchase agreements. If The Mann Group exercises this right, the Company will have 90 days after The Mann Group provides written notice, or the number of days to maturity of the note if less than 90 days, to prepay such advances. However, pursuant to a letter agreement entered into in August 2010, The Mann Group has agreed to not require the Company to prepay amounts outstanding under the amended and restated promissory note if the prepayment would require the Company to use its working capital resources. In addition, The Mann Group entered into a subordination agreement with Deerfield pursuant to which The Mann Group agreed with Deerfield not to demand or accept any payment under The Mann Group Loan Arrangement until the Company’s payment obligations to Deerfield under the Facility Agreement have been satisfied in full. Subject to the foregoing, in the event of a default under The Mann Group Loan Arrangement, all unpaid principal and interest either becomes immediately due and payable or may be accelerated at The Mann Group LLC’s option, and the interest rate will increase to the one-year LIBOR rate calculated on the date of the initial advance or in effect on the date of default, whichever is greater, plus 5% per annum. All borrowings under The Mann Group Loan Arrangement are unsecured. The Mann Group Loan Arrangement contains no financial covenants.

As of December 31, 2016 and 2015, the Company had accrued and unpaid interest related to the above note of $9.3 million and $6.4 million, respectively, and had $30.1 million of available borrowings. Interest expense on the Company’s note payable to the Company’s principal stockholder for each of the years ended December 31, 2016, 2015 and 2014 was $2.9 million.

In May 2015, the Company entered into a sublease agreement with the Alfred Mann Foundation for Scientific Research (the “Mann Foundation”), a California Not-For-Profit Corporation. The lease is for approximately 12,500 square feet of office space in Valencia, California and expires in April 2017. The office space contains the Company’s principal executive offices. Lease payments to the Mann Foundation for the year ended December 31, 2016 and 2015 were $268,000 and $175,000, respectively. There were no lease payments to the Mann Foundation for the year ended December 31, 2014.

In connection with certain meetings of the Company’s board of directors and on other occasions when the Company’s business necessitated air travel for the Company’s principal stockholder and other Company employees, the Company utilized the principal stockholder’s private aircraft, and the Company paid the charter company that manages the aircraft on behalf of the Company’s principal stockholder approximately $18,000 and $79,000 for the years ended December 31, 2015 and 2014, respectively, on the basis of the corresponding cost of commercial airfare. There were no payments to the principal stockholder related to the usage of the aircraft during the year ended December 31, 2016.

The Company has entered into indemnification agreements with each of its directors and executive officers, in addition to the indemnification provided for in its amended and restated certificate of incorporation and amended and restated bylaws (see Note 13 — Commitments and Contingencies).

Borrowings

12 Months Ended

Dec. 31, 2016

Borrowings

7. Borrowings

Borrowings consist of the following (in thousands):


	December 31,
	2016			2015
Facility Financing Obligation (2019 Notes)
Principal amount	$	75,000		$	80,000
Unamortized debt discount		(3,661	)		(5,418	)

Net carrying amount	$	71,339		$	74,582

Senior Convertible Notes (2018 Notes)
Principal amount	$	27,690		$	27,690
Unamortized premium		426			660
Unaccreted debt issuance costs		(481	)		(737	)

Net carrying amount	$	27,635		$	27,613

Note payable to principal stockholder — net carrying amount	$	49,521		$	49,521

Facility Financing Obligation (2019 Notes) — As of December 31, 2016, there were $55.0 million principal amount of 2019 notes and $20.0 million principal amount of Tranche B notes outstanding. As of December 31, 2015, there were $60.0 million principal amount of 2019 notes and $20.0 million principal amount of Tranche B notes outstanding. The 2019 notes accrue interest at annual rate of 9.75% and the Tranche B notes accrue interest at an annual rate of 8.75%. Interest is paid quarterly in arrears on the last day of each March, June, September and December. The Facility Financing Obligation principal repayment schedule is comprised of annual payments beginning on July 1, 2016 and ending December 9, 2019. Future principal payments for the years ended December 31, 2017, 2018 and 2019 are $20.0 million, $20.0 million and $35.0 million, respectively.

In conjunction with the Facility Agreement, the Company entered into a Milestone Rights Agreement with Deerfield which requires the Company to make contingent payments to Deerfield, totaling up to $90.0 million, upon the Company achieving specified commercialization milestones. The Milestone Rights were initially recorded as a short-term liability equal to $3.2 million included in accrued expenses and other current liabilities in the accompanying consolidated balance sheets and a long-term liability equal to $13.1 million included in other liabilities. During the first quarter of 2015, a milestone triggering event was achieved following the Company’s product launch on February 3, 2015, which resulted in a $5.8 million incremental charge to interest expense due to the increase in carrying value of the liability to the required $10.0 million payment made in February of 2015. During the year ended December 31, 2014, the first milestone triggering event was achieved following the Company’s entry into the Sanofi License Agreement, which resulted in a $1.9 million incremental charge to interest expense due to the increase in carrying value of the liability to the required $5.0 million payment, which was paid to Deerfield pursuant to the terms of the Milestone Agreement. As of December 31, 2016 and 2015, the remaining liability balance of $8.9 million is classified as a long-term liability.

As of December 31, 2016, the unamortized debt discount and debt issuance costs were $3.7 million and $0.1 million, respectively.

Accretion of debt issuance cost and debt discount in connection with the Deerfield financing during the years ended December 31, 2016, 2015 and 2014 are as follows (in thousands):


	December 31,
	2016		2015		2014
Accretion expense — debt issuance cost	$	35	$	35	$	326
Accretion expense — debt discount	$	1,722	$	1,553	$	7,550

The Facility Agreement includes customary representations, warranties and covenants, including, a restriction on the incurrence of additional indebtedness, and a financial covenant which requires the Company’s cash and cash equivalents, which includes available borrowings on the note payable to principal stockholder, on the last day of each fiscal quarter to not be less than $25.0 million. As discussed in Note 1 — Description of Business, the Company will need to raise additional capital to support its current operating plans. Due to the uncertainties related to maintaining sufficient resources to comply with the aforementioned covenant, the 2019 notes and the Tranche B notes have been classified as current liabilities in the accompanying consolidated balance sheets as of December 31, 2016 and 2015. In the event of non-compliance, Deerfield may declare all or any portion of the 2019 notes and/or Tranche B notes to be immediately due and payable.

Milestone Rights — The Milestone Agreement includes customary representations and warranties and covenants by the Company, including restrictions on transfers of intellectual property related to Afrezza. The Milestone Rights are subject to acceleration in the event the Company transfers its intellectual property related to Afrezza in violation of the terms of the Milestone Agreement. The Company has initially recorded the Milestone Rights at their estimated fair value — See Note 2 — Summary of Significant Accounting Policies under Milestone Rights Liability.

In determining the fair value of the Milestone Rights, the 13 individual milestone payments were adjusted for both (i) the expected timing and (ii) the probability of achieving the milestones, and then discounted to present value using a discount rate of 14.5%. Once the initial valuation of each specified milestone payment was determined, the individual milestone payments were then aggregated to arrive at a total fair value of $18.4 million. The discount rate was based on the estimated cost of equity which was derived using the capital asset pricing model. In addition, a 5% risk premium was added to the computation of the cost of equity to adjust for non-systemic risk factors, such as the Company’s lack of product diversification and history of financial losses, which were not captured in other model inputs.

Security Agreement — In connection with the Facility Agreement, the Company and its subsidiary, MannKind LLC, entered into a Guaranty and Security Agreement (the “Security Agreement”) with Deerfield and Horizon Sante FLML SA’RL (collectively, the “Purchasers”), pursuant to which the Company and MannKind LLC each granted the Purchasers a security interest in substantially all of their respective assets, including respective intellectual property, accounts, receivables, equipment, general intangibles, inventory and investment property, and all of the proceeds and products of the foregoing. The Security Agreement includes customary covenants by the Company and MannKind LLC, remedies of the Purchasers and representations and warranties by the Company and MannKind LLC. The security interests granted by the Company and MannKind LLC will terminate upon repayment of the 2019 notes and Tranche B notes, if applicable, in full. The Company’s obligations under the Facility Agreement and the Milestone Agreement are also secured by the mortgage on the Company’s facilities in Danbury, Connecticut, which has a carrying value of $28.7 million.

Embedded Derivatives — The Company identified and evaluated a number of embedded features in the notes issued under the Facility Agreement to determine if they represented embedded derivatives that are required to be separated from the notes and accounted for as freestanding instruments. In 2014, the Company analyzed the Tranche B notes and identified embedded derivatives which required separate accounting. However, all of the embedded derivatives were determined to have a de minimis value at December 31, 2016 and 2015.

Conversion Option — During 2014, Deerfield elected to convert a total of $93.5 million of principal, which consisted of $20.0 million, $33.5 million, and $40.0 million of Tranche 1 notes, Tranche 2 notes, and Tranche 3 notes, respectively, into an aggregate 3,464,616 shares of common stock. In conjunction with the conversion by Deerfield, we recorded an aggregate expense of $6.4 million for the difference between the principal amount of the notes converted and their carrying amount (which included unamortized discount and debt issuance costs) which consisted of $1.2 million, $3.0 million, and $2.2 million related to the Tranche 1 notes, Tranche 2 notes, and Tranche 3 notes, respectively. Further, upon Deerfield converting $40.0 million of Tranche 3 notes and $20.0 million of Tranche 1 notes, Deerfield has reached the conversion limits (i.e., “Applicable Limits”) with respect to the Facility Agreement and therefore, no additional amount of the 2019 notes is convertible.

Issuance of new 5.75% Convertible Senior Subordinated Exchange Notes Due 2018 in Exchange for 2015 Notes — On July 28, 2015, the Company entered into privately-negotiated exchange agreements (the “Note Exchange Agreements”) with a select holder of the Company’s 5.75% Senior Convertible Notes due 2015 (the “2015 notes”), pursuant to which the Company agreed to issue $27.7 million aggregate principal amount of new 5.75% Convertible Senior Subordinated Exchange Notes due 2018 (the “2018 notes”) to such holders in exchange for the delivery to the Company of the same principal amount of 2015 notes. The 2018 notes were issued at the closing of the exchange on August 10, 2015. The Company analyzed this exchange and concluded that the exchange represents an extinguishment of the 2015 notes and a new issuance of 2018 notes and recorded such notes at fair value, which resulted in a premium of $0.7 million.

The 2018 notes are the Company’s general, unsecured, senior obligations, except that the 2018 notes were subordinated to the Sanofi Loan facility prior to the extinguishment of the facility on November 9, 2016. The 2018 notes rank equally in right of payment with the Company’s other unsecured senior debt. The 2018 notes bear interest at the rate of 5.75% per year on the principal amount, payable semiannually in arrears in cash on February 15 and August 15 of each year, beginning February 15, 2016, with interest accruing from August 15, 2015. The 2018 notes mature on August 15, 2018. Accrued interest related to these notes is recorded in accrued expenses and other current liabilities on the accompanying consolidated balance sheets.

The 2018 notes are convertible, at the option of the holder, at any time on or prior to the close of business on the business day immediately preceding the stated maturity date, into shares of the Company’s common stock at an initial conversion rate of 29 shares per $1,000 principal amount of the 2018 notes, which is equal to a conversion price of approximately $34.00 per share, the same conversion price as that of the 2015 notes on the date of exchange. The conversion rate is subject to adjustment under certain circumstances described in an indenture governing the 2018 notes dated August 10, 2015 with Wells Fargo, National Association, including in connection with a make-whole fundamental change.

If certain fundamental changes occur, the Company will be obligated to pay a fundamental change make-whole premium on any 2018 notes converted in connection with such fundamental change by increasing the conversion rate on such 2018 notes. In such instances, the amount of the fundamental change make-whole premium will be based on the Company’s common stock price and the effective date of the applicable fundamental change. If the Company undergoes certain fundamental changes, except in certain circumstances, each holder of 2018 notes will have the option to require the Company to repurchase all or any portion of that holder’s 2018 notes. The fundamental change repurchase price will be 100% of the principal amount of the 2018 notes to be repurchased plus accrued and unpaid interest, if any.

On or after the date that is one year following the original issue date of the 2018 notes, the Company will have the right to redeem for cash all or part of the 2018 notes if the last reported sale price of its common stock exceeds 130% of the conversion price then in effect for 20 or more trading days during the 30 consecutive trading day period ending on the trading day immediately prior to the date of the redemption notice. The redemption price will equal the sum of 100% of the principal amount of the 2018 notes to be redeemed, plus accrued and unpaid interest. Under the terms of the 2018 Note Indenture, the conversion option can be net-share settled and the maximum number of shares that could be required to be delivered under the indenture, including the make-whole shares, is fixed and less than the number of authorized and unissued shares less the maximum number of shares that could be required to be delivered during the term of the 2018 notes under existing commitments. Applying the Company’s sequencing policy, the Company performed an analysis at the time of the offering of the 2018 notes and each reporting date since and has concluded that the number of available authorized shares at the time of the offering and each subsequent reporting date was sufficient to deliver the number of shares that could be required to be delivered during the term of the 2018 notes under existing commitments.

The 2018 notes provide that upon an acceleration of certain indebtedness, including the 9.75% Senior Convertible Notes due in 2019 (the “2019 notes”) and the 8.75% Senior Convertible Notes due in 2019 (the “Tranche B notes”) issued to Deerfield pursuant to the Facility Agreement, the holders may elect to accelerate the Company’s repayment obligations under the notes if such acceleration is not cured, waived, rescinded or annulled. There can be no assurance that the holders would not choose to exercise these rights in the event such events were to occur.

The Company incurred approximately $0.8 million in issuance costs, which are recorded as an offset to the 2018 notes in the accompanying consolidated balance sheets. These costs are being accreted to interest expense using the effective interest method over the term of the 2018 notes.

Accretion of debt issuance expense in connection with the 2018 notes during the years ended December 31, 2016 and 2015 was $257,000 and $93,000, respectively. Amortization of the 2018 notes premium during the years ended December 31, 2016 and 2015 was $234,000 and $86,000, respectively.

Issuance of Common Stock in Exchange for the 2015 Notes — On July 28, 2015, the Company entered into separate, privately-negotiated exchange agreements (the “Stock-for-Note Exchange Agreements”) with certain holders of the 2015 notes pursuant to which the Company agreed to issue shares of its common stock to such holders in exchange for the delivery to the Company of up to $56.9 million aggregate principal amount of the 2015 notes.

Pursuant to the Stock-for-Note Exchange Agreements, the parties agreed to price the exchange transactions over a 10 trading day period spanning from July 29, 2015 to and including August 11, 2015. Between July 28, 2015 and August 10, 2015, the Company issued an aggregate of 380,000 shares of common stock to such holders in exchange for such holders’ delivery to the Company of $8.0 million aggregate principal amount of the 2015 notes, resulting in a weighted-average exchange price of $110.00 per share.

Issuance of New 5.75% Convertible Senior Subordinated Exchange Notes Due 2015 in Exchange for the 2015 Notes — On August 14, 2015, the Company exchanged $32.1 million aggregate principal amount of newly issued, 5.75% Convertible Senior Subordinated Exchange Notes due 2015 (the “Exchange Notes”) for the same principal amount of the Company’s previously outstanding 2015 notes. The Exchange Notes, payable at maturity on September 30, 2015, were convertible, at the option of each holder thereof, at any time on or prior to the close of business on the business day immediately preceding the stated maturity date. The holders of the Exchange Notes did not elect to convert any of the outstanding principal amount of the Exchange Notes into shares of the Company’s common stock. As a result, on September 30, 2015, the Company paid $32.1 million to settle the Exchange Notes.

Settlement of 2015 Notes and Exchange Notes — On August 17, 2015, the Company paid $32.2 million to settle the remaining 2015 notes. As of September 30, 2015, all 2015 notes, including the Exchange Notes, have been settled resulting in a total loss on extinguishment of debt equal to $1.0 million. The loss on extinguishment of debt resulted from the write-off of debt discount and debt issuance costs associated with the 2015 notes and Exchange Notes and the difference between the principal amounts being exchanged for shares of the Company’s common stock, pursuant to the various Stock-for-Note Exchange Agreements, and the fair market value of the Company’s common stock issued in exchange for such reduction in principal.

Accretion of debt issuance costs in connection with the 2015 notes during the years ended December 31, 2015 and 2014 was $0.6 million and $0.9 million, respectively.

Refer to Note 6 — Related-Party Arrangements for information regarding the Note payable to principal stockholder.

Collaboration Arrangements

12 Months Ended

Dec. 31, 2016

Collaboration Arrangements

8. Collaboration Arrangements

Receptor Collaboration and License Agreement — On January 20, 2016, the Company entered into a Collaboration and License Agreement (the “CLA”) with Receptor Life Sciences, Inc. (“Receptor”) pursuant to which the Company performed initial formulation studies on compounds identified by Receptor. Following successful completion of the studies, Receptor obtained the option to acquire an exclusive license to develop, manufacture and commercialize certain products that use MannKind’s technology to deliver the compounds via oral inhalation.

The Company received $0.4 million in nonrefundable payments in 2016 prior to Receptor exercising the option. On December 30, 2016, Receptor exercised the option and paid the Company a $1.0 million nonrefundable option exercise and license fee. Under the CLA, the Company may receive the following additional payments:

•

Nonrefundable milestone payments upon the completion of certain technology transfer activities and the achievement of specified sales targets.

•

Royalties upon Receptor’s and its sublicensee’s sale of the product.

•

Milestones upon total worldwide sales reaching certain agreed upon levels.

The Company evaluated the accounting for the payments received in 2016 under the multiple element accounting guidance and determined that the $0.4 million in payments received prior to Receptor exercising its option are separable from the other elements of the agreement and represented payments to offset costs incurred. Therefore, those payments reduced the Company’s research and development expense in 2016. The $1.0 million license fee received in 2016 does not have standalone value from the follow-on transfer of technology. Therefore, the license fee was recorded in deferred payments from collaboration at December 31, 2016 and will be recognized in net revenue — collaboration over four years. See Note 2 — Summary of Significant Accounting Policies for additional information on the Company’s accounting for multiple element arrangements.

Sanofi License Agreement and Sanofi Supply Agreement and Loan Facility — On August 11, 2014, the Company executed a license and collaboration agreement (the “Sanofi License Agreement”) with Sanofi-Aventis Deutschland GmbH (which subsequently assigned its rights and obligations under the agreement to Sanofi-Aventis U.S. LLC (Sanofi)), pursuant to which Sanofi was responsible for global commercial, regulatory and development activities for Afrezza. The Company manufactured Afrezza at its manufacturing facility in Danbury, Connecticut to supply Sanofi’s demand for the product pursuant to a supply agreement dated August 11, 2014 (the “Sanofi Supply Agreement”).

During the term of the Sanofi License Agreement, worldwide profits and losses were determined based on the difference between the net sales of Afrezza and the costs and expenses incurred by the Company and Sanofi that were specifically attributable or related to the development, regulatory filings, manufacturing, or commercialization of Afrezza. These profits and losses were shared 65% by Sanofi and 35% by the Company. On January 4, 2016 the Company received a 90-day notification from Sanofi of its election to terminate in its entirety the Sanofi License Agreement. The effective date of termination (the “Termination Date”) was April 4, 2016. On April 5, 2016 the Company assumed responsibility for the worldwide development and commercialization of Afrezza from Sanofi. Under the terms of the transition agreement, Sanofi continued to fulfill orders for Afrezza in the United States until the Company began distributing MannKind-branded Afrezza product to major wholesalers during the week of July 25, 2016.

The Company analyzed the agreements entered into with Sanofi at their inception to determine whether the consideration, paid or payable to the Company, or a portion thereof, could be recognized as revenue. Under the terms of the Sanofi License Agreement, the Sanofi Supply Agreement and the Sanofi Loan Facility, the Company determined that the arrangement contained significant deliverables including (i) licenses to develop and commercialize Afrezza and to use the Company’s trademarks, (ii) development activities, and (iii) manufacture and supply services for Afrezza. Due to the proprietary nature of the manufacturing services to be provided by the Company, the Company determined that all of the significant deliverables should be combined into a single unit of accounting. The Company believed that the manufacturing services are proprietary due to the fact that since the late 1990’s, the Company has developed proprietary knowledge and patented equipment and tools that are used in the manufacturing process of Afrezza. Due to the complexities of particle formulation and the specialized knowledge and equipment needed to handle the Afrezza powder, neither Sanofi nor, to the Company’s knowledge, any third-party contract manufacturing organization currently possesses the capability of manufacturing Afrezza.

In order for revenue to be recognized, the seller’s price to the buyer must be fixed or determinable. Prior to December 31, 2015, because the Company did not have the ability to estimate the amount of costs that would potentially be incurred under the loss share provision related to the Sanofi License Agreement and the Sanofi Supply Agreement, the Company believed this requirement for revenue recognition had not been met. Therefore, the Company had recorded the $150.0 million up-front payment and the two milestone payments of $25.0 million each as deferred payments from collaboration. In addition, as of December 31, 2015 the Company had recorded $17.5 million in Afrezza product shipments to Sanofi as deferred sales from collaboration and recorded $13.5 million as deferred costs from collaboration. Deferred costs from collaboration represented the costs of product manufactured and shipped to Sanofi, as well as certain direct costs associated with a firm purchase commitment entered into in connection with the collaboration with Sanofi.

In the first and second quarters of 2016, after the Company received notice of termination from Sanofi, the Company evaluated whether the revenue recognition criteria had been met. The Company determined that the requirement had not been met because Sanofi had not finalized necessary adjustments to the profit and loss share provision statements and Sanofi had not yet transferred all of the information to enable the Company to commercialize Afrezza on its own. Therefore, the Company was still unable to estimate the costs to be incurred under the agreement with Sanofi. During the three months ended September 30, 2016, Sanofi provided enough information to the Company to enable it to reasonably estimate the remaining costs under the Sanofi License Agreement and the Sanofi Supply Agreement. Accordingly, the fixed or determinable fee requirement for revenue recognition was met and there were no future obligations to Sanofi. Therefore, the Company recognized $172.0 million of net revenue — collaboration for the year ended December 31, 2016. The revenue recognized includes the upfront payment of $150.0 million and the two milestone payments of $25.0 million each, net of $64.9 million of net loss share with Sanofi, as well as $17.5 million in sales of Afrezza and $19.4 million from sales of bulk insulin, both to Sanofi. These payments and sales were made pursuant to the contractual terms of the agreements with Sanofi.

Sanofi Loan Facility — On September 23, 2014, the Company entered into the Sanofi Loan Facility, consisting of a senior secured revolving promissory note and a guaranty and security agreement (the “Security Agreement”) with an affiliate of Sanofi, which provided the Company with a secured loan facility of up to $175.0 million to fund the Company’s share of net losses under the Sanofi License Agreement.

The obligations of the Company under the Sanofi Loan Facility were guaranteed by the Company’s wholly-owned subsidiary, MannKind LLC, and were secured by a first priority security interest in certain insulin inventory located in the United States and any contractual rights and obligations pursuant to which the Company purchases or has purchased such insulin, and a second priority security interest in the Company’s assets that secure the Company’s obligations under the Facility Agreement, as amended. In addition, the Company granted to Sanofi, as additional security for the obligations under the Sanofi Loan Facility, a first priority mortgage on the Company’s facility in Valencia, California, which had a carrying value of $17.9 million as of December 31, 2015.

Advances under the Sanofi Loan Facility bore interest at a rate of 8.5% per annum and were payable in-kind and compounded quarterly and added to the outstanding principal balance under the Sanofi Loan Facility. The Company was required to make mandatory prepayments on the outstanding loans under the Sanofi Loan Facility from its share of any profits (as defined in the Sanofi License Agreement) under the Sanofi License Agreement within 30 days of receipt of its share of any such profits.

The Company’s total portion of the loss sharing was $57.7 million for the year ended December 31, 2015, of which $44.5 million was borrowed under the Sanofi Loan Facility as of December 31, 2015. Subsequent to December 31, 2015, the Company borrowed $17.9 million under the Sanofi Loan Facility to finance the portion of the Company’s loss for the quarter ended December 31, 2015. The total amount owed to Sanofi at December 31, 2015 was $62.4 million, which includes $1.7 million of paid-in-kind interest.

On November 9, 2016, the Company entered into a settlement agreement with Sanofi (the “Settlement Agreement”). Under the terms of the Settlement Agreement, the promissory note between the Company and Aventisub LLC (“Aventisub”), a Sanofi affiliate, was terminated, with Aventisub agreeing to forgive the full outstanding loan balance of $72.0 million. Sanofi also agreed to purchase $10.2 million of insulin from the Company in December 2016 under an existing insulin put option as well as make a cash payment of $30.6 million to the Company in early January 2017 as acceleration and in replacement of all other payments that Sanofi would otherwise have been required to make in the future pursuant to the insulin put option, without the Company being required to deliver any insulin for such payment. The Company was also relieved of its obligation to pay Sanofi $0.5 million in previously uncharged costs pursuant to the Sanofi License Agreement. The Company and Sanofi also agreed to a general release of potential claims against each other.

The forgiveness of the full outstanding loan balance on the Sanofi Loan Facility and the previously uncharged costs related to the collaboration were accounted for in (gain) loss on extinguishment of debt in the accompanying consolidated statements of operations. The $10.2 million sale of insulin was accounted for as net revenue — collaboration, consistent with the Company’ sales of insulin to Sanofi in the third quarter of 2016 (see Note 2 — Summary of Significant Accounting Policies — Revenue Recognition — Net Revenue — Collaboration). The $30.6 million accelerated put option payment was recognized as a receivable from Sanofi at December 31, 2016 and an increase in the recognized loss on purchase commitments as the purchase commitment obligation had previously been reduced to reflect the Company’s expectation that amounts associated with purchases of insulin were recoverable (see Note 2 — Summary of Significant Accounting Policies — Inventories).

Fair Value of Financial Instruments

12 Months Ended

Dec. 31, 2016

Fair Value of Financial Instruments

9. Fair Value of Financial Instruments

The carrying amounts reported in the accompanying consolidated financial statements for cash, accounts receivable, accounts payable and accrued expenses and other current liabilities approximate their fair value due to their relatively short maturities. The fair value of the cash equivalents, note payable to principal stockholder, senior convertible notes, the Facility Financing Obligation (as defined below), the Milestone Rights (as defined below) and warrant liability are discussed below.

Cash Equivalents — As of December 31, 2016 and 2015, the Company held $20.5 million and $55.8 million, respectively, of cash equivalents, consisting of money market funds. The fair value of these money market funds was determined by using quoted prices for identical investments in an active market (Level 1 in the fair value hierarchy).

Note Payable to Principal Stockholder — The fair value of the note payable to the Company’s principal stockholder cannot be reasonably estimated as the Company would not be able to obtain a similar credit arrangement in the current economic environment. Therefore, the fair value is based upon carrying value.

Financial Liabilities — The following tables set forth the fair value of the Company’s financial instruments (in millions):


	As of December 31, 2016
	Carrying Value		Level 1		Level 2		Level 3		Total
Financial liabilities:
Senior convertible notes	$	27.6	$	—	$	—	$	22.9	$	22.9
Facility Financing Obligation		71.3		—		—		74.5		74.5
Milestone Rights		8.9		—		—		18.4		18.4
Warrant liability (at recurring fair values)		7.4		—		—		7.4		7.4

Total financial liabilities	$	115.2	$	—	$	—	$	123.2	$	123.2


	As of December 31, 2015
	Carrying Value		Level 1		Level 2		Level 3		Total
Financial liabilities:
Senior convertible notes	$	27.6	$	—	$	—	$	21.3	$	21.3
Facility Financing Obligation		74.6		—		—		78.4		78.4
Milestone Rights		8.9		—		—		14.4		14.4
Sanofi Loan Facility		44.5		—		—		36.5		36.5

Total financial liabilities	$	155.6	$	—	$	—	$	150.6	$	150.6

The following table provides a roll forward of the fair values of financial assets and liabilities that are carried at fair value (in millions):


	Warrants			Assets Held for Sale
Fair value, January 1, 2015	$	—		$	—
Additions		—			—
Changes in fair value		—			—
Payments		—			—

Fair value, December 31, 2015	$	—		$	—

Additions		12.8			17.3
Changes in fair value		(5.4	)		(0.6	)
Payments		—			—

Fair value, December 31, 2016	$	7.4		$	16.7

Senior Convertible Notes — The estimated fair value of the 2018 notes was calculated based on model-derived valuations where inputs were observable, such as the Company’s stock price and yields on U.S. Treasury notes and actively traded bonds, and non-observable, such as the Company’s longer-term historical volatility, and estimated yields implied from any available market trades of the Company’s issued debt instruments. As there is no current active and observable market for the 2018 notes, the Company determined the estimated fair value using a convertible bond valuation model within a lattice framework. The convertible bond valuation model combined expected cash flows based on terms of the notes with market-based assumptions regarding risk-free rate, risk-adjusted yields (20%), stock price volatility (111%) and recent price quotes and trading information regarding Company issued debt instruments and shares of common stock into which the notes are convertible.

Facility Financing Obligation — As discussed in Note 7 — Borrowings, in connection with the Facility Agreement, the Company issued 2019 notes and subsequently issued Tranche B notes (the “Facility Financing Obligation”). As there is no current observable market for the Facility Financing Obligation, the Company determined the estimated fair value using a bond valuation model based on a discounted cash flow methodology. The bond valuation model combined expected cash flows associated with principal repayment and interest based on the contractual terms of the debt agreement discounted to present value using a selected market discount rate. On December 31, 2016 the market discount rate was recalculated at 12.0% for the Facility Financing Obligation. Under the terms of the Facility Agreement, the Company is restricted from distributing any of its assets or declaring and distributing a dividend to its stockholders.

Milestone Rights Liability — In addition to the Facility Financing Obligation, the Company also issued certain rights to receive payments of up to $90.0 million upon occurrence of specified strategic and sales milestones (the “Milestone Rights”). These rights are not reflected in the Facility Financing Obligation. The estimated fair value of the Milestone Rights was calculated using the income approach in which the cash flows associated with the specified contractual payments were adjusted for both the expected timing and the probability of achieving the milestones discounted to present value using a selected market discount rate (Level 3 in the fair value hierarchy). The expected timing and probability of achieving the milestones, starting in 2014, was developed with consideration given to both internal data, such as the Company’s forecast, progress made to date towards meeting the milestones, and assessment of criteria required for achievement, and external data, such as market research studies. The discount rate (14.5%) was selected based on an estimation of required rate of returns for similar investment opportunities using available market data. As of December 31, 2016, the carrying value of the Milestone Rights is $8.9 million, classified as a long-term liability and the fair value is estimated at $18.4 million.

Warrant Liability — Warrant liabilities are measured at fair value using a Monte Carlo pricing valuation model and various assumptions. The significant unobservable input used in measuring the fair value of the common stock warrant liabilities is the expected volatility. Significant increases in volatility would result in a higher fair value measurement (Level 3 in the fair value hierarchy). See Note 16 — Warrants for further discussion of the valuation technique and inputs used in the fair value measurement.

Sanofi Loan Facility — As discussed in Note 8 — Collaboration Arrangements, the Sanofi Loan Facility consisted of a senior secured revolving promissory note and a guaranty and security agreement with an affiliate of Sanofi which provided the Company with a secured loan facility of up to $175.0 million to fund the Company’s share of net losses under the Sanofi License Agreement. The estimated fair value was determined using a discounted cash flow model where time outstanding and discount rate were primary variables. This method considered the key elements of the contractual terms of the Sanofi Loan Facility, market-based estimated cost of capital, and time value of money, namely the amount of time to settlement and the estimated discount rate (11%) appropriate for the liability (Level 3 in the fair value hierarchy). The Sanofi Loan Facility was forgiven on November 9, 2016.

There were no transfers of assets or liabilities between the fair value measurement levels during the twelve months ended December 31, 2016, 2015 and 2014.

Assets and Liabilities Measured at Fair Value on a Non-recurring Basis — Land, buildings, and machinery and equipment, with a carrying amount of $189.2 million, were written down to a fair value of $48.8 million, resulting in an impairment charge of $140.4 million, which is included in our consolidated statements of operations for the year ended December 31, 2015. See Note 4- Property and Equipment for further discussion of the valuation technique and inputs used in the fair value measurement.

An additional impairment of $0.7 million was charged for the year ended December 31, 2016. At that time, an analysis of the lower of carrying value to fair value, which was deemed to be the sales price of the property, less selling costs determined a loss of $0.6 million, which is included in property and equipment impairment on the consolidated statement of operations for 2016.

Our assessment of the real property includes Level 3 inputs, and was based on a combination of the income, market and cost approaches and the market approach was used for machinery and equipment which required Level 3 inputs.

Embedded Derivatives — The Company identified and evaluated a number of embedded features in the notes issued under the Facility Agreement to determine if they represented embedded derivatives that are required to be separated from the notes and accounted for as freestanding instruments. The Company analyzed the Tranche B notes and identified embedded derivatives, which required separate accounting. However, all of the embedded derivatives were determined to have a de minimis value at December 31, 2016 and 2015.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Common and Preferred Stock

12 Months Ended

Dec. 31, 2016

Common and Preferred Stock

10. Common and Preferred Stock

On March 1, 2017, the Company effected a 1-for-5 reverse stock split of the Company’s outstanding common stock. As a result, all common stock share amounts included in these consolidated financial statements have been retroactively reduced by a factor of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the Company’s common stock par value. See Note 1 — Description of Business.

The Company is authorized to issue 140,000,000 shares of common stock, par value $0.05 per share, and 10,000,000 shares of undesignated preferred stock, par value $0.01 per share, issuable in one or more series as designated by the Company’s board of directors. No other class of capital stock is authorized. As of December 31, 2016 and 2015, 95,680,831 and 85,734,188 shares of common stock, respectively, were issued and outstanding and no shares of preferred stock were outstanding.

As more fully described in Note 16 — Warrants, in May 2016, the Company sold in a registered offering an aggregate of 9,708,737 shares of common stock together with certain warrants exercisable for up to an aggregate of 7,281,553 shares of common stock (“A Warrants”) and certain warrants exercisable for up to an aggregate of 2,427,184 shares of common stock (“B Warrants”) in a direct offering for proceeds of $50.0 million.

On November 9, 2015, the Company entered into a series of stock purchase agreements to sell up to an aggregate of 10,000,000 shares of its common stock in a registered direct offering to selected investment funds in Israel that hold securities included within certain stock indexes of the Tel Aviv Stock Exchange (the “TASE”). Pursuant to the agreements, the shares of common stock were sold at a price per share equal to 97% of the closing price of the Company’s common stock on the TASE on November 12, 2015. During November 2015, the Company sold 2,770,487 shares of common stock for an aggregate price of approximately $34,710,000, or $13.05 per share, which is net of $1,432,000 of issuance costs.

The Company engaged Sunrise Securities Corporation as its exclusive placement agent in connection with the offering of the 10,000,000 shares. In connection with the services provided, the Company issued to Sunrise Securities Corporation, or its designee, restricted warrants to purchase a number of shares of the Company’s common stock in an aggregate equal to 1.15% of the aggregate shares sold in the offering, which totaled 31,860 shares on November 16, 2015. The warrants are exercisable for a five year period at an exercise price of $13.05, the price paid per share in connection with the offering. The Company had an obligation to register the common stock that may be issued pursuant to the exercise of the warrants, which resulted in their initial classification as liability and were deemed immaterial. On December 15, 2015 the warrants were reclassified to equity as the Company registered the common stock pursuant to a registration statement and continue to be classified in equity as of December 31, 2016.

Included in the common stock outstanding as of December 31, 2014 is 1,800,000 shares of common stock loaned to Bank of America under a share lending agreement in connection with the offering of the $100.0 million aggregate principal amount of the 2015 notes. Bank of America was obligated to return the borrowed shares (or, in certain circumstances, the cash value thereof) to the Company on or about the 45th business day following the date as of which the entire principal amount of the 2015 notes ceases to be outstanding, subject to extension or acceleration in certain circumstances or early termination at Bank of America’s option. On October 23, 2015, the 1,800,000 shares of common stock loaned to Bank of America were returned, as the Company settled all payments and deliveries in respect of such convertible notes on August 17, 2015. The Company did not receive any proceeds from the sale of the borrowed shares by Bank of America, but the Company did receive a nominal lending fee of $0.05 per share from Bank of America for the use of borrowed shares.

On February 8, 2012, the Company sold 7,187,500 units in an underwritten public offering, including 937,500 units sold pursuant to the full exercise of an over-allotment option granted to the underwriters, with each unit consisting of one share of common stock and a warrant to purchase 0.1 of a share of common stock. All of the securities were offered by the Company at a combined price to the public of $12.00 per unit and the underwriters purchased the units at a price of $11.28 per unit. Net proceeds from this offering were approximately $80.6 million, excluding any warrant exercises. The 4,312,500 shares of common stock underlying the warrants are exercisable at $12.00 per share and expire four years from the date of the issuance.

For the years ended December 31, 2015 and 2014, the Company received $10.1 million and $27.8 million in proceeds, respectively, from the exercise of the February 2012 public offering warrants. There were no warrant exercises during the year ended December 31, 2016 and any unexercised February 2012 public offering warrants expired on February 8, 2016.

Net Income (Loss) per Common Share

12 Months Ended

Dec. 31, 2016

Net Income (Loss) per Common Share

11. Net Income (Loss) per Common Share

Basic net income (loss) per share excludes dilution for potentially dilutive securities and is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share reflects the potential dilution under the treasury method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. For periods where the Company has presented a net loss, potentially dilutive securities are excluded from the computation of diluted net loss per share as they would be antidilutive. During 2015, 1,800,000 shares of the Company’s common stock, which were loaned to Bank of America pursuant to the terms of a share lending agreement, were issued and outstanding, with the holder of the borrowed shares having all the rights of a holder of the Company’s common stock. As the share borrower was required to return all borrowed shares to the Company, the borrowed shares were not considered outstanding for the purpose of computing and reporting basic or diluted loss per share during the period presented for 2015. These shares were returned to the Company in the third quarter of 2015.

The following tables summarize the components of the basic and diluted net income (loss) per common share computations:


	Year Ended December 31,
	2016		2015			2014
	(In thousands, except per share data)
Basic EPS:
Net income (loss) (numerator)	$	125,664	$	(368,445	)	$	(198,382	)

Weighted average common shares (denominator)		92,053		81,233			77,045

Net income (loss) per share	$	1.37	$	(4.54	)	$	(2.57	)

Diluted EPS:
Net income (loss) (numerator)	$	125,664	$	(368,445	)	$	(198,382	)

Weighted average common shares		92,053		81,233			77,045
Effect of dilutive securities — common shares issuable		32		—			—

Adjusted weighted average common shares (denominator)		92,085		81,233			77,045

Net income (loss) per share	$	1.36	$	(4.54	)	$	(2.57	)

Common shares issuable represents incremental shares of common stock which consist of stock options, restricted stock units, warrants, and shares that could be issued upon conversion of the senior convertible notes.

Potentially dilutive securities outstanding that are considered antidilutive are summarized as follows (in shares):


	December 31,
	2016		2015		2014
Exercise of common stock options		5,530,256		3,955,845		4,308,332
Conversion of senior convertible notes into common stock		814,561		814,561		3,464,616
Exercise of common stock warrants		9,740,597		814,919		1,997,575
Vesting of restricted stock units		702,867		360,924		522,144

		16,788,281		5,946,249		10,292,667

Stock Award Plans

12 Months Ended

Dec. 31, 2016

Stock Award Plans

12. Stock Award Plans

On May 23, 2013, the Company adopted the 2013 Equity Incentive Plan (the “2013 Plan”) as the successor to and continuation of the 2004 Equity Incentive Plan (the “2004 Plan”). The 2013 Plan consists of 4.3 million additional shares and the number of unallocated shares remaining available for grant for new awards under the 2004 Plan. The 2013 Plan provides for the granting of stock awards including stock options and restricted stock units, to employees, directors and consultants. The 2013 Plan also provides for the automatic, non-discretionary grant of options to the Company’s non-employee directors. No additional awards will be granted under the 2004 Plan or under the 2004 Non-Employee Directors’ Stock Option Plan (the “NED Plan”) as all future awards will be made out of the 2013 Plan.

The following table summarizes information about the Company’s stock-based award plans as of December 31, 2016:


	Outstanding Options		Outstanding Restricted Stock Units		Shares Available for Future Issuance
2004 Equity Incentive Plan		2,052,345		14,203		97,574
2013 Equity Incentive Plan		3,399,245		723,763		3,743,013
2004 Non-Employee Directors’ Stock Option Plan		78,666		—		—

Total		5,530,256		737,966		3,840,587

In March 2004, as part of the 2004 Plan, the Company’s board of directors approved the Employee Stock Purchase Plan (“ESPP”), which became effective upon the closing of the Company’s initial public offering. Initially, the aggregate number of shares that could be sold under the 2004 Plan was 400,000 shares of common stock. On January 1 of each year, for a period of ten years beginning January 1, 2005, the share reserve automatically increased by the lesser of: 140,000 shares, 1% of the total number of shares of common stock outstanding on that date, or an amount as may be determined by the board of directors. However, under no event can the annual increase cause the total number of shares reserved under the ESPP to exceed 10% of the total number of shares of capital stock outstanding on December 31 of the prior year. On January 1, 2013 and 2014 the ESPP share reserve was increased each year by 140,000 shares. There was no ESPP share reserve increases during 2015 or 2016. As of December 31, 2016, 445,782 shares were available for issuance under the ESPP. For the years ended December 31, 2016, 2015 and 2014, the Company sold 104,758, 64,245 and 61,015 shares, respectively, of its common stock to employees participating in the ESPP. The ESPP purchase of 43,672 shares for the period ending December 31, 2016 was initiated prior to year-end but did not settle until January 5, 2017. As a result, the shares sold are reflected in the ESPP share reserves but are excluded from common stock outstanding as of December 31, 2016.

The Company’s board of directors determines eligibility, vesting schedules and criteria and exercise prices for stock awards granted under the 2013 Plan. Options and restricted stock unit awards under the 2013 Plan expire not more than ten years from the date of the grant and are exercisable upon vesting. Stock options that vest over time generally vest over four years. Current time-based vesting stock option grants vest and become exercisable at the rate of 25% after one year and ratably on a monthly basis over a period of 36 months thereafter. Restricted stock units with time-based vesting generally vest at a rate of 25% per year over four years with consideration satisfied by service to the Company. The Company also issues stock awards with performance conditions. The 2013 Plan provides for full acceleration of vesting if an employee is terminated within three months of a change in control, as defined in the 2013 Plan.

Share-based payment transactions are recognized as compensation cost based on the fair value of the instrument on the date of grant. The Company accounts for non-employee stock-based compensation expense based on the estimated fair value of the options, which is determined using the Black-Scholes option valuation model and amortizes such expense on a straight-line basis over the service period for time-based awards and over the expected dates of achievement for performance-based awards. These awards are subject to re-measurement until service is complete. As of December 31, 2016, there were options to purchase 100,697 shares of common stock outstanding to consultants.

During the years ended December 31, 2016, 2015 and 2014 the Company recorded stock-based compensation expense of $5.1 million, $8.7 million and $48.6 million, respectively.

Total stock-based compensation expense recognized in the accompanying consolidated statements of operations is as follows (in thousands):


	Year Ended December 31,
	2016		2015		2014
Employee-related	$	5,135	$	8,407	$	48,622
Consultant-related		—		318		—

Total	$	5,135	$	8,725	$	48,622

Total stock-based compensation expense recognized in the accompanying consolidated statements of operations is included in the following categories (in thousands):


	Year Ended December 31,
	2016		2015		2014
Cost of goods sold	$	695	$	—	$	—
Research and development		1,309		3,029		22,357
Selling, general and administrative		3,131		5,696		26,265

Total	$	5,135	$	8,725	$	48,622

The Company uses the Black-Scholes option valuation model to estimate the grant date fair value of employee stock options. The expected term of an option granted is based on combining historical exercise data with expected weighted time outstanding. Expected weighted time outstanding is calculated by assuming the settlement of outstanding awards is at the midpoint between the remaining weighted average vesting date and the expiration date.

The expected volatility assumption is based on an assessment of the historical volatility, with consideration of implied volatility, derived from an analysis of historical trade activity. The Company has selected risk-free interest rates based on U.S. Treasury securities with an equivalent expected term in effect on the date the options were granted. Additionally, the Company uses historical data and management judgment to estimate stock option exercise behavior and employee turnover rates to estimate the number of stock option awards that will eventually vest. The Company calculated the fair value of employee stock options granted during the years ended December 31, 2016, 2015 and 2014 using the following assumptions:


	Year Ended December 31,
	2016	2015	2014
Risk-free interest rate	1.18% — 1.80%	1.61% —1.86%	1.64% — 2.11%
Expected lives	5.13 — 5.82 years	5.79 — 5.86 years	5.77 — 6.09 years
Volatility	77.57% — 82.75%	69.76% — 71.84%	73.98% — 84.85%
Dividends	—	—	—

The following table summarizes information about stock options outstanding:


	Number of Shares			Weighted Average Exercise Price per Share		Aggregate Intrinsic Value ($000)
Outstanding at January 1, 2016		3,955,845		$	22.70	$	—
Granted		2,236,693			4.50
Exercised		(55,231	)		8.45
Forfeited		(407,161	)		13.60
Expired		(199,890	)		23.65

Outstanding at December 31, 2016		5,530,256		$	16.10	$	2
Vested and expected to vest at December 31, 2016		5,399,777		$	16.35	$	2
Exercisable at December 31, 2016		3,414,586		$	22.50	$	—

The weighted average grant date fair value of the stock options granted during the years ended December 31, 2016, 2015 and 2014 was $3.05, $12.80 and $23.80 per option, respectively. The total intrinsic value of options exercised during the years ended December 31, 2016, 2015 and 2014 was $0.1 million, $6.2 million and $14.9 million, respectively. Intrinsic value is measured using the fair market value at the date of exercise for options exercised or at December 31 for outstanding options, less the applicable exercise price.

Cash received from the exercise of options during the years ended December 31, 2016, 2015 and 2014 was approximately $0.5 million, $3.3 million and $11.0 million, respectively. The weighted-average remaining contractual terms for options outstanding, vested and expected to vest and exercisable at December 31, 2016 was 5.31 years, 5.22 years and 2.93 years, respectively.

A summary of restricted stock unit activity for the year ended December 31, 2016 is presented below:


	Number of Shares			Weighted Average Grant Date Fair Value per Share
Outstanding at January 1, 2016		360,924		$	24.25
Granted		800,530			4.50
Vested		(131,000	)		21.70
Forfeited		(292,488	)		11.60

Outstanding at December 31, 2016		737,966		$	8.40

The total restricted stock units expected to vest as of December 31, 2016 was 629,424 with a weighted average grant date fair value of $8.60 per share. The total intrinsic value of restricted stock units expected to vest as of December 31, 2016 was $2.0 million. Intrinsic value of restricted stock units expected to vest is measured using the closing share price at December 31, 2016.

Total intrinsic value of restricted stock units vested during the years ended December 31, 2016, 2015 and 2014 was $0.6 million, $5.2 million and $62.7 million, respectively. Intrinsic value of restricted stock units vested is measured using the closing share price on the day prior to the vest date. The total grant date fair value of restricted stock units vested during the years ended December 31, 2016, 2015 and 2014 was $2.6 million, $5.5 million and $36.4 million, respectively.

As of December 31, 2016, there was $4.0 million and $4.8 million of unrecognized compensation expense related to options and restricted stock units with performance conditions, respectively, which is expected to be recognized over the weighted average vesting period of 2.9 years. The Company evaluates stock awards with performance conditions as to the probability that the performance conditions will be met and uses that information to estimate the date at which those performance conditions will be met in order to properly recognize stock-based compensation expense over the requisite service period.

As of December 31, 2016, the Company reviewed the probability of achieving the performance conditions for each of the four vesting tranches of the performance-based stock options and determined that it was probable that the Company would achieve the first vesting tranche in December 2017. Therefore, the Company recorded a non-material cumulative catchup of the expense from the grant date through December 31, 2016 and will record the unrecognized compensation cost related to the first tranche in the amount of $0.3 million through December 31, 2017. The Company further determined that no compensation costs would be recognized for the second, third and fourth vesting tranches as it had not been determined that it was probable that the performance conditions related to these tranches would be achieved.

During the year ended December 31, 2015, there was $1.6 million of stock compensation expense related to certain executives who entered into severance agreements which resulted in a modification to the terms of their awards. The severance agreements generally allowed for the separated executives to continue to vest under their original award terms for a stated period of time without providing substantive services. There were no modifications in 2016.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies

13. Commitments and Contingencies

Operating Leases — The Company leases its executive offices in Valencia, California and certain equipment under various operating leases, which expire at various dates through 2017 and beyond. Future payments are insignificant.

Rent expense under all operating leases, including office space and equipment, for the years ended December 31, 2016, 2015 and 2014 was approximately $373,000, $426,000 and $737,000, respectively.

Guarantees and Indemnifications — In the ordinary course of its business, the Company makes certain indemnities, commitments and guarantees under which it may be required to make payments in relation to certain transactions. The Company, as permitted under Delaware law and in accordance with its Bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal. The Company has not recorded any liability for these indemnities in the accompanying consolidated balance sheets. However, the Company accrues for losses for any known contingent liability, including those that may arise from indemnification provisions, when future payment is probable and the amount can be reasonably estimated. No such losses have been recorded to date.

Litigation — The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. As of December 31, 2016, the Company believes that the final disposition of such matters will not have a material adverse effect on the consolidated financial position, results of operations or cash flows of the Company and no accrual has been recorded. The Company maintains liability insurance coverage to protect the Company’s assets from losses arising out of or involving activities associated with ongoing and normal business operations. The Company records a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company’s policy is to accrue for legal expenses in connection with legal proceeding and claims as they are incurred.

Following the public announcement of Sanofi’s election to terminate the Sanofi License Agreement and the subsequent decline of the price of its common stock, several complaints were filed in the U.S. District Court for the Central District of California against the Company and certain of its officers and directors on behalf of certain purchasers of its common stock, which were consolidated into a single action. The amended complaint alleged that the Company and certain of its officers and directors violated federal securities laws by making materially false and misleading statements regarding the prospects for Afrezza, thereby artificially inflating the price of its common stock. The Company and the named defendants brought a motion to dismiss the class action that was pending against them, which the District Court granted in August 2016 without leave to amend the complaint. The lead plaintiff appealed that decision to the Ninth Circuit Court of Appeals. On March 2, 2017, the lead plaintiff filed a voluntary motion to dismiss his appeal, which the Court of Appeals granted on March 9, 2017.

Following the public announcement of Sanofi’s election to terminate the Sanofi License Agreement and the subsequent decline of the price of its common stock, two motions were submitted to the District Court at Tel Aviv, Economic Department for the certification of a class action against the Company and certain of its officers and directors. In general, the complaints allege that the Company and certain of its officers and directors violated Israeli and U.S. securities laws by making materially false and misleading statements regarding the prospects for Afrezza, thereby artificially inflating the price of its common stock. The plaintiffs are seeking monetary damages. In November 2016, the district court dismissed one of the actions without prejudice. In the remaining action, a hearing is scheduled for May 2017 to determine whether Israeli or U.S. law is applicable before the case can be certified as a class action. The Company will vigorously defend against these claims.

Subsequent to the filing of the federal securities class action against the Company, two shareholder derivative complaints were filed in the Superior Court for the State of California, County of Los Angeles against certain of the Company’s directors and officers. The complaints allege breaches of fiduciary duties by the defendants and other violations of law. Among other allegations, the complaints allege that the defendants caused the Company to make false and misleading statements or omissions of material fact regarding the Company’s business and the prospects for sales of Afrezza, thereby artificially inflating the price of the Company’s common stock. Following the dismissal of the federal securities class action, each derivative complaint was voluntarily dismissed by its plaintiff.

Contingencies — In connection with the Facility Agreement, on July 1, 2013 the Company also entered into a Milestone Rights Purchase Agreement (the “Milestone Agreement”) with Deerfield Private Design Fund and Horizon Santé FLML SÁRL (collectively, the “Milestone Purchasers”), pursuant to which the Company sold the Milestone Purchasers the Milestone Rights to receive payments up to $90.0 million upon the occurrence of specified strategic and sales milestones, including the first commercial sale of an Afrezza product in the United States and the achievement of specified net sales figures (see Note 7 — Borrowings).

Commitment — On July 31, 2014, the Company entered into a supply agreement (the “Insulin Supply Agreement”) with Amphastar France Pharmaceuticals S.A.S., a French corporation (Amphastar), pursuant to which Amphastar will manufacture for and supply to the Company certain quantities of recombinant human insulin for use in Afrezza. Under the terms of the Insulin Supply Agreement, Amphastar will be responsible for manufacturing the insulin in accordance with the Company’s specifications and agreed-upon quality standards. The Company had agreed to purchase annual minimum quantities of insulin for calendar years 2015 through 2019 under the Insulin Supply Agreement of an aggregate total of approximately €120.1 million. The Company could have requested to purchase additional quantities of insulin over such annual minimum quantities with a cancellation fee.

On November 9, 2016, the supply agreement with Amphastar was amended to extend the term over which the Company is required to purchase insulin, without reducing the total amount of insulin to be purchased. Under the amendment, annual minimum quantities of insulin to be purchased for calendar years 2017 through 2023 total an aggregate purchase price of €93.0 million at December 31, 2016. The Insulin Supply Agreement specifies that Amphastar will be deemed to have satisfied its obligations with respect to quantity, if the actual quantity supplied is within plus or minus ten percent (+/- 10%) of the quantity set forth in the applicable purchase order. In addition, the aggregate cancellation fees that the Company would incur in the event that the above insulin quantities are not purchased was lowered from $5.3 million for the period October 1, 2016 through 2018 to $3.4 million over the same period. The annual purchase requirements under the contract are as follows:


2017	€	2.7 million
2018	€	8.9 million
2019	€	11.6 million
2020	€	15.5 million
2021	€	15.5 million
2022	€	19.4 million
2023	€	19.4 million

Unless earlier terminated, the term of the Insulin Supply Agreement expires on December 31, 2023 and can be renewed for additional, successive two year terms upon 12 months’ written notice given prior to the end of the initial term or any additional two year term. The Company and Amphastar each have normal and customary termination rights, including termination for material breach that is not cured within a specific time frame or in the event of liquidation, bankruptcy or insolvency of the other party. In addition, the Company may terminate the Insulin Supply Agreement upon two years’ prior written notice to Amphastar without cause or upon 30 days’ prior written notice to Amphastar if a controlling regulatory authority withdraws approval for Afrezza, provided, however, in the event of a termination pursuant to either of the latter two scenarios, the provisions of the Insulin Supply Agreement require the Company to pay the full amount of all unpaid purchase commitments due over the initial term within 60 calendar days of the effective date of such termination.

The Company also has another firm commitment with another supplier for an aggregate of $0.9 million.

Employee Benefit Plans	12 Months Ended
Employee Benefit Plans	Dec. 31, 2016
Employee Benefit Plans	14. Employee Benefit Plans The Company administers a 401(k) savings retirement plan (the “MannKind Retirement Plan”) for its employees. For the years ended December 31, 2016, 2015 and 2014, the Company contributed $418,000, $593,000 and $623,000, respectively, to the MannKind Retirement Plan.

Income Taxes

12 Months Ended

Dec. 31, 2016

Income Taxes

15. Income Taxes

At December 31, 2016, the Company has concluded that it is more likely than not that the Company may not realize the benefit of its deferred tax assets due to its history of losses. There is no provision for income taxes in 2015 or 2014 because the Company had incurred operating losses since inception. Accordingly, the net deferred tax assets have been fully reserved. The provision for income taxes consists of the following (in thousands):


	Year Ended December 31,
	2016			2015			2014
Current
U.S. federal	$	—		$	—		$	—
U.S. state		—			—			—
Non-U.S.		—			—			—

Total current		—			—			—

Deferred
U.S. federal		(43,814	)		109,512			57,873
U.S. state		(4,311	)		(29,394	)		7,631
Non-U.S.		—			—			—

Total deferred		(48,125	)		80,118			65,504

Valuation allowance		48,125			(80,118	)		(65,504	)

Total	$	—		$	—		$	—

Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes. A valuation allowance is established when uncertainty exists as to whether all or a portion of the net deferred tax assets will be realized. Components of the net deferred tax assets as of December 31, 2016 and 2015, are as follows (in thousands):


	December 31,
	2016			2015
Deferred tax assets:
Net operating loss carryforwards	$	712,124		$	721,588
Research and development credits		77,998			73,646
Capitalized research		5,117			5,872
Payments from collaboration		—			52,484
Milestone Rights		3,242			3,242
Accrued expenses		440			251
Loss on purchase commitment		36,775			24,084
Non-qualified stock option expense		17,331			16,941
Capitalized patent costs		8,781			8,574
Other		7,380			7,186
Depreciation		45,310			48,755

Total net deferred tax assets		914,498			962,623
Valuation allowance		(914,498	)		(962,623	)

Net deferred tax assets	$	—		$	—

The table of deferred tax assets and liabilities does not include certain deferred tax assets as of December 31, 2016, that arose directly from tax deductions related to equity compensation which are greater than the compensation recognized for financial reporting. Equity would be increased by $11.6 million if and when such deferred tax assets are ultimately realized. The Company considers certain realization requirements when excess tax benefits have been realized.

The Company’s effective income tax rate differs from the statutory federal income tax rate as follows for the years ended December 31, 2016, 2015 and 2014:


	December 31,
	2016			2015			2014
Federal tax benefit rate		35.0	%		35.0	%		35.0	%
Permanent items		(1.9	)		—			0.9
Intercompany transfer of intellectual property		0.9			(1.0	)		(4.1	)
Valuation allowance		(34.0	)		(34.0	)		(31.8	)

Effective income tax rate		—	%		—	%		—	%

Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Management has concluded, in accordance with the applicable accounting standards, that it is more likely than not that the Company may not realize the benefit of its deferred tax assets. Accordingly, the net deferred tax assets have been fully reserved. Management reevaluates the positive and negative evidence on an annual basis. During the years ended December 31, 2016, 2015 and 2014, the change in the valuation allowance was $(48.1) million, $80.1 million and $65.5 million, respectively, for income taxes.

At December 31, 2016, the Company had federal and state net operating loss carryforwards of approximately $1.9 billion and $1.3 billion available, respectively, to reduce future taxable income. The federal net operating loss carryforwards will expire at various dates beginning in 2018 and the state net operating loss carryforwards have started expiring, starting in the current year through various future dates. As a result of the Company’s initial public offering, an ownership change within the meaning of Internal Revenue Code Section 382 occurred in August 2004. As a result, federal net operating loss and credit carry forwards of approximately $216.0 million are subject to an annual use limitation of approximately $13.0 million. The annual limitation is cumulative and therefore, if not fully utilized in a year can be utilized in future years in addition to the Section 382 limitation for those years. The federal net operating losses generated subsequent to the Company’s initial public offering in August 2004 are currently not subject to any such limitation as there have been no ownership changes since August 2004 within the meaning of Internal Revenue Code Section 382. At December 31, 2016, the Company had research and development credits of $53.0 million and $38.5 million for federal and state purposes, respectively. The federal credits begin to expire in 2024, and the state credits may be carried forward indefinitely.

The Company has evaluated the impact of uncertainty related to income taxes on its consolidated financial statements. The evaluation of an uncertain tax position is a two-step process. The first step is recognition: the enterprise determines whether it is more-likely-than-not that a tax position will be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. In evaluating whether a tax position has met the more-likely-than-not recognition threshold, the enterprise should presume that the position will be examined by the appropriate taxing authority that would have full knowledge of all relevant information. The second step is measurement: a tax position that meets the more-likely-than-not recognition threshold is measured to determine the amount of benefit to recognize in the financial statements. The tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not recognition threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its consolidated financial position. Therefore, no liabilities for uncertain income tax positions have been recorded. Tax years since 2012 remain subject to examination by the major tax jurisdictions in which the Company is subject to tax.

Warrants

12 Months Ended

Dec. 31, 2016

Warrants

16. Warrants

In May 2016, the Company sold in a registered offering an aggregate of 9,708,737 shares of common stock together with A Warrants exercisable for up to an aggregate of 7,281,553 shares of common stock and B Warrants exercisable for up to an aggregate of 2,427,184 shares of common stock with a total fair value of $44.7 million. Each of the warrants has an exercise price of $7.50 per share. The A Warrants became exercisable upon issuance and will expire two years thereafter. The B Warrants will become exercisable beginning in May 2017 and will expire 30 months after the date of issuance. The shares of common stock and the warrants are immediately separable and issued separately. There have been no warrants exercised as of December 31, 2016.

The Company determined that the A Warrants require liability classification primarily due to a price-protection clause that applies in the event of certain dilutive financings. The fair value of the A Warrants was recorded as warrant liability in the consolidated balance sheet at issuance and is adjusted to fair value at each reporting period until exercise or expiration. The Company determined that the B Warrants met the criteria for equity classification and has accounted for such warrants in additional paid in capital.

As of December 31, 2016 and May 12, 2016, the fair value of the A Warrants liability was $7.4 million and $12.8 million, respectively. As of May 12, 2016, the fair value of the B Warrants at issuance was $5.0 million. The fair value of the A Warrants liability as of December 31, 2016 was estimated using a Monte Carlo valuation pricing model with the following underlying assumptions: (a) a risk-free interest rate of 1.1%; (b) an assumed dividend yield of zero percent; (c) an expected term of 1.4 years; and (d) an expected volatility of 118%. The fair value of the A Warrants liability as of May 12, 2016, was estimated using a Monte Carlo valuation pricing model with the following underlying assumptions: (a) a risk-free interest rate of 0.76%; (b) an assumed dividend yield of zero percent; (c) an expected term of 2.0 years; and (d) an expected volatility of 95%. The Company assumed a probability of a dilutive financing event or an equity event, as defined in the agreement, of 10% for the each of the measurement periods.

For the year ended December 31, 2016, the Company recognized a change in fair value of warrant liability of $5.4 million in the consolidated statements of operations to reflect the fair value adjustments of the A Warrant liability from the date of issuance.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Selling, General and Administrative Expenses

12 Months Ended

Dec. 31, 2016

Selling, General and Administrative Expenses

17. Selling, General and Administrative Expenses

Selling, general and administrative expenses consist of the following (in thousands):


	Year Ended December 31,
	2016		2015		2014
Selling and marketing	$	19,854	$	1,587	$	3,556
General and administrative		27,074		39,373		75,827

Total selling, general and administrative	$	46,928	$	40,960	$	79,383

Restructuring Charges

12 Months Ended

Dec. 31, 2016

Restructuring Charges

18. Restructuring Charges

In September 2016, the Company initiated a restructuring of its organization in order to conserve resources for commercial sales and marketing of Afrezza and to align cost of goods sold in support of these commercial efforts (2016 Restructuring). In connection with the 2016 Restructuring, the Company reduced its total workforce by approximately 18% to 155 employees. The Company recorded charges of approximately $1.5 million, primarily for employee severance as well as other related termination benefits. The $1.5 million of costs associated with the 2016 Restructuring are included in cost of goods sold, research and development and selling, general and administrative in the consolidated statements of operations as $0.4 million, $0.7 million and $0.4 million, respectively, for the year ended December 31, 2016. The Company substantially paid out the obligation for the 2016 Restructuring in the fourth quarter of 2016, resulting in a remaining accrual balance for the 2016 Restructuring of $0.2 million at December 31, 2016. The Company expects to substantially pay out the remainder of this obligation by the first quarter of 2017.

In 2015, the Company initiated a restructuring of the organization as a result of its shift to commercial production of Afrezza (“2015 Restructuring”). In connection with the 2015 Restructuring, the Company reduced its total workforce by approximately 26% to 198 employees. The Company recorded charges of approximately $6.0 million, primarily for employee severance as well as other related termination benefits. The $6.0 million of costs associated with the 2015 Restructuring are included in operating expenses for cost of goods sold, research and development and selling, general and administrative in the consolidated statements of operations as $1.4 million, $1.3 million and $3.3 million, respectively, for the year ended December 31, 2015. As of December 31, 2016 and 2015, the Company had a remaining accrual balance for the 2015 Restructuring of $1.2 million and $3.0 million, respectively. Certain of the severance arrangements for executives in the 2015 Restructuring were long-term, which the Company expects to substantially pay out the remainder of this obligation by the third quarter of 2017.

A reconciliation of beginning and ending liability balances for the 2016 and 2015 Restructuring charges, which is included in accrued expenses and other current liabilities, is as follows (in thousands):


Description	2016 Restructuring			2015 Restructuring			Total
Accrual — January 1, 2015	$	—		$	—		$	—
Costs incurred and charged to expense		—			6,040			6,040
Costs paid or settled		—			(3,012	)		(3,012	)

Accrual — December 31, 2015		—			3,028			3,028
Costs incurred and charged to expense		1,475			560			2,035
Costs paid or settled		(1,266	)		(2,421	)		(3,687	)

Accrual — December 31, 2016	$	209		$	1,167		$	1,376

Selected quarterly financial data (unaudited)

12 Months Ended

Dec. 31, 2016

Selected quarterly financial data (unaudited)

19. Selected quarterly financial data (unaudited)

Summarized quarterly financial data for the years ended December 31, 2016 and 2015, are set forth in the following tables:


	March 31			June 30			September 30			December 31
	(In thousands, except per share data)
2016
Net revenues	$	—		$	—		$	162,354		$	12,404

Net income (loss)	$	(24,873	)	$	(29,959	)	$	126,520			53,976

Net income (loss) per share — basic	$	(0.29	)	$	(0.33	)	$	1.32		$	0.56

Net income (loss) per share — diluted	$	(0.29	)	$	(0.33	)	$	1.31		$	0.56

Weighted average common shares used to compute basic net income (loss) per share		85,771			91,061			95,627			95,676

Weighted average common shares used to compute diluted net income (loss) per share		85,771			91,061			96,548			96,510

2015
Net loss	$	(30,658	)	$	(28,910	)	$	(31,857	)	$	(277,020	)

Net loss per share — basic and diluted	$	(0.38	)	$	(0.36	)	$	(0.39	)	$	(3.30	)

Weighted average common shares used to compute basic and diluted net loss per share		79,783			80,203			81,039			83,862

Impairment charges of $242.7 million were recorded in the fourth quarter of 2015 related to long-lived assets, inventory and loss on purchase commitments.

In the third quarter of 2016, the Company recognized net revenue-collaboration of $161.8 million attributable to collaboration with Sanofi (See Note 8 — Collaboration Arrangements).

In the fourth quarter of 2016, the Company recognized net revenue-collaboration of $10.2 million attributable to collaboration with Sanofi and $72.0 million gain on extinguishment of debt (See Note 8 — Collaboration Arrangements)

Subsequent Events

12 Months Ended

Dec. 31, 2016

Subsequent Events

20. Subsequent Events

Reverse Stock Split — On September 14, 2016, NASDAQ notified the Company that the bid price of the Company’s common stock had closed below the required $1.00 per share for 30 consecutive trading days, and, accordingly, the Company did not comply with the applicable NASDAQ minimum bid price requirement. The Company was provided 180 calendar days by NASDAQ, or until March 13, 2017, to regain compliance with this requirement.

On March 1, 2017, the Company held a Special Meeting of Stockholders at which the Company’s stockholders approved a proposal to amend the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock at a ratio to be determined in the discretion of the Company’s board of directors and with such reverse stock split to be effected at such time and date as determined by the Company’s board of directors in its sole discretion, and to reduce the number of authorized shares of the Company’s common stock in a corresponding proportion to the reverse stock split, rounded to the nearest whole share.

On March 1, 2017, following stockholder approval of the reverse split proposal, the Company’s board of directors approved a reverse stock split ratio of 1-for-5. On March 1, 2017, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of the Company’s Amended and Restated Certificate of Incorporation to effect the 1-for-5 reverse stock split of the Company’s outstanding common stock and to reduce the authorized number of shares of the Company’s common stock from 700,000,000 to 140,000,000 shares. The Company’s common stock began trading on The NASDAQ Global Market on a split-adjusted basis when the market opened on March 3, 2017.

As of the date of this filing, the shares of the Company’s common stock have maintained a minimum bid closing price of at least $1.00 per share for 10 consecutive business days. Accordingly, the Company expects to receive a notice from the Listing Qualifications Department of the NASDAQ Stock Market indicating that the Company has regained compliance with the minimum closing bid price requirement.

Sale of Valencia Facility — On January 6, 2017, the Company and Rexford Industrial Realty, L.P. (“Rexford”) entered into an Agreement of Purchase and Sale and Joint Escrow Instructions (the “Purchase Agreement”), pursuant to which the Company agreed to sell and Rexford agreed to purchase certain parcels of real estate owned by the Company in Valencia, California and certain related improvements, personal property, equipment, supplies and fixtures (collectively, the “Property”) for $17.3 million. The sale and purchase of the aforementioned Property for $17.3 million pursuant to the terms of the Purchase Agreement, as amended, was completed on February 17, 2017. Net proceeds were approximately $16.7 million after deducting broker’s commission and other fees of approximately $624,000 paid by the Company. In the fourth quarter of 2016 the property met the requirements for reclassification from property and equipment, net to asset held for sale when it became probable that the property would be sold within one year. At that time, an analysis of the lower of carrying value which was deemed to be the sales price of the property, to fair value less selling costs determined a loss of $564,000, which was recorded as a property and equipment impairment on the consolidated statement of operations for 2016. At December, 31 2016, this property had a carrying value of $16.7 million and was classified as held for sale. The sale of this property will be reflected in the consolidated financial statements for the quarter ended March 31, 2017.

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2016
Business	Business — MannKind Corporation and subsidiaries (the “Company”) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. The Company’s only approved product, Afrezza, (insulin human [rDNA origin]) inhalation powder, is a rapid-acting inhaled insulin that was approved by the U.S. Food and Drug Administration (the “FDA”) on June 27, 2014 to improve glycemic control in adult patients with diabetes.
Basis of Presentation	Basis of Presentation — On August 11, 2014, the Company entered into a license and collaboration agreement (the “Sanofi License Agreement”) with Sanofi-Aventis Deutschland GmbH (which subsequently assigned its rights and obligations under the agreement to Sanofi-Aventis U.S. LLC (“Sanofi”)), pursuant to which Sanofi was responsible for Afrezza global commercial, regulatory and development activities for Afrezza. On January 4, 2016, the Company received written notification from Sanofi of its election to terminate in its entirety the Sanofi License Agreement. The effective date of termination (the “Termination Date”) was April 4, 2016, which was when the Company assumed responsibility for worldwide development and commercialization of Afrezza. Under terms of a transition agreement, Sanofi continued to fulfill orders for Afrezza in the United States until the Company began distributing MannKind-branded Afrezza product to major wholesalers in late July 2016. The Company began recognizing commercial product sales revenue when MannKind-branded Afrezza was dispensed from pharmacies to patients in August 2016. On November 9, 2016, the Company entered into a settlement agreement with Sanofi (the “Settlement Agreement”). Under the terms of the Settlement Agreement, the promissory note (the “Sanofi Loan Facility”) between the Company and Aventisub LLC (“Aventisub”), a Sanofi affiliate, was terminated, with Aventisub agreeing to forgive the full outstanding loan balance of $72.0 million, which includes $0.5 million of previously uncharged costs pursuant to the Sanofi License Agreement. Sanofi also agreed to purchase $10.2 million of insulin from the Company in December 2016 under an existing insulin put option as well as make a cash payment of $30.6 million to the Company in early January 2017 as acceleration and in replacement of all other payments that Sanofi would otherwise have been required to make in the future pursuant to the insulin put option, without the Company being required to deliver any insulin for such payment. The Company and Sanofi also agreed to a general release of potential claims against each other. During their initial transition of the commercial responsibilities from Sanofi, the Company utilized a contract sales organization to promote Afrezza while the Company focused its internal resources on establishing a channel strategy, entering into distribution agreements and developing co-pay assistance programs, a voucher program, data agreements and payor relationships. In early 2017, the Company recruited their own sales force, which included some of the sales reps that previously were employed by the contract sales organization. The Company intend to continue the commercialization of Afrezza in the United States through their own commercial organization. The Company’s current strategy for the future commercialization of Afrezza outside of the United States, subject to receipt of the necessary foreign regulatory approvals, is to seek and establish regional partnerships in foreign jurisdictions where there are appropriate commercial opportunities. It has been costly to develop our therapeutic product, conduct clinical studies, and market and sell Afrezza. As of and for the year ended December 31, 2016, the Company has reported an accumulated deficit of $2.7 billion and has reported negative cash flow from operations for each year since inception, except for 2014, when the Company received the $150.0 million upfront payment from Sanofi. At December 31, 2016, the Company’s capital resources consisted of cash and cash equivalents of $22.9 million. The Company expects to continue to incur significant expenditures to support commercial manufacturing and sales and marketing of Afrezza and the development of other product candidates. The facility agreement (the “Facility Agreement”) with Deerfield Private Design Fund II, L.P. (Deerfield Private Design Fund) and Deerfield Private Design International II, L.P. (collectively, “Deerfield”) and the First Amendment to Facility Agreement and Registration Rights Agreement (the “First Amendment”) that resulted in additional sales of an additional tranche of notes (the “Tranche B notes”) (see Note 7 — Borrowings) requires the Company to maintain at least $25.0 million, which can be comprised of cash and cash equivalents and available borrowings under the loan arrangement, dated as of October 2, 2007, between the Company and The Mann Group LLC (as amended, restated, or otherwise modified as of the date hereof, “the Mann Group Loan Arrangement”), as of the last day of each fiscal quarter. Additional funding sources that are, or in certain circumstances may be available to the Company, include approximately $30.1 million principal amount of available borrowings under The Mann Group Loan Arrangement. A portion of these available borrowings may be used to capitalize accrued interest into principal, upon mutual agreement of the parties, as it becomes due and payable under The Mann Group Loan Arrangement (see Note 6 — Related-party Arrangements). The Company cannot provide assurances that its plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. The Company will need to raise additional capital, whether through a sale of equity or debt securities, a strategic business collaboration with a pharmaceutical company, the establishment of other funding facilities, licensing arrangements, asset sales or other means, in order to continue the commercialization of Afrezza and development of other product candidates and to support its other ongoing activities. The Company cannot provide assurances that such additional capital will be available on acceptable terms or at all. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. On September 14, 2016, the Company received notice from the Listing Qualifications Department of the NASDAQ Stock Market indicating that, for the previous 30 consecutive business days, the bid price for the common stock closed below the minimum $1.00 per share required for continued inclusion on The NASDAQ Global Market. The notification letter stated that the Company would be afforded 180 calendar days, or until March 13, 2017, to regain compliance with the minimum bid price requirement. In order to regain compliance, shares of the Company’s common stock must maintain a minimum bid closing price of at least $1.00 per share for a minimum of 10 consecutive business days.
Reverse Stock Split	Reverse Stock Split — On March 1, 2017, following stockholder approval, the Company’s board of directors approved a reverse stock split ratio of 1-for-5. On March 1, 2017, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of the Company’s Amended and Restated Certificate of Incorporation to effect the 1-for-5 reverse stock split of the Company’s outstanding common stock and to reduce the authorized number of shares of the Company’s common stock from 700,000,000 to 140,000,000 shares. The Company’s common stock began trading on The NASDAQ Global Market on a split-adjusted basis when the market opened on March 3, 2017. See Note 20 — Subsequent Events for further information. As a result, all common stock share amounts included in these consolidated financial statements have been retroactively reduced by a factor of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the Company’s common stock par value.
Principles of Consolidation	Principles of Consolidation — The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated.
Segment Information	Segment Information — Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company has viewed its operations and manages its business as one segment operating in the United States of America.
Financial Statement Estimates	Financial Statement Estimates — The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies, and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. The more significant estimates reflected in these accompanying consolidated financial statements include revenue recognition, assessing long-lived assets for impairment, accrued expenses, including clinical study expenses, inventory recoverability, valuation of the facility financing obligation, loss on purchase commitment, warrant liability, milestone rights, stock-based compensation and the determination of the provision for income taxes and corresponding deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets.
Reclassifications	Reclassifications — Certain amounts from previous periods have been reclassified to conform to the 2016 presentation. Specifically, accrued interest — note payable to principal stockholder has been reclassified from the previously reported classification of other liabilities in the accompanying consolidated balance sheets. Additionally, the remaining balance from the previously reported classification of other liabilities is now identified as milestone rights liability, and is disclosed as a separate line item on the consolidated statements of cash flows. Additionally, on the consolidated statement of operations, product manufacturing has been renamed to cost of goods sold. The Company also reclassified (gain) loss on foreign currency translation from the previously reported classification of product manufacturing in the accompanying consolidated statements of operations. Additionally, certain balances from prepaid expenses and other current assets were reclassed to (gain) loss on foreign currency translation in the consolidated statements of cash flows.
Revenue Recognition	Revenue Recognition — Revenue is recognized when the four basic criteria of revenue recognition are met: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. When the accounting requirements for revenue recognition are not met, the Company defers the recognition of revenue by recording deferred revenue on the consolidated balance sheets until such time that all criteria are met. To date, the Company has had revenue from collaborations, commercial sales of Afrezza, and from sales of bulk insulin, which are described more fully below.
Revenue Recognition - Net Revenue - Collaboration	Revenue Recognition — Net Revenue — Collaborations — The Company enters into collaborations under which we must perform certain obligations and we receive periodic payments. We evaluate the collaborations under the multiple element revenue recognition accounting guidance. Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered elements have stand-alone value to the customer. When deliverables are separable, consideration received is allocated to the separate units of accounting based on the relative selling price of each deliverable and the appropriate revenue recognition principles are applied to each unit. The assessment of multiple element arrangements requires judgment in order to determine the appropriate units of accounting and the points in time that, or periods over which, revenue should be recognized. The terms of and the accounting for the Company’s collaborations are described more fully in Note 8 — Collaboration Arrangements.
Revenue Recognition - Net Revenue - Commercial Product Sales	Revenue Recognition — Net Revenue — Commercial Product Sales — Between July 1, 2016 and December 15, 2016, the Company sold Afrezza to Integrated Commercialization Solutions Direct (ICS) and title and risk of loss transferred to ICS upon shipment. After December 15, 2016, ICS became a third party logistics provider and stopped taking title and risk of loss upon shipment of Afrezza to ICS. The Company sells Afrezza in the United States to wholesale pharmaceutical distributors through ICS, and ultimately to retail pharmacies, which are collectively referred to as “customers”. The Company provides the right of return to ICS (through December 15, 2016) and its wholesale distributors and, through them, to its retail pharmacy customers for unopened product for a period beginning six months prior to and ending twelve months after its expiration date. Once the product has been prescribed and dispensed to the patient, any right of return ceases to exist. Given the Company’s limited sales history for Afrezza, the Company cannot reliably estimate expected returns of the product at the time of shipment into the distribution channel. Accordingly, the Company defers recognition of revenue on Afrezza product shipments until the right of return no longer exists, which occurs at the earlier of the time Afrezza is dispensed from pharmacies to patients or expiration of the right of return. The Company recognizes revenue based on Afrezza patient prescriptions dispensed as estimated by syndicated data provided by a third party. The Company also analyzes additional data points to ensure that such third-party data is reasonable including data related to inventory movements within the channel and ongoing prescription demand. For the year ended December 31, 2016, net revenue from commercial product sales consisted of $1.9 million of net sales of Afrezza dispensed to patients. As of December 31, 2016, the Company recorded $3.4 million in deferred revenue on its consolidated balance sheet, of which $1.6 million (net of estimated gross-to-net adjustments) represents product shipped to the Company’s third-party logistics provider and wholesale distributors, but not yet dispensed to patients. The difference represents deferred revenue from bulk insulin sales, which is described more fully under the heading Revenue Recognition — Revenue — Bulk Insulin Sales below.
Gross-to-net Adjustments	Gross-to-net Adjustments — Estimated gross-to-net adjustments for Afrezza include wholesaler distribution fees, prompt pay discounts, estimated rebates and patient discount and co-pay assistance programs, and are based on estimated amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of the Company’s agreements with its customers and the levels of inventory within the distribution and retail channels that may result in future rebates or discounts taken. In certain cases, such as patient support programs, the Company recognizes the cost of patient discounts as a reduction of revenue based on estimated utilization. If actual future results vary, the Company may need to adjust these estimates, which could have an effect on product revenue in the period of adjustment. The Company records product sales deductions in the consolidated statements of operations at the time product revenue is recognized. At December 31, 2016, year to date total gross-to-net adjustments were approximately $0.8 million, which represents 30% of gross revenue from product sales.
Wholesaler Distribution Fees	Wholesaler Distribution Fees — The Company pays distribution fees to certain wholesale distributors based on contractually determined rates. The Company accrues the distribution fees on shipment to the respective wholesale distributors and recognizes the distribution fees as a reduction of revenue in the same period the related revenue is recognized.
Prompt Pay Discounts	Prompt Pay Discounts — The Company offers cash discounts to its customers, generally 2% of the sales price, as an incentive for prompt payment. The Company accounts for cash discounts by reducing accounts receivable by the prompt pay discount amount and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized. Rebates — The Company participates in federal and state government-managed Medicare and Medicaid rebate programs and intends to pursue participation in certain other qualifying federal and state government programs whereby discounts and rebates are provided to participating federal and state government entities. Rebates provided through these other qualifying programs are included in the Medicaid and Medicare rebate accrual. The Company accounts for these rebates by establishing an accrual equal to the estimate of rebate claims attributable to a sale and determines its estimate of the rebates accrual based on historical payor data provided by a third-party vendor along with additional data including a forecasted participation rate for Medicare and Medicaid. From that data, as well as input received from MannKind’s commercial team, an estimated participation rate for Medicare and Medicaid is determined and applied at the mandated rate for those sales. Any new information regarding changes in the programs’ regulations and guidelines or any changes in the Company’s government price reporting calculations that would impact the amount of the rebates will also be taken into account in determining or modifying the appropriate reserve. The time period between the date the product is sold into the channel and the date such rebates are paid ranges from approximately six to nine months. As such, continuous monitoring of these estimates are performed on a periodic basis and if necessary, adjusted to reflect new facts and circumstances. Rebates are recognized as a reduction of revenue in the period the related revenue is recognized.
Patient Discount and Co-Pay Assistance Programs	Patient Discount and Co-Pay Assistance Programs — The Company offers discount card programs to patients for Afrezza in which patients receive discounts on their prescriptions or a reduction in their co-pay amounts that are reimbursed by the Company. The Company estimates the total amount that will be redeemed based on levels of inventory in the distribution and retail channels and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized.
Product Returns	Product Returns — The Company does not provide a reserve for product returns of sales of Afrezza due to its revenue recognition policy of deferring recognition of revenue on product shipments of Afrezza until the right of return no longer exists.
Revenue Recognition - Revenue - Bulk Insulin Sales	Revenue Recognition — Revenue — Bulk Insulin Sales — In 2016, revenue from bulk insulin sales was recognized after delivery and customer acceptance of the bulk insulin. When the accounting requirements for revenue recognition of bulk insulin sales are not met, the Company defers recognition of revenue by recording deferred revenue on the balance sheet until such time that all criteria are met. Deferred revenue includes $1.8 million received from a sale of surplus bulk insulin to a third party that was delivered prior to, but accepted after, December 31, 2016. No deferred cost was recognized related to this sale because the inventory was written off on December 31, 2015.
Deferred costs	Deferred Costs from Collaboration — Deferred costs from collaboration represents the costs of product manufactured and sold to Sanofi, as well as certain direct costs associated with a firm purchase commitment entered into in connection with the collaboration with Sanofi. During the third quarter of 2016, the costs related to the Sanofi product sales were recognized as costs of revenue — collaboration in the consolidated statements of operations, as related revenue was recognized at that time. Deferred Costs from Commercial Product Sales — Deferred costs from commercial product sales represents the cost of product (including labor, overhead and costs to ship to third party logistics) shipped to ICS and wholesale distributors, but not yet dispensed by pharmacies to patients.
Cost of Goods Sold	Cost of Goods Sold — Cost of goods sold includes the costs related to Afrezza product dispensed by pharmacies to patients as well as under-absorbed labor and overhead and inventory write-offs, which are recorded as expenses in the period in which they are incurred, rather than as a portion of the inventory cost.
Cash and Cash Equivalents	Cash and Cash Equivalents — The Company considers all highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase, that are readily convertible into cash to be cash equivalents. As of December 31, 2016 and 2015, cash equivalents were comprised of money market accounts with maturities less than 90 days from the date of purchase.
Concentration of Credit Risk	Concentration of Credit Risk — Financial instruments which potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Cash and cash equivalents are held in high credit quality institutions. Cash equivalents consist of interest-bearing money market accounts, which are regularly monitored by management.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts — Accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectability of its accounts receivable in its calculation of the allowance for doubtful accounts. As of December 31, 2016 and 2015, there was no allowance for doubtful accounts.
Inventories	Inventories — Inventories are stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out, or FIFO, method. The Company capitalizes inventory costs associated with the Company’s products based on management’s judgment that future economic benefits are expected to be realized; otherwise, such costs are expensed as cost of goods sold. The Company periodically analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value, and writes down such inventories as appropriate. In addition, the Company’s products are subject to strict quality control and monitoring which the Company performs throughout the manufacturing process. If certain batches or units of product no longer meet quality specifications or become obsolete due to expiration, the Company will record a charge to write down such unmarketable inventory to its estimated net realizable value. The Company analyzed its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value. The Company performed an assessment of projected sales and evaluated the lower of cost or net realizable value and the potential excess inventory on hand at December 31, 2016 and 2015. As a result of these assessments, the Company recorded a $0.2 million charge at December 31, 2016 to write-off inventory that will expire prior to sale. At December 31, 2015, the Company recorded a charge of $39.3 million to record the inventory raw materials on hand at the lower of cost or net realizable value, inventory expiry and write-off other inventory related assets.
State Research and Development Credit Exchange Receivable	State Research and Development Credit Exchange Receivable — The State of Connecticut provides certain companies with the opportunity to exchange certain research and development income tax credit carryforwards for cash in exchange for foregoing the carryforward of the research and development credits. The program provides for an exchange of research and development income tax credits for cash equal to 65% of the value of corporation tax credit available for exchange. Estimated amounts receivable under the program are recorded as a reduction of research and development expenses. These amounts are included in prepaid expenses and other current assets on the consolidated balance sheets.
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets — As of December 31, 2016 and 2015, prepaid expenses and other current assets primarily consist of prepaid expenses for goods and services to be received and includes a certificate of deposit for $350,000 as collateral as required by an agreement with the bank.
Sale of intellectual property	Sale of intellectual property — On July 18, 2014, the Company entered into an assignment agreement with a third party whereby the third party acquired all proprietary rights, technology and know-how that related to a small molecule inhibitor compound and all pre-clinical data and results related thereto. Under the terms of the assignment agreement, the Company received total consideration of $9.3 million and accrued $1.4 million in expense for a net amount of $7.9 million recorded as other income. In 2015, the Company recorded other income of $1.4 million related to the relief of the $1.4 million accrual for expenses associated with the sale of intellectual property related to oncology in 2014, which was subsequently resolved without payment.
Assets Held for Sale	Assets Held for Sale — The Company classifies long-lived assets anticipated to be sold within one year as held for sale at the lower of their carrying value or fair value less estimated selling costs.
Property and Equipment	Property and Equipment — Property and equipment are depreciated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the term of the lease or the service lives of the improvements, whichever is shorter. Maintenance and repairs are expensed as incurred. Assets under construction are not depreciated until placed into service. Impairment of Long-Lived Assets — The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Assets are considered to be impaired if the carrying value may not be recoverable. If the Company believes an asset to be impaired, the impairment recognized is the amount by which the carrying value of the asset exceeds the fair value of the asset. Fair value is determined using the market, income or cost approaches as appropriate for the asset. Any write-downs are treated as permanent reductions in the carrying amount of the asset and an operating loss would be recognized. The Company recorded an asset impairment of $1.3 million and $140.4 million for the years ended December 31, 2016 and 2015, respectively. No asset impairment was recognized during the year ended December 31, 2014 (see Note 4 — Property and Equipment and Note 20 — Subsequent Events).
Recognized Loss on Purchase Commitments	Recognized Loss on Purchase Commitments — The Company assesses whether losses on long term purchase commitments should be accrued. Losses that are expected to arise from firm, non-cancellable, commitments for the future purchases of inventory items are recognized unless recoverable. The recognized loss on purchase commitments is reduced as inventory items are purchased. Changes in estimates are recorded in the relevant period in (gain) loss on purchase commitments. During the year ended December 31, 2015, the Company recorded a loss on purchase commitments amounting to $116.2 million offset by $50 million expected to be recovered from Sanofi, primarily due to a long term purchase commitment for insulin raw materials. During the year ended December 31, 2016, the balance was adjusted for the recovery received from Sanofi, current purchases on the contracts and a reduction in the recognized loss related to amendments to purchase contracts. No new contracts were identified in 2016 requiring a new loss on purchase commitment accrual.
Milestone Rights Liability	Milestone Rights Liability — On July 1, 2013, in conjunction with the execution of the Facility Agreement, the Company issued Milestone Rights to Deerfield whereby the Company agreed to provide Deerfield with pre-specified Milestone Payments upon the achievement of 13 specific Milestone Events related to the commercial release and future cumulative net sales of Afrezza. The Company analyzed the Milestone Rights and determined that the agreement does not meet the definition of a freestanding derivative. Since the Company has not elected to apply the fair value option to the Milestone Rights Purchase Agreement, the Company recorded the Milestone Rights at their estimated initial fair value and accounted for the Milestone Rights as a liability. The initial fair value estimate of the Milestone Rights was calculated using the income approach in which the cash flows associated with the specified contractual payments were adjusted for both the expected timing and the probability of achieving the milestones and discounted to present value using a selected market discount rate. The expected timing and probability of achieving the milestones was developed with consideration given to both internal data, such as progress made to date and assessment of criteria required for achievement, and external data, such as market research studies. The discount rate was selected based on an estimation of required rate of returns for similar investment opportunities using available market data. The Milestone Rights liability will be remeasured as the specified milestone events are achieved. Specifically, as each milestone event is achieved, the portion of the initially recorded Milestone Rights liability that pertains to the milestone event being achieved, will be remeasured to the amount of the specified related milestone payment. The resulting change in the balance of the Milestone Rights liability due to remeasurement will be recorded in the Company’s consolidated statements of operations as interest expense. Furthermore, the Milestone Rights liability will be reduced upon the settlement of each milestone payment. As a result, each milestone payment would be effectively allocated between a reduction of the recorded Milestone Rights liability and an expense representing a return on a portion of the Milestone Rights liability paid to the investor for the achievement of the related milestone event (see Note 7 — Borrowings). As of December 31, 2016, the remaining liability balance is $8.9 million.
Fair Value of Financial Instruments	Fair Value of Financial Instruments — The Company utilizes fair value measurement guidance to value its financial instruments. The guidance includes a definition of fair value, prescribes methods for measuring fair value, establishes a fair value hierarchy based on the inputs used to measure fair value and expands disclosures about the use of fair value measurements. The valuation techniques utilized are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect internal market assumptions. These two types of inputs create the following fair value hierarchy: Level 1 — Quoted prices for identical instruments in active markets. Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3 — Significant inputs to the valuation model are unobservable.
Income Taxes	Income Taxes — The provisions for federal, foreign, state and local income taxes are calculated on pre-tax income based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce net deferred income tax assets to amounts that are more likely than not to be realized. Income tax positions are considered for uncertainty. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no liabilities for uncertain income tax positions have been recorded. If a tax position does not meet the minimum statutory threshold to avoid payment of penalties, the Company recognizes an expense for the amount of the penalty in the period the tax position is claimed in the tax return of the Company. The Company recognizes interest accrued related to unrecognized tax benefits in income tax expense, if any. Penalties, if probable and reasonably estimable, are recognized as a component of income tax expense. Significant management judgment is involved in determining the provision for income taxes, deferred tax assets, deferred tax liabilities, and any valuation allowance recorded against deferred tax assets. Due to uncertainties related to the realization of the Company’s deferred tax assets as a result of its history of operating losses, a full valuation allowance has been established against the total deferred tax asset balance. The valuation allowance is based on management’s estimates of taxable income by jurisdiction in which the Company operates and the period over which deferred tax assets will be recoverable. In the event that actual results differ from these estimates or the Company adjusts these estimates in future periods, a change in the valuation allowance may be needed.
Contingencies	Contingencies — The Company records a loss contingency for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These accruals represent management’s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may revise its estimates.
Stock-Based Compensation	Stock-Based Compensation — As of December 31, 2016, the Company had three active stock-based compensation plans, which are described more fully in Note 12 — Stock Award Plans. The Company accounts for all share-based payments to employees, including grants of stock awards and the compensatory elements of the employee stock purchase plan. All share-based payments to employees, including grants of stock options, restricted stock units, performance-based awards and the compensatory elements of employee stock purchase plans, are recognized in the consolidated statements of operations based upon the fair value of the awards at the grant date. The Company uses the Black-Scholes option valuation model to estimate the grant date fair value of employee stock options and the compensatory elements of employee stock purchase plans. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate and the expected dividend yield. The expected volatility assumption is based on an assessment of the historical volatility, with consideration of implied volatility, derived from an analysis of historical trade activity. Restricted stock units are valued based on the market price on the grant date. The Company evaluates stock awards with performance conditions as to the probability that the performance conditions will be met and estimates the date at which the performance conditions will be met in order to properly recognize stock-based compensation expense over the requisite service period.
Warrants	Warrants — The Company has issued warrants to purchase shares of its common stock. The Company accounts for its warrants as either equity or liabilities based upon the characteristics and provisions of each instrument and evaluation of sufficient authorized shares available to satisfy the obligations. Warrants classified as derivative liabilities are recorded on the Company’s consolidated balance sheets at their fair value on the date of issuance and are revalued at each subsequent balance sheet date, with fair value changes recognized in the consolidated statements of operations. The Company estimates the fair value of its derivative liabilities using a third party valuation analysis that utilizes a Monte Carlo pricing valuation model and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as expected volatility, expected life, yield and a risk-free interest rate. The expected volatility assumption is primarily based on an assessment of the historical volatility, with consideration of implied volatility, derived from an analysis of historical trade activity. Warrants classified as equity are recorded within additional paid in capital at the issuance date and are not re-measured in subsequent periods, unless the underlying assumptions change to trigger liability accounting.
Comprehensive Income (Loss)	Comprehensive Income (Loss) — Other comprehensive income (loss) requires that all components of comprehensive income (loss) to be reported in the financial statements in the period in which they are recognized. Other comprehensive income (loss) includes certain changes in stockholders’ equity that are excluded from net income (loss). Specifically, the Company includes unrealized gains and losses on foreign exchange translation in accumulated other comprehensive loss on the consolidated balance sheets.
Research and Development Expenses	Research and Development Expenses — Research and development expenses consist of costs associated with the clinical trials of the Company’s product candidates, manufacturing supplies and other development materials, compensation and other expenses for research and development personnel, costs for consultants and related contract research, facility costs, and depreciation. Research and development costs, which are net of any tax credit exchange recognized for the Connecticut state research and development credit exchange program, are expensed as incurred. The Company began commercial manufacturing in the latter part of the fourth quarter of 2014. Commercial manufacturing costs incurred in the fourth quarter of 2014 were included in research and development expense and were immaterial for the year ended December 31, 2014.
State Research and Development Credit Exchange Receivable	State Research and Development Credit Exchange Receivable — The State of Connecticut provides certain companies with the opportunity to exchange certain research and development income tax credit carryforwards for cash in exchange for forgoing the carryforward of the research and development income tax credits. The program provides for an exchange of research and development income tax credits for cash equal to 65% of the value of corporation tax credit available for exchange. Estimated amounts receivable under the program are recorded as a reduction of research and development expenses. During the years ended December 31, 2016, 2015 and 2014, research and development expenses were offset by research and development tax credits of $246,000, $743,000 and $816,000, respectively.
Clinical Trial Expenses	Clinical Trial Expenses — Clinical trial expenses, which are reflected in research and development expenses in the accompanying consolidated statements of operations, result from obligations under contracts with vendors, consultants and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The appropriate level of trial expenses are reflected in the Company’s consolidated financial statements by matching period expenses with period services and efforts expended. These expenses are recorded according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. Clinical trial accrual estimates are determined through discussions with internal clinical personnel and outside service providers as to the progress or state of completion of trials, or the services completed. Service provider status is then compared to the contractually obligated fee to be paid for such services. During the course of a clinical trial, the Company may adjust the rate of clinical expense recognized if actual results differ from management’s estimates.
Interest Expense	Interest Expense — Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized. Interest cost capitalized for the years ended December 31, 2015 and 2014 was $0.1 million and $0.8 million, respectively. There were no capitalized interest costs for the year ended December 31, 2016.
Net Income (Loss) Per Share of Common Stock	Net Income (Loss) Per Share of Common Stock — Basic net income (loss) per share excludes dilution for potentially dilutive securities and is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share reflects the potential dilution under the treasury method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. For periods where the Company has presented a net loss, potentially dilutive securities are excluded from the computation of diluted net loss per share as they would be antidilutive.
Recently Issued Accounting Standards	Recently Issued Accounting Standards — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s consolidated financial position or results of operations upon adoption. In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which requires an entity to recognize the amount of revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. This new guidance supersedes previous revenue recognition requirements, along with most existing industry-specific guidance. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In 2016 the FASB has issued additional ASUs which clarify certain aspects of the new guidance. The Company will adopt the new guidance for the year beginning January 1, 2018. The Company has the option to either apply the new guidance retrospectively for all prior reporting periods presented (full retrospective) or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (modified retrospective). The Company currently anticipates it will apply the new guidance using the modified retrospective approach with the cumulative effect of initial application recognized as of January 1, 2018. The Company plans to continue analyzing the potential impacts of the application throughout 2017 and, depending on factors that may impact the results, could elect to apply the new guidance on a full retrospective basis. Currently, for commercial sales of Afrezza, the Company has limited sales and returns history, and as such, is unable to reliably estimate expected returns of the product at the time of shipment into the distribution channel. Accordingly, the Company defers recognition of revenue on Afrezza product shipments until the right of return no longer exists, which occurs at the earlier of the time Afrezza is dispensed from pharmacies to patients or expiration of the right of return. The Company recognizes revenue based on Afrezza patient prescriptions dispensed, a sell-through model, as estimated by syndicated data provided by a third party. The Company also analyzes additional data points to ensure that such third-party data is reasonable, including data related to inventory movements within the channel and ongoing prescription demand. Upon adoption of the new guidance, the Company expects that it will move from its current sell-through model to a sell-to model for revenue related to commercial sales of Afrezza and will record revenue at the time title and risk of loss passes to its distributors (generally at shipment or delivery to the distributors) along with an estimate of potential returns as variable consideration. The Company also anticipates that its ability to estimate potential returns will improve with an additional 12 months of sales history that it will have obtained by January 1, 2018. In addition, the Company has historically entered into collaborative agreements with third-parties under which periodic payments have been received. Revenue recognition for certain payments received has been deferred until the price is fixed and determinable. Further, revenue for certain payments to be received in the future has been prohibited from recognition until received. The Company expects that some of these amounts will be considered variable consideration and may be able to be recognized earlier under the new guidance. The Company has begun its evaluation of the impact of adoption and plans to continue its evaluation throughout 2017. The financial impact upon adoption will be dependent upon a number of factors including; the amount of revenue that has been deferred under the sell-through model for Afrezza, the amount of the revenue deferred under collaborative arrangements and the Company’s estimates of variable consideration at the date of adoption. At this time, the Company has not completed its evaluation of the inputs, assumptions and methodologies that will be used to recognize revenue related to variable consideration under the new guidance. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. Topic 330 currently requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. The amendments indicate that after adoption an entity should measure inventory within the scope of this ASU at the lower of cost or net realizable value. The amendments are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The amendments should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of ASU No. 2015-11 will have no impact on the Company’s annual consolidated financial statements because the Company currently measures inventory at the lower of cost or net realizable value. In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements — Going Concern, which requires management of an entity to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued or available to be issued. This update was effective for annual periods ending after December 15, 2016. The adoption of this standard did not have a material impact on its consolidated financial statements. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments — Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The update is intended to improve the recognition and measurement of financial instruments. The update is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company is evaluating the impact the adoption of ASU 2016-01 will have on its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The new standard will be effective on January 1, 2019. The Company is evaluating the impact the adoption of ASU No. 2016-02 will have on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. For public business entities, the amendments in this standard are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company has evaluated the effect that this guidance will have on its consolidated financial statements and related disclosures and has determined it will not result in a material impact. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new standard seeks to reduce diversity in practice related to the classification of certain transactions in the statement of cash flows. For public business entities, the amendments in this standard are effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. The amendments should be applied using a retrospective transition method to each period presented. If it is impracticable to apply the amendments retrospectively for some of the issues, the amendments for those issues would be applied prospectively as of the earliest date practicable. The Company is evaluating the impact the adoption of ASU No. 2016-15 will have on its consolidated financial statements. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. This ASU requires that the reconciliation of the beginning-of-period and end-of-period amounts shown in the statement of cash flows include cash and restricted cash equivalents. ASU 2016-08 is effective for fiscal years beginning after December 15, 2018, including interim periods within those periods, using a retrospective transition method to each period presented. The Company has evaluated the effect that this guidance will have on its consolidated financial statements and related disclosures and has determined it will not result in a material impact.

Inventories (Tables)

12 Months Ended

Dec. 31, 2016

Components of Inventories

Inventories consist of the following (in thousands):


	December 31,
	2016		2015
Raw materials	$	—	$	—
Work-in-process		2,120		—
Finished goods		211		—

Total Inventory	$	2,331	$	—

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2016

Property and Equipment, Net

Property and equipment consist of the following (in thousands):


	Estimated Useful Life (Years)		December 31,
	Estimated Useful Life (Years)		2016			2015
Land		—	$	875		$	3,435
Buildings		39-40		17,389			21,590
Building improvements		5-40		34,957			60,584
Machinery and equipment		3-15		62,992			68,434
Furniture, fixtures and office equipment		5-10		3,556			4,114
Computer equipment and software		3		8,531			9,519
Construction in progress				202			586

				128,502			168,262
Less accumulated depreciation				(99,575	)		(119,513	)

Total property and equipment, net			$	28,927		$	48,749

Accrued Expenses and Other Current Liabilities (Tables)

12 Months Ended

Dec. 31, 2016

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities are comprised of the following (in thousands):


	December 31,
	2016		2015
Salary and related expenses	$	3,814	$	2,634
Restructuring		1,376		3,028
Sales and marketing services		144		—
Professional fees		875		931
Discounts and allowances for commercial product sales		754		—
Accrued interest		619		615
Other		355		483
Construction in progress		—		238

Accrued expenses and other current liabilities	$	7,937	$	7,929

Borrowings (Tables)

12 Months Ended

Dec. 31, 2016

Summary of Borrowings

Borrowings consist of the following (in thousands):


	December 31,
	2016			2015
Facility Financing Obligation (2019 Notes)
Principal amount	$	75,000		$	80,000
Unamortized debt discount		(3,661	)		(5,418	)

Net carrying amount	$	71,339		$	74,582

Senior Convertible Notes (2018 Notes)
Principal amount	$	27,690		$	27,690
Unamortized premium		426			660
Unaccreted debt issuance costs		(481	)		(737	)

Net carrying amount	$	27,635		$	27,613

Note payable to principal stockholder — net carrying amount	$	49,521		$	49,521

Accretion of Debt Issuance Cost and Debt Discount

Accretion of debt issuance cost and debt discount in connection with the Deerfield financing during the years ended December 31, 2016, 2015 and 2014 are as follows (in thousands):


	December 31,
	2016		2015		2014
Accretion expense — debt issuance cost	$	35	$	35	$	326
Accretion expense — debt discount	$	1,722	$	1,553	$	7,550

Fair Value of Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2016

Fair Value of Financial Instruments

The following tables set forth the fair value of the Company’s financial instruments (in millions):


	As of December 31, 2016
	Carrying Value		Level 1		Level 2		Level 3		Total
Financial liabilities:
Senior convertible notes	$	27.6	$	—	$	—	$	22.9	$	22.9
Facility Financing Obligation		71.3		—		—		74.5		74.5
Milestone Rights		8.9		—		—		18.4		18.4
Warrant liability (at recurring fair values)		7.4		—		—		7.4		7.4

Total financial liabilities	$	115.2	$	—	$	—	$	123.2	$	123.2


	As of December 31, 2015
	Carrying Value		Level 1		Level 2		Level 3		Total
Financial liabilities:
Senior convertible notes	$	27.6	$	—	$	—	$	21.3	$	21.3
Facility Financing Obligation		74.6		—		—		78.4		78.4
Milestone Rights		8.9		—		—		14.4		14.4
Sanofi Loan Facility		44.5		—		—		36.5		36.5

Total financial liabilities	$	155.6	$	—	$	—	$	150.6	$	150.6

Fair Values of Financial Liabilities which Include Level 3 Instruments

The following table provides a roll forward of the fair values of financial assets and liabilities that are carried at fair value (in millions):


	Warrants			Assets Held for Sale
Fair value, January 1, 2015	$	—		$	—
Additions		—			—
Changes in fair value		—			—
Payments		—			—

Fair value, December 31, 2015	$	—		$	—

Additions		12.8			17.3
Changes in fair value		(5.4	)		(0.6	)
Payments		—			—

Fair value, December 31, 2016	$	7.4		$	16.7

Net Income (Loss) per Common Share (Tables)

12 Months Ended

Dec. 31, 2016

Components of Basic and Diluted Net Income (Loss) Per Common Share Computations

The following tables summarize the components of the basic and diluted net income (loss) per common share computations:


	Year Ended December 31,
	2016		2015			2014
	(In thousands, except per share data)
Basic EPS:
Net income (loss) (numerator)	$	125,664	$	(368,445	)	$	(198,382	)

Weighted average common shares (denominator)		92,053		81,233			77,045

Net income (loss) per share	$	1.37	$	(4.54	)	$	(2.57	)

Diluted EPS:
Net income (loss) (numerator)	$	125,664	$	(368,445	)	$	(198,382	)

Weighted average common shares		92,053		81,233			77,045
Effect of dilutive securities — common shares issuable		32		—			—

Adjusted weighted average common shares (denominator)		92,085		81,233			77,045

Net income (loss) per share	$	1.36	$	(4.54	)	$	(2.57	)

Potential Dilutive Securities Outstanding that are Considered Antidilutive

Potentially dilutive securities outstanding that are considered antidilutive are summarized as follows (in shares):


	December 31,
	2016		2015		2014
Exercise of common stock options		5,530,256		3,955,845		4,308,332
Conversion of senior convertible notes into common stock		814,561		814,561		3,464,616
Exercise of common stock warrants		9,740,597		814,919		1,997,575
Vesting of restricted stock units		702,867		360,924		522,144

		16,788,281		5,946,249		10,292,667

Stock Award Plans (Tables)

12 Months Ended

Dec. 31, 2016

Stock Based Award Plans

The following table summarizes information about the Company’s stock-based award plans as of December 31, 2016:


	Outstanding Options		Outstanding Restricted Stock Units		Shares Available for Future Issuance
2004 Equity Incentive Plan		2,052,345		14,203		97,574
2013 Equity Incentive Plan		3,399,245		723,763		3,743,013
2004 Non-Employee Directors’ Stock Option Plan		78,666		—		—

Total		5,530,256		737,966		3,840,587

Stock Based Compensation Expense Recognized in Accompanying Consolidated Statements of Operations

Total stock-based compensation expense recognized in the accompanying consolidated statements of operations is as follows (in thousands):


	Year Ended December 31,
	2016		2015		2014
Employee-related	$	5,135	$	8,407	$	48,622
Consultant-related		—		318		—

Total	$	5,135	$	8,725	$	48,622

Stock Based Compensation Expense Recognized in Accompanying Consolidated Statements of Operations by Category

Total stock-based compensation expense recognized in the accompanying consolidated statements of operations is included in the following categories (in thousands):


	Year Ended December 31,
	2016		2015		2014
Cost of goods sold	$	695	$	—	$	—
Research and development		1,309		3,029		22,357
Selling, general and administrative		3,131		5,696		26,265

Total	$	5,135	$	8,725	$	48,622

Assumptions Used to Calculate Fair Value of Employee Stock Options

The Company calculated the fair value of employee stock options granted during the years ended December 31, 2016, 2015 and 2014 using the following assumptions:


	Year Ended December 31,
	2016	2015	2014
Risk-free interest rate	1.18% — 1.80%	1.61% —1.86%	1.64% — 2.11%
Expected lives	5.13 — 5.82 years	5.79 — 5.86 years	5.77 — 6.09 years
Volatility	77.57% — 82.75%	69.76% — 71.84%	73.98% — 84.85%
Dividends	—	—	—

Summary of Stock Options Outstanding

The following table summarizes information about stock options outstanding:


	Number of Shares			Weighted Average Exercise Price per Share		Aggregate Intrinsic Value ($000)
Outstanding at January 1, 2016		3,955,845		$	22.70	$	—
Granted		2,236,693			4.50
Exercised		(55,231	)		8.45
Forfeited		(407,161	)		13.60
Expired		(199,890	)		23.65

Outstanding at December 31, 2016		5,530,256		$	16.10	$	2
Vested and expected to vest at December 31, 2016		5,399,777		$	16.35	$	2
Exercisable at December 31, 2016		3,414,586		$	22.50	$	—

Summary of Restricted Stock Unit Activity

A summary of restricted stock unit activity for the year ended December 31, 2016 is presented below:


	Number of Shares			Weighted Average Grant Date Fair Value per Share
Outstanding at January 1, 2016		360,924		$	24.25
Granted		800,530			4.50
Vested		(131,000	)		21.70
Forfeited		(292,488	)		11.60

Outstanding at December 31, 2016		737,966		$	8.40

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2016

Annual Purchase Requirements under Contract

The annual purchase requirements under the contract are as follows:


2017	€	2.7 million
2018	€	8.9 million
2019	€	11.6 million
2020	€	15.5 million
2021	€	15.5 million
2022	€	19.4 million
2023	€	19.4 million

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2016

Provision for Income Taxes

The provision for income taxes consists of the following (in thousands):


	Year Ended December 31,
	2016			2015			2014
Current
U.S. federal	$	—		$	—		$	—
U.S. state		—			—			—
Non-U.S.		—			—			—

Total current		—			—			—

Deferred
U.S. federal		(43,814	)		109,512			57,873
U.S. state		(4,311	)		(29,394	)		7,631
Non-U.S.		—			—			—

Total deferred		(48,125	)		80,118			65,504

Valuation allowance		48,125			(80,118	)		(65,504	)

Total	$	—		$	—		$	—

Components of Net Deferred Tax Assets

Components of the net deferred tax assets as of December 31, 2016 and 2015, are as follows (in thousands):


	December 31,
	2016			2015
Deferred tax assets:
Net operating loss carryforwards	$	712,124		$	721,588
Research and development credits		77,998			73,646
Capitalized research		5,117			5,872
Payments from collaboration		—			52,484
Milestone Rights		3,242			3,242
Accrued expenses		440			251
Loss on purchase commitment		36,775			24,084
Non-qualified stock option expense		17,331			16,941
Capitalized patent costs		8,781			8,574
Other		7,380			7,186
Depreciation		45,310			48,755

Total net deferred tax assets		914,498			962,623
Valuation allowance		(914,498	)		(962,623	)

Net deferred tax assets	$	—		$	—

Effective Income Tax Rate

The Company’s effective income tax rate differs from the statutory federal income tax rate as follows for the years ended December 31, 2016, 2015 and 2014:


	December 31,
	2016			2015			2014
Federal tax benefit rate		35.0	%		35.0	%		35.0	%
Permanent items		(1.9	)		—			0.9
Intercompany transfer of intellectual property		0.9			(1.0	)		(4.1	)
Valuation allowance		(34.0	)		(34.0	)		(31.8	)

Effective income tax rate		—	%		—	%		—	%

Selling, General and Administrative Expenses (Tables)

12 Months Ended

Dec. 31, 2016

Schedule of Selling, General and Administrative Expenses

Selling, general and administrative expenses consist of the following (in thousands):


	Year Ended December 31,
	2016		2015		2014
Selling and marketing	$	19,854	$	1,587	$	3,556
General and administrative		27,074		39,373		75,827

Total selling, general and administrative	$	46,928	$	40,960	$	79,383

Restructuring Charges (Tables)

12 Months Ended

Dec. 31, 2016

Reconciliation of Beginning and Ending Liability Balances for Restructuring Charges


Description	2016 Restructuring			2015 Restructuring			Total
Accrual — January 1, 2015	$	—		$	—		$	—
Costs incurred and charged to expense		—			6,040			6,040
Costs paid or settled		—			(3,012	)		(3,012	)

Accrual — December 31, 2015		—			3,028			3,028
Costs incurred and charged to expense		1,475			560			2,035
Costs paid or settled		(1,266	)		(2,421	)		(3,687	)

Accrual — December 31, 2016	$	209		$	1,167		$	1,376

Selected quarterly financial data (unaudited) (Tables)

12 Months Ended

Dec. 31, 2016

Selected Quarterly Financial Data

Summarized quarterly financial data for the years ended December 31, 2016 and 2015, are set forth in the following tables:


	March 31			June 30			September 30			December 31
	(In thousands, except per share data)
2016
Net revenues	$	—		$	—		$	162,354		$	12,404

Net income (loss)	$	(24,873	)	$	(29,959	)	$	126,520			53,976

Net income (loss) per share — basic	$	(0.29	)	$	(0.33	)	$	1.32		$	0.56

Net income (loss) per share — diluted	$	(0.29	)	$	(0.33	)	$	1.31		$	0.56

Weighted average common shares used to compute basic net income (loss) per share		85,771			91,061			95,627			95,676

Weighted average common shares used to compute diluted net income (loss) per share		85,771			91,061			96,548			96,510

2015
Net loss	$	(30,658	)	$	(28,910	)	$	(31,857	)	$	(277,020	)

Net loss per share — basic and diluted	$	(0.38	)	$	(0.36	)	$	(0.39	)	$	(3.30	)

Weighted average common shares used to compute basic and diluted net loss per share		79,783			80,203			81,039			83,862

Description of Business - Additional Information (Detail) - USD ($)		1 Months Ended	3 Months Ended		12 Months Ended
	Nov. 09, 2016	Jan. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Net revenue from collaboration					$ 171,965,000
Gain on extinguishment of debt					72,024,000	$ (1,049,000)
Accumulated deficit			$ (2,737,565,000)		(2,737,565,000)	(2,863,229,000)
Cash and cash equivalents			22,895,000		22,895,000	59,074,000	$ 120,841,000	$ 70,790,000
Loan Arrangement
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Amount available for future borrowings			30,100,000		30,100,000	$ 30,100,000
License and Collaboration Agreement with Sanofi
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Gain on extinguishment of debt	$ 500,000
Insulin Put
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Net revenue from collaboration					10,200,000
Principal stockholder \| Loan Arrangement
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Amount available for future borrowings			30,100,000		30,100,000
Aventisub LLC
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Outstanding loan balance forgive	$ 72,000,000
Sanofi-Aventis Deutschland GmbH \| License and Collaboration Agreement with Sanofi
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Net revenue from collaboration			10,200,000	$ 161,800,000	172,000,000
Gain on extinguishment of debt			72,000,000
Up-front fee					150,000,000
Sanofi-Aventis Deutschland GmbH \| Insulin Put \| License and Collaboration Agreement with Sanofi
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Net revenue from collaboration					19,400,000
Sanofi-Aventis Deutschland GmbH \| Subsequent Event \| Put Option
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Payment for insulin put option		$ 30,600,000
Deerfield \| Senior convertible notes due December 31, 2019 \| Minimum \| Less portion of commitment asset
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Available amount of credit facility under covenant restrictions			$ 25,000,000		$ 25,000,000

Summary of Significant Accounting Policies - Additional Information (Detail) € in Millions		12 Months Ended
	Jul. 18, 2014 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2016 EUR (€)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Jul. 01, 2013 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Deferred revenue		$ 3,419,000
Net revenue - commercial product sales		$ 1,895,000
Cash discount as incentive for prompt payment		2.00%
Deferred revenue from sale of raw insulin		$ 1,800,000
Deferred cost related to sale of raw insulin		$ 0
Maturity period of cash equivalents		90 days or less at the time of purchase	90 days or less at the time of purchase
Inventory charge		$ 200,000		$ 39,300,000
Percentage of credit exchange receivable		65.00%	65.00%
Prepaid expenses and other current assets		$ 4,364,000		4,018,000
Other income (expense)		(597,000)		1,366,000	$ 1,679,000
Property and equipment impairment		1,259,000		140,412,000	0
Purchase commitment obligation		116,200,000
long term purchase commitment \| €			€ 93.0
Estimated amounts receivable under program		246,000		743,000	816,000
Interest cost capitalized		0		100,000	800,000
Third party logistics
Summary Of Significant Accounting Policies [Line Items]
Deferred revenue		1,600,000
Intellectual property
Summary Of Significant Accounting Policies [Line Items]
Total consideration received	$ 9,300,000
Intellectual property sold, net	7,900,000
Accrued expense associated with intellectual property	$ 1,400,000
Other income (expense)					$ 1,400,000
Certificates of Deposit
Summary Of Significant Accounting Policies [Line Items]
Prepaid expenses and other current assets		350,000		350,000
Sanofi-Aventis Deutschland GmbH
Summary Of Significant Accounting Policies [Line Items]
long term purchase commitment		50,000,000
Deerfield \| Milestone Rights Liability
Summary Of Significant Accounting Policies [Line Items]
Long term liability		8,900,000
Deerfield \| Milestone Rights Liability \| Senior convertible notes due December 31, 2019
Summary Of Significant Accounting Policies [Line Items]
Long term liability		8,900,000		$ 8,900,000		$ 13,100,000
AFREZZA product sales
Summary Of Significant Accounting Policies [Line Items]
Product sales revenue gross to net adjustments		$ 800,000
Product sales revenue gross to net adjustments percentage		30.00%	30.00%
Minimum \| AFREZZA product sales
Summary Of Significant Accounting Policies [Line Items]
Sales return right following product expiration in months		6 months	6 months
Maximum \| AFREZZA product sales
Summary Of Significant Accounting Policies [Line Items]
Sales return right following product expiration in months		12 months	12 months

Components of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Inventory [Line Items]
Raw materials	$ 0	$ 0
Work-in-process	2,120
Finished goods	211
Total Inventory	$ 2,331

Inventory - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Inventory [Line Items]
Raw materials	$ 0	$ 0

Property and Equipment, Net (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property and equipment - gross	$ 128,502	$ 168,262
Less accumulated depreciation	(99,575)	(119,513)
Total property and equipment, net	28,927	48,749
Land
Property, Plant and Equipment [Line Items]
Property and equipment - gross	875	3,435
Buildings
Property, Plant and Equipment [Line Items]
Property and equipment - gross	$ 17,389	21,590
Buildings \| Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	39 years
Buildings \| Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	40 years
Building Improvements
Property, Plant and Equipment [Line Items]
Property and equipment - gross	$ 34,957	60,584
Building Improvements \| Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	5 years
Building Improvements \| Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	40 years
Machinery and Equipment
Property, Plant and Equipment [Line Items]
Property and equipment - gross	$ 62,992	68,434
Machinery and Equipment \| Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	3 years
Machinery and Equipment \| Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	15 years
Furniture, fixtures and office equipment
Property, Plant and Equipment [Line Items]
Property and equipment - gross	$ 3,556	4,114
Furniture, fixtures and office equipment \| Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	5 years
Furniture, fixtures and office equipment \| Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	10 years
Computer Equipment and Software
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	3 years
Property and equipment - gross	$ 8,531	9,519
Construction in Progress
Property, Plant and Equipment [Line Items]
Property and equipment - gross	$ 202	$ 586

Property and Equipment - Additional Information (Detail) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2015 USD ($)	Dec. 31, 2016 USD ($) asset_group	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Depreciation and Other Amortization Expenses [Line Items]
Depreciation and amortization expense		$ 2.4	$ 11.0	$ 9.8
Number of primary asset groups \| asset_group		2
Impairment charge	$ 242.7
Impairment charges allocated to assets			140.4
Valencia
Depreciation and Other Amortization Expenses [Line Items]
Impairment charge		$ 1.8
Danbury Facility
Depreciation and Other Amortization Expenses [Line Items]
Impairment charge			$ 138.6
Property And Equipment Impairment
Depreciation and Other Amortization Expenses [Line Items]
Impairment charge		0.7
Asset held for sale
Depreciation and Other Amortization Expenses [Line Items]
Impairment charge		$ 0.6

Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accrued Expenses and Other Current Liabilities [Line Items]
Salary and related expenses	$ 3,814	$ 2,634
Restructuring	1,376	3,028
Sales and marketing services	144
Professional fees	875	931
Discounts and allowances for commercial product sales	754
Accrued interest	619	615
Other	355	483
Construction in progress		238
Accrued expenses and other current liabilities	$ 7,937	$ 7,929

Related-Party Arrangements - Additional Information (Detail)	1 Months Ended		12 Months Ended
	Oct. 31, 2013 USD ($)	Oct. 31, 2007 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Jan. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	May 31, 2015 ft²
Related Party Transaction [Line Items]
Accrued interest of related party debt			$ 9,300,000	$ 6,400,000
Interest expense on note payable principal stockholder			2,901,000	2,894,000		$ 2,894,000
Expenses related to charter service on behalf of principal shareholder			0	18,000		79,000
Loan Arrangement
Related Party Transaction [Line Items]
Amount available for future borrowings			$ 30,100,000	$ 30,100,000
Mann Foundation \| Sublease Agreement
Related Party Transaction [Line Items]
Area of office space leased \| ft²							12,500
Lease expiration period			2017-04
Lease payment			$ 268,000		$ 175,000	$ 0
Principal stockholder
Related Party Transaction [Line Items]
Loan agreement with related party	$ 370,000,000	$ 350,000,000
Principal stockholder \| Loan Arrangement
Related Party Transaction [Line Items]
Principal amount outstanding under credit facility			49,500,000
Amount available for future borrowings			$ 30,100,000
Fixed borrowing rate			5.84%
Related party transaction prepayment period			90 days
Aggregate principal amount cancelled			$ 105,000,000
Principal stockholder \| Loan Arrangement \| Maximum
Related Party Transaction [Line Items]
Amount prepaid for cancellation of indebtedness			$ 200,000,000
Principal stockholder \| Loan Arrangement \| Minimum
Related Party Transaction [Line Items]
Number of months advances outstanding			12 months
Principal stockholder \| Amended Agreement
Related Party Transaction [Line Items]
Maturity date			Jan. 05, 2020
Related Party Debt \| Letter Agreement
Related Party Transaction [Line Items]
Description of variable rate interest			The interest rate will increase to the one-year LIBOR rate calculated on the date of the initial advance or in effect on the date of default, whichever is greater, plus 5% per annum.
Related Party Debt \| Letter Agreement \| LIBOR
Related Party Transaction [Line Items]
Interest rate (LIBOR)			5.00%

Summary of Borrowings (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Aug. 10, 2015
Debt Instrument [Line Items]
Note payable to principal stockholder - net carrying amount	$ 49,521	$ 49,521
Senior convertible notes due December 31, 2019
Debt Instrument [Line Items]
Principal amount	75,000	80,000
Unamortized debt discount	(3,661)	(5,418)
Net carrying amount	71,339	74,582
5.75% Senior convertible notes due August 15, 2018
Debt Instrument [Line Items]
Principal amount	27,690	27,690	$ 27,700
Unamortized premium	426	660	$ 700
Unaccreted debt issuance costs	(481)	(737)
Net carrying amount	$ 27,635	$ 27,613

Borrowings - Additional Information (Detail)							3 Months Ended	12 Months Ended
Borrowings - Additional Information (Detail)	Sep. 30, 2015 USD ($)	Aug. 17, 2015 USD ($)	Aug. 10, 2015 USD ($) $ / shares shares	Aug. 10, 2015 USD ($) d $ / shares	Jul. 28, 2015 USD ($)	Dec. 31, 2013 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($) shares	Aug. 14, 2015 USD ($)	Jul. 01, 2013 USD ($)	Aug. 18, 2010 USD ($)
Debt Instrument [Line Items]
Facility Agreement, total principle payment in 2017								$ 20,000,000
Facility Agreement, total principle payment in 2018								20,000,000
Facility Agreement, total principle payment in 2019								35,000,000
Interest expense on notes								15,576,000	$ 21,231,000	$ 17,549,000
Aggregate principal amount for conversion										93,500,000
Payments on senior notes									64,287,000
Loss on extinguishment of debt								72,024,000	(1,049,000)
2018 Notes
Debt Instrument [Line Items]
Accretion of debt issuance costs								$ 257,000	93,000
2015 Notes
Debt Instrument [Line Items]
Accretion of debt issuance costs									600,000	900,000
Deerfield
Debt Instrument [Line Items]
Principal repayment schedule, start date								Jul. 01, 2016
Principal repayment schedule, end date								Dec. 09, 2019
Aggregate principal amount for conversion										$ 93,500,000
Conversion Option, shares \| shares										3,464,616
Conversion Option, aggregate expense										$ 6,400,000
Premium of issuance of 2018 debt								$ 1,722,000	1,553,000	7,550,000
Deerfield \| Milestone Rights Liability
Debt Instrument [Line Items]
Long term liability								8,900,000
Deerfield \| Milestone Rights Liability \| Maximum
Debt Instrument [Line Items]
Contingent liability for milestone payments												$ 90,000,000
Deerfield \| Tranche 1 note
Debt Instrument [Line Items]
Aggregate principal amount for conversion										20,000,000
Conversion Option, aggregate expense										1,200,000
Deerfield \| Tranche 2 note
Debt Instrument [Line Items]
Aggregate principal amount for conversion										33,500,000
Conversion Option, aggregate expense										3,000,000
Deerfield \| Tranche 3 note
Debt Instrument [Line Items]
Aggregate principal amount for conversion										40,000,000
Conversion Option, aggregate expense										2,200,000
5.75% Senior convertible notes due August 15, 2018
Debt Instrument [Line Items]
Debt facility principal amount			$ 27,700,000	$ 27,700,000				27,690,000	27,690,000
Senior notes, effective interest rate			5.75%	5.75%
Unamortized debt issuance cost								481,000	737,000
Carrying value								27,635,000	27,613,000
Unamortized premium			$ 700,000	$ 700,000				$ 426,000	660,000
Maturity date								Aug. 15, 2018
No of convertible shares				29
Principal amount per share \| $ / shares				$ 1,000
Conversion price of shares \| $ / shares			$ 34.00	$ 34.00
Percentage of repurchase price				100.00%
Debt Instrument, redemption description								On or after the date that is one year following the original issue date of the 2018 notes, the Company will have the right to redeem for cash all or part of the 2018 notes if the last reported sale price of its common stock exceeds 130% of the conversion price then in effect for 20 or more trading days during the 30 consecutive trading day period ending on the trading day immediately prior to the date of the redemption notice. The redemption price will equal the sum of 100% of the principal amount of the 2018 notes to be redeemed, plus accrued and unpaid interest.
Percentage of conversion price equaling stock price				130.00%
Number of trading days \| d				20
Consecutive trading days				30 days
Debt Issuance Cost													$ 800,000
Premium of issuance of 2018 debt								$ 234,000	86,000
Senior convertible notes due August 15, 2015
Debt Instrument [Line Items]
Debt facility principal amount										100,000,000	$ 32,100,000
Senior notes, effective interest rate											5.75%
Aggregate principal amount for conversion					$ 56,900,000
Conversion Option, shares \| shares			380,000
Conversion price of shares \| $ / shares			$ 110.00	$ 110.00
Principal amount of debt converted			$ 8,000,000
Payments on senior notes	$ 32,100,000	$ 32,200,000
Loss on extinguishment of debt		$ 1,000,000
Senior convertible notes due December 31, 2019
Debt Instrument [Line Items]
Debt facility principal amount								75,000,000	80,000,000
Unamortized debt discount								3,661,000	5,418,000
Carrying value								71,339,000	74,582,000
Senior convertible notes due December 31, 2019 \| Deerfield
Debt Instrument [Line Items]
Debt facility principal amount								$ 55,000,000	60,000,000
Senior notes, effective interest rate								9.75%
Senior convertible notes due December 31, 2019 \| Deerfield \| Facility Agreement
Debt Instrument [Line Items]
Unamortized debt discount								$ 3,700,000
Unamortized debt issuance cost								100,000
Senior convertible notes due December 31, 2019 \| Deerfield \| Milestone Rights Liability
Debt Instrument [Line Items]
Short term liability												3,200,000
Long term liability								8,900,000	8,900,000			$ 13,100,000
Interest expense on notes							$ 5,800,000
Required payment pursuant to the terms of the Milestone Agreement							$ 10,000,000
Discount rate						14.50%
Risk premium						5.00%
Fair value of milestone rights						$ 18,400,000
Senior convertible notes due December 31, 2019 \| Deerfield \| Milestone Rights Liability \| Danbury Facility
Debt Instrument [Line Items]
Carrying value								28,700,000
Senior convertible notes due December 31, 2019 \| Deerfield \| Less portion of commitment asset
Debt Instrument [Line Items]
Debt facility principal amount								$ 20,000,000	$ 20,000,000
Senior notes, effective interest rate								8.75%
Senior convertible notes due December 31, 2019 \| Deerfield \| Less portion of commitment asset \| Minimum
Debt Instrument [Line Items]
Available amount of credit facility under covenant restrictions								$ 25,000,000
Senior convertible notes due December 31, 2019 \| Deerfield \| Less portion of commitment asset \| Minimum \| Facility Agreement
Debt Instrument [Line Items]
Available amount of credit facility under covenant restrictions								$ 25,000,000
Senior convertible notes due December 31, 2019 \| Sanofi-Aventis Deutschland GmbH \| Milestone Rights Liability
Debt Instrument [Line Items]
Interest expense on notes										1,900,000
Required payment pursuant to the terms of the Milestone Agreement										$ 5,000,000

Accretion of Debt Issuance Cost and Debt Discount in Connection with Facility Financing Agreement (Detail) - Deerfield - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Accretion expense - debt issuance cost	$ 35	$ 35	$ 326
Accretion expense - debt discount	$ 1,722	$ 1,553	$ 7,550

Collaborative Arrangement - Additional Information (Detail) - USD ($)					1 Months Ended	3 Months Ended		12 Months Ended
	Dec. 30, 2016	Nov. 09, 2016	Feb. 10, 2016	Jan. 04, 2016	Jan. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Sep. 23, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration								$ 171,965,000
Paid-in-kind interest								4,478,000	$ 1,652,000
Gain on extinguishment of debt								72,024,000	(1,049,000)
Balance payment of settlement agreement						$ 30,557,000		30,557,000	23,000
Insulin Put
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration								10,200,000
Sanofi-Aventis Deutschland GmbH \| Subsequent Event \| Put Option
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payment for insulin put option					$ 30,600,000
Sanofi-Aventis Deutschland GmbH \| Mortgage Loan
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Carrying value									17,900,000
Aventisub LLC
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Outstanding loan balance forgiven		$ 72,000,000
Receptor
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Nonrefundable payments								400,000
Nonrefundable option exercise and license fee	$ 1,000,000
Reduction in research and development expense								400,000
Deferred revenue - nonrefundable license fee						1,000,000		$ 1,000,000
Deferred revenue recognition period								4 years
License and Collaboration Agreement with Sanofi
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Profits and losses sharing percentage								35.00%
Termination date				Apr. 04, 2016
Maximum secured loan facility										$ 175,000,000
Senior notes, effective interest rate										8.50%
Gain on extinguishment of debt		$ 500,000
License and Collaboration Agreement with Sanofi \| Sanofi-Aventis Deutschland GmbH
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue - nonrefundable license fee						150,000,000		$ 150,000,000
Profits and losses sharing percentage								65.00%
Milestone receivable						25,000,000		$ 25,000,000
Deferred cost									13,500,000
Net revenue from collaboration						10,200,000	$ 161,800,000	172,000,000
Maximum secured loan facility						175,000,000		175,000,000
Secured loan facility, amount borrowed			$ 17,900,000						44,500,000
Secured loan facility, amount owed									62,400,000
Paid-in-kind interest									1,700,000
Gain on extinguishment of debt						$ 72,000,000
License and Collaboration Agreement with Sanofi \| Sanofi-Aventis Deutschland GmbH \| AFREZZA product sales
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue - nonrefundable license fee									17,500,000
Net revenue from collaboration								17,500,000
License and Collaboration Agreement with Sanofi \| Sanofi-Aventis Deutschland GmbH \| Up Front Payment [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration								150,000,000
License and Collaboration Agreement with Sanofi \| Sanofi-Aventis Deutschland GmbH \| Milestone Payment One
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration								25,000,000
License and Collaboration Agreement with Sanofi \| Sanofi-Aventis Deutschland GmbH \| Milestone Payment Two
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration								25,000,000
License and Collaboration Agreement with Sanofi \| Sanofi-Aventis Deutschland GmbH \| Insulin Put
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration								19,400,000
License and Collaboration Agreement with Sanofi \| Sanofi-Aventis Deutschland GmbH \| Operating loss Sharing
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration								$ (64,900,000)
Company's total portion of loss sharing									$ 57,700,000

Fair Value of Financial Instruments - Additional Information (Detail) - USD ($)		12 Months Ended
	Dec. 31, 2013	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	May 31, 2016	Sep. 23, 2014	Jul. 01, 2013
Fair Value of Financial Instruments [Line Items]
Cash equivalents, money market funds		$ 20,500,000	$ 55,800,000
Fair value of Milestone Rights					$ 44,700,000
Property and equipment, net		28,927,000	48,749,000
Property and equipment impairment		1,259,000	140,412,000	$ 0
Gain (loss) on property, plant and equipment		$ (600,000)
Carrying Value
Fair Value of Financial Instruments [Line Items]
Property and equipment, net			189,200,000
Sanofi-Aventis Deutschland GmbH
Fair Value of Financial Instruments [Line Items]
Loan facility forgiven date		Nov. 09, 2016
License and Collaboration Agreement with Sanofi
Fair Value of Financial Instruments [Line Items]
Maximum secured loan facility						$ 175,000,000
License and Collaboration Agreement with Sanofi \| Sanofi-Aventis Deutschland GmbH
Fair Value of Financial Instruments [Line Items]
Maximum secured loan facility		$ 175,000,000
Milestone Rights Liability \| Deerfield
Fair Value of Financial Instruments [Line Items]
Long term liability		8,900,000
Milestone Rights Liability \| Deerfield \| Maximum
Fair Value of Financial Instruments [Line Items]
Contingent liability for milestone payments							$ 90,000,000
Milestone Rights Liability \| Senior convertible notes due December 31, 2019 \| Deerfield
Fair Value of Financial Instruments [Line Items]
Market discount rate	14.50%
Long term liability		8,900,000	8,900,000				$ 13,100,000
Fair Value, Inputs, Level 3
Fair Value of Financial Instruments [Line Items]
Property, plant, and equipment, fair value			48,800,000
Property and equipment impairment		700,000	$ (140,412,000)
Fair Value, Inputs, Level 3 \| Milestone Rights Liability
Fair Value of Financial Instruments [Line Items]
Fair value of Milestone Rights		$ 18,400,000
Fair Value, Inputs, Level 3 \| Market Approach Valuation Technique \| 5.75% Senior convertible notes due August 15, 2018 \| Convertible Debt Securities
Fair Value of Financial Instruments [Line Items]
Fair value assumption, risk-free rate		20.00%
Fair value assumption, stock price volatility		111.00%
Fair Value, Inputs, Level 3 \| Income Approach Valuation Technique \| Sanofi-Aventis Deutschland GmbH
Fair Value of Financial Instruments [Line Items]
Market discount rate		11.00%
Fair Value, Inputs, Level 3 \| Income Approach Valuation Technique \| Senior convertible notes due December 31, 2019
Fair Value of Financial Instruments [Line Items]
Market discount rate		12.00%
Fair Value, Inputs, Level 3 \| Income Approach Valuation Technique \| Milestone Rights Liability
Fair Value of Financial Instruments [Line Items]
Market discount rate		14.50%

Fair Value of Financial Instruments (Detail) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Warrant Liability
Financial liabilities:
Financial liabilities fair value	$ 7.4
Carrying Value
Financial liabilities:
Financial liabilities fair value	115.2	$ 155.6
Carrying Value \| Sanofi-Aventis Deutschland GmbH
Financial liabilities:
Financial liabilities fair value		44.5
Carrying Value \| Warrant Liability
Financial liabilities:
Financial liabilities fair value	7.4
Carrying Value \| Milestone Rights Liability
Financial liabilities:
Financial liabilities fair value	8.9	8.9
Carrying Value \| Senior Convertible Notes \| Convertible Debt Securities
Financial liabilities:
Financial liabilities fair value	27.6	27.6
Carrying Value \| Facility Financing Obligation
Financial liabilities:
Financial liabilities fair value	71.3	74.6
Estimate of Fair Value Measurement
Financial liabilities:
Financial liabilities fair value	123.2	150.6
Estimate of Fair Value Measurement \| Sanofi-Aventis Deutschland GmbH
Financial liabilities:
Financial liabilities fair value		36.5
Estimate of Fair Value Measurement \| Warrant Liability
Financial liabilities:
Financial liabilities fair value	7.4
Estimate of Fair Value Measurement \| Milestone Rights Liability
Financial liabilities:
Financial liabilities fair value	18.4	14.4
Estimate of Fair Value Measurement \| Fair Value, Inputs, Level 3
Financial liabilities:
Financial liabilities fair value	123.2	150.6
Estimate of Fair Value Measurement \| Fair Value, Inputs, Level 3 \| Sanofi-Aventis Deutschland GmbH
Financial liabilities:
Financial liabilities fair value		36.5
Estimate of Fair Value Measurement \| Fair Value, Inputs, Level 3 \| Warrant Liability
Financial liabilities:
Financial liabilities fair value	7.4
Estimate of Fair Value Measurement \| Fair Value, Inputs, Level 3 \| Milestone Rights Liability
Financial liabilities:
Financial liabilities fair value	18.4	14.4
Estimate of Fair Value Measurement \| Senior Convertible Notes \| Convertible Debt Securities
Financial liabilities:
Financial liabilities fair value	22.9	21.3
Estimate of Fair Value Measurement \| Senior Convertible Notes \| Fair Value, Inputs, Level 3 \| Convertible Debt Securities
Financial liabilities:
Financial liabilities fair value	22.9	21.3
Estimate of Fair Value Measurement \| Facility Financing Obligation
Financial liabilities:
Financial liabilities fair value	74.5	78.4
Estimate of Fair Value Measurement \| Facility Financing Obligation \| Fair Value, Inputs, Level 3
Financial liabilities:
Financial liabilities fair value	$ 74.5	$ 78.4

Fair Values of Financial Assets and Liabilities Carried at Fair Value (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Warrant Liability
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Additions	$ 12.8
Changes in fair value	(5.4)
Payments	0.0	$ 0.0
Fair values of financial liabilities, ending balance	7.4
Assets Held for Sale
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Additions	17.3
Changes in fair value	(0.6)
Payments	0.0	$ 0.0
Fair values of financial assets, ending balance	$ 16.7

Common and Preferred Stock - Additional Information (Detail)					1 Months Ended		12 Months Ended
	Mar. 01, 2017 shares	Nov. 09, 2016 shares	Nov. 16, 2015 shares	Feb. 08, 2012 USD ($) $ / shares $ / Right shares	May 31, 2016 USD ($) $ / shares shares	Nov. 01, 2015 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2015 USD ($) $ / shares shares	Dec. 31, 2014 USD ($) $ / shares shares	Sep. 30, 2016 shares	Oct. 23, 2015 shares	Aug. 14, 2015 USD ($)
Class of Stock [Line Items]
Common stock, shares authorized							140,000,000	110,000,000		700,000,000
Common stock, par value \| $ / shares							$ 0.05	$ 0.05
Undesignated preferred stock, shares authorized							10,000,000	10,000,000
Undesignated preferred stock, par value \| $ / shares							$ 0.01	$ 0.01
Common stock, shares issued							95,680,831	85,734,188
Common stock, shares outstanding							95,680,831	85,734,188
Common stock shares sold aggregate price \| $								$ 27,843,000
Issuance costs associated with the Tel Aviv Stock Exchange \| $								548,000
Percentage of shares of common stock issued for offering			1.15%
Restricted warrants issued to purchase number of common stock for offering			31,860
Exercise price of restricted warrants per share in connection with the offering \| $ / shares					$ 7.50		$ 13.05
Warrants exercisable period							5 years
Common stock loaned under share lending agreement, shares									1,800,000
Nominal lending fee \| $ / shares									$ 0.05
Returned shares of common stock under share lending agreement											1,800,000
Number of Unit Sold in an Underwritten public offering				7,187,500
Warrant to purchase of a share of common stock \| $ / Right				0.1
Net proceeds from offering \| $				$ 80,600,000
Proceeds from exercise warrants \| $							$ 0	10,123,000	$ 27,779,000
Warrants expiration, date							Feb. 08, 2016
Maximum \| A Warrants
Class of Stock [Line Items]
Warrants to purchase of common stock					7,281,553
Maximum \| B Warrants
Class of Stock [Line Items]
Warrants to purchase of common stock					2,427,184
Registered Offering
Class of Stock [Line Items]
Number of shares sold in underwritten public offering					9,708,737
Direct Offering
Class of Stock [Line Items]
Proceeds from issuance of warrants \| $					$ 50,000,000
Warrant Liability
Class of Stock [Line Items]
Exercise price of restricted warrants per share in connection with the offering \| $ / shares				$ 12.00
Number of warrants are exercisable				4,312,500
Duration for Expiration of warrants				4 years
Underwriters
Class of Stock [Line Items]
Number of Unit Sold in an Underwritten public offering				937,500
Purchased Price of the units by underwriters \| $ / Right				11.28
Public
Class of Stock [Line Items]
Purchased Price of the units by underwriters \| $ / Right				12.00
Related Party
Class of Stock [Line Items]
Units sold composition description				Each unit consisting of one share of common stock and a warrant to purchase 0.1 of a share of common stock
TEL AVIV STOCK EXCHANGE
Class of Stock [Line Items]
Common stock, shares authorized		10,000,000
Percentage of shares price per share		97.00%
Common stock shares sold						2,770,487
Common stock shares sold aggregate price \| $						$ 34,710,000		34,710,000
Share price \| $ / shares						$ 13.05
Issuance costs associated with the Tel Aviv Stock Exchange \| $						$ 1,432,000		$ 1,432,000
Senior convertible notes due August 15, 2015
Class of Stock [Line Items]
Principal amount \| $									$ 100,000,000			$ 32,100,000
Subsequent Event
Class of Stock [Line Items]
Stock split of common stock	0.2
Common stock, shares authorized	140,000,000

Net Income (Loss) per Common Share - Additional Information (Detail)	Mar. 01, 2017	Dec. 31, 2015 shares
Net Income Loss Per Common Share [Line Items]
Common shares loaned under the share lending arrangement, issued and outstanding		1,800,000
Subsequent Event
Net Income Loss Per Common Share [Line Items]
Stock split of common stock	0.2

Components of Basic and Diluted Net Income (Loss) Per Common Share Computations (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Basic EPS:
Net income (loss) (numerator)	$ 53,976	$ 126,520	$ (29,959)	$ (24,873)	$ (277,020)	$ (31,857)	$ (28,910)	$ (30,658)	$ 125,664	$ (368,445)	$ (198,382)
Weighted average common shares (denominator)	95,676	95,627	91,061	85,771					92,053	81,233	77,045
Net income (loss) per share	$ 0.56	$ 1.32	$ (0.33)	$ (0.29)					$ 1.37	$ (4.54)	$ (2.57)
Diluted EPS:
Net income (loss) (numerator)	$ 53,976	$ 126,520	$ (29,959)	$ (24,873)	$ (277,020)	$ (31,857)	$ (28,910)	$ (30,658)	$ 125,664	$ (368,445)	$ (198,382)
Weighted average common shares	95,676	95,627	91,061	85,771					92,053	81,233	77,045
Effect of dilutive securities - common shares issuable									32
Adjusted weighted average common shares (denominator)	96,510	96,548	91,061	85,771					92,085	81,233	77,045
Net income (loss) per share	$ 0.56	$ 1.31	$ (0.33)	$ (0.29)					$ 1.36	$ (4.54)	$ (2.57)

Potentially Dilutive Securities Outstanding that are Antidilutive (Detail) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding	16,788,281	5,946,249	10,292,667
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding	5,530,256	3,955,845	4,308,332
Convertible Debt Securities
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding	814,561	814,561	3,464,616
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding	9,740,597	814,919	1,997,575
Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding	702,867	360,924	522,144

Stock Award Plans - Additional Information (Detail)		1 Months Ended	12 Months Ended
Stock Award Plans - Additional Information (Detail)	Mar. 01, 2017	Mar. 31, 2004 shares	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2015 USD ($) $ / shares shares	Dec. 31, 2014 USD ($) $ / shares shares	May 23, 2013 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share reserve \| shares				140,000	140,000
Share of common stock outstanding		1.00%
Shares sold to employees \| shares			104,758	64,245	61,015
Shares purchased under ESPP \| shares			43,672
Stock option grants vest exercisable rate			25.00%
Vesting period			4 years
Options to purchase common stock \| shares			5,530,256	3,955,845
Stock based compensation expense			$ 5,135,000	$ 8,725,000	$ 48,622,000
Weighted average grant date fair value of the stock options granted \| $ / shares			$ 3.05	$ 12.80	$ 23.80
Total intrinsic value of options exercised			$ 100,000	$ 6,200,000	$ 14,900,000
Cash received from the exercise of options			$ 500,000	$ 3,300,000	$ 11,000,000
Weighted-average remaining contractual term			5 years 3 months 22 days	5 years 2 months 19 days	2 years 11 months 5 days
Restricted stock units expected to vest \| shares			629,424
Weighted average grant date fair value \| $ / shares			$ 8.60
Total intrinsic value of restricted stock units expected to vest			$ 2,000,000
Total intrinsic value of restricted stock units vested			600,000	$ 5,200,000	$ 62,700,000
Fair value of restricted stock units vested			$ 2,600,000	5,500,000	36,400,000
Weighted average vesting period for unrecognized compensation cost			2 years 10 months 24 days
Stock compensation expense			$ 5,135,000	8,725,000	$ 48,622,000
Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock split of common stock	0.2
Employee Severance \| Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense				$ 1,600,000
Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock vesting rate			25.00%
Unrecognized compensation cost related to options			$ 300,000
Tranche achievement date			2017-12
Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non vested stock options			$ 0
Tranche Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non vested stock options			0
Tranche Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non vested stock options			$ 0
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved under ESPP		10.00%
Options granted expiry term			10 years
Consultant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options to purchase common stock \| shares			100,697
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			36 months
Unrecognized compensation cost related to non vested stock options			$ 4,000,000
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			4 years
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non vested stock options			$ 4,800,000
2013 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity incentive plan, shares \| shares						4,300,000
Options to purchase common stock \| shares			3,399,245
Employee Stock Purchase Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for issuance \| shares		400,000	445,782
Share reserve automatic increase each year \| shares		140,000

Stock Based Award Plans (Detail) - shares	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Options	5,530,256	3,955,845
Outstanding Restricted Stock Units	737,966	360,924
Shares Available for Future Issuance	3,840,587
2004 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Options	2,052,345
Outstanding Restricted Stock Units	14,203
Shares Available for Future Issuance	97,574
2013 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Options	3,399,245
Outstanding Restricted Stock Units	723,763
Shares Available for Future Issuance	3,743,013
2004 Non Employee Directors Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Options	78,666

Stock Based Compensation Expense Recognized in Accompanying Consolidated Statements of Operation (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	$ 5,135	$ 8,725	$ 48,622
Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	$ 5,135	8,407	$ 48,622
Consultant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation		$ 318

Stock Based Compensation Expense Recognized in Accompanying Consolidated Statements of Operations by Category (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	$ 5,135	$ 8,725	$ 48,622
Cost of Sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	695
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	1,309	3,029	22,357
Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	$ 3,131	$ 5,696	$ 26,265

Fair Value of Employee Stock Options Assumptions (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Risk free interest rate, minimum	1.18%	1.61%	1.64%
Risk free interest rate, maximum	1.80%	1.86%	2.11%
Volatility, minimum	77.57%	69.76%	73.98%
Volatility, maximum	82.75%	71.84%	84.85%
Dividends	0.00%	0.00%	0.00%
Minimum
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Expected lives	5 years 1 month 17 days	5 years 9 months 15 days	5 years 9 months 7 days
Maximum
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Expected lives	5 years 9 months 26 days	5 years 10 months 10 days	6 years 1 month 2 days

Summary of Stock Options Outstanding (Detail) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($) $ / shares shares
Number of Shares
Outstanding at January 1, 2016 \| shares	3,955,845
Granted \| shares	2,236,693
Exercised \| shares	(55,231)
Forfeited \| shares	(407,161)
Expired \| shares	(199,890)
Outstanding at December 31, 2016 \| shares	5,530,256
Vested and expected to vest at December 31, 2016 \| shares	5,399,777
Exercisable at December 31, 2016 \| shares	3,414,586
Weighted Average Exercise Price per Share
Outstanding at January 1, 2016 \| $ / shares	$ 22.70
Granted \| $ / shares	4.50
Exercised \| $ / shares	8.45
Forfeited \| $ / shares	13.60
Expired \| $ / shares	23.65
Outstanding at December 31, 2016 \| $ / shares	16.10
Vested and expected to vest at December 31, 2016 \| $ / shares	16.35
Exercisable at December 31, 2016 \| $ / shares	$ 22.50
Aggregate Intrinsic Value
Outstanding at December 31, 2016 \| $	$ 2
Vested and expected to vest at December 31, 2016 \| $	2
Exercisable at December 31, 2016 \| $	$ 0

Summary of Restricted Stock Unit Activity (Detail)	12 Months Ended
Summary of Restricted Stock Unit Activity (Detail)	Dec. 31, 2016 $ / shares shares
Number of shares
Outstanding at January 1, 2016 \| shares	360,924
Granted \| shares	800,530
Vested \| shares	(131,000)
Forfeited \| shares	(292,488)
Outstanding at December 31, 2016 \| shares	737,966
Weighted average grant date fair value Per share
Outstanding at January 1, 2016 \| $ / shares	$ 24.25
Granted \| $ / shares	4.50
Vested \| $ / shares	21.70
Forfeited \| $ / shares	11.60
Outstanding at December 31, 2016 \| $ / shares	$ 8.40

Commitments and Contingencies - Additional Information (Detail) € in Millions		12 Months Ended				24 Months Ended
	Jul. 31, 2014 EUR (€)	Dec. 31, 2016 USD ($)	Dec. 31, 2016 EUR (€)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Oct. 01, 2018 USD ($)	Jul. 01, 2013 USD ($)
Commitments and Contingencies [Line Items]
Operating lease rent expenses		$ 373,000		$ 426,000	$ 737,000
Purchase commitment amount under Insulin Supply Agreement \| €			€ 93.0
Supply Agreement expiration period		Dec. 31, 2023	Dec. 31, 2023
Supply Agreement renewal period		2 years	2 years
Purchase commitment obligation		$ 116,200,000
Before Amendment
Commitments and Contingencies [Line Items]
Purchase commitment amount under Insulin Supply Agreement \| €	€ 120.1
Scenario Forecast
Commitments and Contingencies [Line Items]
Purchase commitment cancellation fees						$ 3,400,000
Scenario Forecast \| Before Amendment
Commitments and Contingencies [Line Items]
Purchase commitment cancellation fees						$ 5,300,000
Supply Commitment
Commitments and Contingencies [Line Items]
Purchase commitment obligation		$ 900,000
Deerfield \| Milestone Rights Liability \| Maximum
Commitments and Contingencies [Line Items]
Contingent liability for milestone payments							$ 90,000,000

Annual Purchase Requirements under Contract (Detail) € in Millions	Dec. 31, 2016 EUR (€)
Annual Purchase Requirements under Contract
2017	€ 2.7
2018	8.9
2019	11.6
2020	15.5
2021	15.5
2022	19.4
2023	€ 19.4

Employee Benefit Plans - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Employer contribution savings retirement plan	$ 418,000	$ 593,000	$ 623,000

Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current
U.S. federal	$ 0	$ 0	$ 0
U.S. state	0	0	0
Non-U.S.	0	0	0
Total current	0	0	0
Deferred
U.S. federal	(43,814)	109,512	57,873
U.S. state	(4,311)	(29,394)	7,631
Non-U.S.	0	0	0
Total deferred	(48,125)	80,118	65,504
Valuation allowance	48,125	(80,118)	(65,504)
Total	$ 0	$ 0	$ 0

Components of Net Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Net operating loss carryforwards	$ 712,124	$ 721,588
Research and development credits	77,998	73,646
Capitalized research	5,117	5,872
Payments from collaboration		52,484
Milestone Rights	3,242	3,242
Accrued expenses	440	251
Loss on purchase commitment	36,775	24,084
Non-qualified stock option expense	17,331	16,941
Capitalized patent costs	8,781	8,574
Other	7,380	7,186
Depreciation	45,310	48,755
Total net deferred tax assets	914,498	962,623
Valuation allowance	(914,498)	(962,623)
Net deferred tax assets	$ 0	$ 0

Income Taxes -Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Aug. 31, 2004	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Line Items]
Amount Equity would be increased		$ 11,600
Change in the valuation allowance		(48,100)	$ 80,100	$ 65,500
Federal operating loss carryforwards		1,900,000
State operating loss carryforwards		1,300,000
Net operating loss carryforwards	$ 216,000
Net operating loss and credit carryforwards, annual use limitation	$ 13,000
Research and development credits		$ 77,998	$ 73,646
Federal
Income Taxes [Line Items]
Net operating loss carryforwards, expiration year		2018
Research and development credits		$ 53,000
Federal research and development credits begin to expire		2024
State
Income Taxes [Line Items]
Research and development credits		$ 38,500

Effective Income Tax Rate (Detail)	12 Months Ended
Effective Income Tax Rate (Detail)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Schedule Of Income Taxes [Line Items]
Federal tax benefit rate	35.00%	35.00%	35.00%
Permanent items	(1.90%)		0.90%
Intercompany transfer of intellectual property	0.90%	(1.00%)	(4.10%)
Valuation allowance	(34.00%)	(34.00%)	(31.80%)
Effective income tax rate	0.00%	0.00%	0.00%

Warrants - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions		1 Months Ended	12 Months Ended
	May 12, 2016	May 31, 2016	Dec. 31, 2016
Class of Warrant or Right [Line Items]
Fair value of warrants liability		$ 44.7
Exercise price of warrants		$ 7.50	$ 13.05
Class of warrants exercised			0
A Warrants
Class of Warrant or Right [Line Items]
Fair value of warrants liability	$ 12.8		$ 7.4
Class of warrants expiration period upon issuance		2 years
Valuation technique			Monte Carlo valuation pricing model
Warrant liability fair value assumptions, risk-free rate	0.76%		1.10%
Warrant liability fair value assumptions, dividend yield	0.00%		0.00%
Warrant liability fair value assumptions, remaining term	2 years		1 year 4 months 24 days
Warrant liability fair value assumptions, volatility rate	95.00%		118.00%
Warrant liability fair value assumptions, assumed probability	10.00%		10.00%
Warrant fair value adjustments			$ 5.4
B Warrants
Class of Warrant or Right [Line Items]
Fair value of warrants liability	$ 5.0
Class of warrants expiration period upon issuance		30 months
Warrants exercisable date		2017-05
Maximum \| A Warrants
Class of Warrant or Right [Line Items]
Warrants to purchase of common stock		7,281,553
Maximum \| B Warrants
Class of Warrant or Right [Line Items]
Warrants to purchase of common stock		2,427,184
Registered Offering
Class of Warrant or Right [Line Items]
Number of shares sold in underwritten public offering		9,708,737

Schedule of Selling, General and Administrative Expenses (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Selling General And Administrative Expenses [Line Items]
Selling and marketing	$ 19,854	$ 1,587	$ 3,556
General and administrative	27,074	39,373	75,827
Selling, general and administrative expenses	$ 46,928	$ 40,960	$ 79,383

Restructuring Charges - Additional information (Detail) $ in Thousands	1 Months Ended	12 Months Ended
	Sep. 30, 2016 USD ($) Employee	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($) Employee
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 2,035	$ 6,040
Restructuring liability		1,376	3,028
Remaining accrual balance		1,376	$ 3,028
Twenty Sixteen Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Percentage of workforce reduction	18.00%
Number of employees eliminated \| Employee	155
Restructuring charges	$ 1,500	1,475
Restructuring liability		1,500
Remaining accrual balance		209
Twenty Sixteen Restructuring Plan \| Cost of Sales
Restructuring Cost and Reserve [Line Items]
Restructuring charges		400
Twenty Sixteen Restructuring Plan \| Research and development
Restructuring Cost and Reserve [Line Items]
Restructuring charges		700
Twenty Sixteen Restructuring Plan \| Selling, General and Administrative Expenses
Restructuring Cost and Reserve [Line Items]
Restructuring charges		400
Twenty Fifteen Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Percentage of workforce reduction			26.00%
Number of employees eliminated \| Employee			198
Restructuring charges		560	$ 6,040
Remaining accrual balance		$ 1,167	3,028
Twenty Fifteen Restructuring Plan \| Cost of Sales
Restructuring Cost and Reserve [Line Items]
Restructuring charges			1,400
Twenty Fifteen Restructuring Plan \| Research and development
Restructuring Cost and Reserve [Line Items]
Restructuring charges			1,300
Twenty Fifteen Restructuring Plan \| Selling, General and Administrative Expenses
Restructuring Cost and Reserve [Line Items]
Restructuring charges			$ 3,300

Reconciliation of Beginning and Ending Liability Balances for Restructuring Charges (Detail) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Accrual - Beginning balance		$ 3,028
Costs incurred and charged to expense		2,035	$ 6,040
Costs paid or settled		(3,687)	(3,012)
Accrual - Ending balance		1,376	3,028
Twenty Sixteen Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Costs incurred and charged to expense	$ 1,500	1,475
Costs paid or settled		(1,266)
Accrual - Ending balance		209
Twenty Fifteen Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Accrual - Beginning balance		3,028
Costs incurred and charged to expense		560	6,040
Costs paid or settled		(2,421)	(3,012)
Accrual - Ending balance		$ 1,167	$ 3,028

Selected Quarterly Financial Data (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Interim Reporting [Line Items]
Net revenues	$ 12,404	$ 162,354							$ 174,758
Net income (loss)	$ 53,976	$ 126,520	$ (29,959)	$ (24,873)	$ (277,020)	$ (31,857)	$ (28,910)	$ (30,658)	$ 125,664	$ (368,445)	$ (198,382)
Net income (loss) per share - basic	$ 0.56	$ 1.32	$ (0.33)	$ (0.29)					$ 1.37	$ (4.54)	$ (2.57)
Net loss per share - basic and diluted					$ (3.30)	$ (0.39)	$ (0.36)	$ (0.38)
Net income (loss) per share - diluted	$ 0.56	$ 1.31	$ (0.33)	$ (0.29)					$ 1.36	$ (4.54)	$ (2.57)
Weighted average common shares used to compute basic and diluted net loss per share					83,862	81,039	80,203	79,783
Weighted average common shares used to compute basic net income (loss) per share	95,676	95,627	91,061	85,771					92,053	81,233	77,045
Weighted average common shares used to compute diluted net income (loss) per share	96,510	96,548	91,061	85,771					92,085	81,233	77,045

Selected Quarterly Financial Data - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended			12 Months Ended
	Nov. 09, 2016	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Interim Reporting [Line Items]
Asset impairment charges				$ 242,700
Net revenue from collaboration					$ 171,965
Gain (loss) on extinguishment of debt					72,024	$ (1,049)
License and Collaboration Agreement with Sanofi
Interim Reporting [Line Items]
Gain (loss) on extinguishment of debt	$ 500
License and Collaboration Agreement with Sanofi \| Sanofi-Aventis Deutschland GmbH
Interim Reporting [Line Items]
Net revenue from collaboration		$ 10,200	$ 161,800		$ 172,000
Gain (loss) on extinguishment of debt		$ 72,000

Subsequent Events - Additional Information (Detail)						12 Months Ended
Subsequent Events - Additional Information (Detail)	Mar. 16, 2017 $ / shares	Mar. 01, 2017 shares	Feb. 17, 2017 USD ($)	Jan. 06, 2017 USD ($)	Sep. 14, 2016 $ / shares	Dec. 31, 2016 USD ($) shares	Dec. 31, 2015 USD ($) shares	Sep. 30, 2016 shares
Subsequent Event [Line Items]
Common stock, shares authorized \| shares						140,000,000	110,000,000	700,000,000
Cash received from property, plant and equipment						$ 17,000	$ 82,000
Gain (loss) on property, plant and equipment						$ (600,000)
Subsequent Event
Subsequent Event [Line Items]
Stock split of common stock		0.2
Common stock, shares authorized \| shares		140,000,000
Minimum closing bid price of common stock \| $ / shares	$ 1.00
Subsequent Event \| Land, Buildings and Improvements \| California
Subsequent Event [Line Items]
Amount of divestiture of long-lived				$ 17,300,000
Cash received from property, plant and equipment			$ 17,300,000
Net cash received from property, plant and equipment				16,700,000
Payments for commissions and other fees				624,000
Gain (loss) on property, plant and equipment				$ (564,000)
NASDAQ
Subsequent Event [Line Items]
Bid price of common stock, closing price \| $ / shares					$ 1.00
Bid price of common stock, period less than required closing bid price					30 years
Bid price of common stock, period provided to regain compliance					180 years
Bid price of common stock, date provided to regain compliance					Mar. 13, 2017